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ABSTRACT

ESSAYS ON AGING-RELATED DISEASE IN THE U.S. POPULATION
Ezra Fishman
Dissertation supervised by Samuel H. Preston and Irma T. Elo
I research three topics in adult morbidity in the United States, focusing on two
increasingly prevalent chronic diseases, diabetes and dementia. In the first essay, I
investigate changes in age-specific diabetes prevalence across cohorts born in the 20th
century and use the cross-cohort comparisons to generate model age patterns of diabetes
prevalence and incidence. I show that most of the increase in diabetes prevalence over
time is attributable to increases in age-specific prevalence from one cohort to the next.
Because the risk of diabetes is embodied in cohorts, diabetes prevalence is likely to
increase in the future even if the prevalence of risk factors such as obesity plateau.
In the second essay, I use multiple-decrement life tables to estimate age-specific
lifetime risks of dementia for a dementia-free person. I estimate that about a quarter of
dementia-free 70-year-old males and a third of females will develop dementia in their
lifetimes. Although interventions that delay dementia onset could substantially reduce
dementia risk, the results indicate a widespread need to prepare for a life stage with
dementia.
In the third essay, I use recent advances in propensity-score matching techniques
to estimate the association between incidence diabetes and subsequent accumulation of
mobility limitations. Among observationally similar pairs of individuals, those who
iv

developed diabetes reported an average of 25% more mobility limitations at study exit
than those who did not develop diabetes. My estimates of this association are smaller
than those found in most of the existing literature, but they are likely less biased.
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Introduction
As adult mortality continues its long-run decline in industrialized countries,
demographers have paid increasing attention to morbidity (Crimmins & Beltrán-Sánchez
2010; Vaupel 2010). In the following chapters, I research three topics in adult morbidity
in the United States, focusing on two increasingly prevalent chronic diseases, diabetes
and dementia. Increases in diabetes prevalence are associated with changes in the risk
profile of the population, especially the prevalence and duration of obesity (Abdullah et
al. 2011; Gregg, Boyle, et al. 2013; Reis et al. 2013). Increases in dementia prevalence
are largely attributable to the declining risk of death at “younger old” ages, allowing a
larger fraction individuals to live long enough to develop dementia (Deckers et al. 2014;
Hurd, Martorell, Delavande, Mullen, & Langa 2013; Plassman et al. 2011).
A life-course perspective on chronic disease in the United States unites the three
chapters that follow. In Chapter 1, I consider the life course of cohorts, using the fact that
young-age characteristics of a cohort stay with the cohort as it ages, predicting later-life
cohort characteristics. This perspective enables the estimation of model age patterns of
diabetes prevalence and incidence that reflect what cohorts actually experience as they
age. In Chapter 2, I investigate the life-cycle implications of dementia incidence and
mortality for an average older adult. The life table methods used in Chapter 2 synthesize
population rates back to the level of the individual life course. In Chapter 3, I isolate the
role of incident diabetes in the subsequent accumulation of mobility limitations, reducing
biases found in studies that use diabetes presence as the exposure.

1

Another unifying theme is the distinction – and interaction – between disease
incidence and prevalence. Incidence is a classic demographic rate: the ratio of new cases
to person-time at risk. Prevalence is the proportion of the population with the disease at a
given time. Chapter 1 uses an innovative cohort-based method to infer incidence from
prevalence and differential mortality. Chapter 2 uses incidence and prevalence to refine
estimates of differential mortality, and synthesizes the different rates to develop the
lifetime risk estimate. Lifetime risk would be equivalent to prevalence in a stationary
population if there were no differential mortality; the large mortality differentials
between people with dementia and their age-contemporaries without it necessitate a life
table based estimate (Preston, Heuveline, & Guillot 2001). Finally, Chapter 3 shows that
examining incident disease as a risk factor for subsequent outcomes, in this case mobility
limitations, can generate somewhat different results than examining prevalent disease as a
risk factor.

The cohort dynamics of diabetes in the United States
(Note: This chapter was co-authored with Prof. Samuel H. Preston and Andrew Stokes.)
Diabetes is a leading cause of mortality, disability, and health care costs in the
United States (Murray 2013). Few national studies provide detail on age patterns of
diabetes prevalence above age 65 (Y. J. Cheng et al. 2013; Menke, Casagrande, Geiss, &
Cowie 2015). Since future gains in life expectancy are likely to be concentrated at old
ages (Li, Lee, & Gerland 2013), such age-detail is valuable. Furthermore, data limitations
reduce our ability to get good estimates of age-specific disease incidence, and of trends
2

over time, especially since changes in diagnostic criteria for diabetes and awareness of
the disease among the public make self-reported data of questionable quality (e.g. Gregg
et al. 2014). Most generally, there is insufficient understanding in chronic disease
epidemiology of the importance of birth cohorts as embodiments of lifetimes of risk
factors that presage future trends in prevalence and incidence.
Chapter 1 addresses these gaps in the literature by examining age patterns of
diabetes prevalence across birth cohorts, using a stable measure of blood glucose
collected from population-representative samples in the National Health and Nutrition
Examination Surveys (NHANES), 1988 to 2010. In the cross-section, prevalence appears
to decline after age 75, a result that could arise if people with diabetes at those ages die
more quickly than new cases occur. However, Chapter 1 will show that this result appears
in the cross-section because older cohorts had lower diabetes prevalence throughout their
lives than younger cohorts had.
The value of the cohort-based approach is demonstrated in an age/period/cohort
model of diabetes prevalence. To avoid the classic identification problem in such models,
where any one of age, period, and cohort is a linear combination of the other two (Mason
& Fienberg 1985), the chapter uses a single continuous measure to capture cohort-based
risks of diabetes: the prevalence of obesity in the cohort at age 25. In addition to avoiding
the classic identification problem, this approach also identifies cohort effects with an
intuitively appealing risk factor, rather than with complex mathematical transformations
(e.g. Reither et al. 2009). I find that including this single continuous variable reduces all
period coefficients to nearly zero. In other words, increases in diabetes prevalence over
3

time are almost entirely explained by increases in the age-25 obesity prevalence of
successively younger cohorts.
In a cohort closed to migration, increases in diabetes prevalence from one age to
the next result only from incidence and mortality differentials between the diabetic and
non-diabetic populations. Using the cohort perspective, I develop a model age pattern of
diabetes incidence by measuring within-cohort changes in prevalence and adjusting for
differential mortality. The results show that diabetes incidence peaks in late middle age
(55 to 64) and declines at older ages. To my knowledge, these are the first estimates of
diabetes incidence using nationally representative data with a stable, objective measure of
blood glucose.
The main insight of Chapter 1 is that the risk of diabetes is embodied in cohorts.
One implication is that the possible plateauing of obesity prevalence recently observed
(Flegal, Carroll, Kit, & Ogden 2012) does not imply that diabetes prevalence will soon
plateau as well. As current young-adult cohorts age, they are likely to experience higher
levels diabetes prevalence at any given age than past cohorts. More generally, a
perspective that integrates the life course of a cohort into the measurement of disease
occurrence can provide deeper understandings of past trends and perhaps better ability to
predict future trends.

Lifetime risk of dementia in the United States
Dementia imposes a financial cost of over $40,000 per affected person per year,
comparable to the financial costs of heart disease and cancer (Hurd et al. 2013).
4

Americans over 60 reported fearing dementia more than any other disease, including
cancer (Alzheimer’s Association 2014). As the U.S. population ages, the number of
Americans with dementia is very likely to increase in the coming decades (He & Larsen
2014; Kasper, Freedman, Spillman, & Wolff 2015). Using nationally representative,
longitudinal data from the Aging, Demographics, and Memory Study (ADAMS), fielded
2001 to 2009, Chapter 2 estimates the probability that an average dementia-free person
will develop dementia in the course of life.
An approach that incorporates the competing risks of death and dementia
incidence in a prospective cohort allows one to estimate the risk that the average
dementia-free individual will develop dementia in the future. It can also provide an
estimate of the related measures of dementia-free life expectancy and life expectancy
with dementia. These quantities are important for individuals, businesses, and
governments as they plan for retirement, save and contribute to pensions, and assess
future health care costs and caregiving needs. For demographers and epidemiologists,
these quantities provide meaningful insight into the question of whether long-run gains in
survivorship are being experienced in healthy or unhealthy states (Crimmins & BeltránSánchez 2010; Crimmins, Hayward, & Hagedorn 2009).
To my knowledge, this is the first study of the life cycle implications of dementia
that uses data representative of the U.S. old-age population and explicitly accounts for the
competing risk of death. The study will also utilize stationary population relations to
refine estimates of a difficult-to-estimate quantity, the age-specific relative risk of death
with dementia (versus without dementia). Finally, I will use the competing-risks model to
5

simulate the effects of interventions that delay onset of dementia or reduce its risk
throughout old age.
My findings suggest that the lifetime risk of dementia for an average adult are
considerably higher than estimates extrapolated from non-national samples (Seshadri &
Wolf 2007; Seshadri et al. 1997). Furthermore, my simulations suggest that, even in a
population subject to interventions that substantially delay or reduce the risk of dementia,
more than 20% of dementia-free 70-year-olds are likely to develop the disease before
they die. The results suggest a widespread and underappreciated need to prepare for a
life stage with dementia.

Incident diabetes and mobility limitations: reducing bias using risk-set matching
Although diabetes is an increasingly important cause of death in the U.S. (Murray
2013), its consequences in terms of morbidity are also important. In Chapter 3, I
investigate the relation between incident diabetes and the accumulation of mobility
limitations using the Health and Retirement Study (HRS), a longitudinal survey
representative of the U.S. population above age 50, covering 1992 to 2010. There is no
agreed-upon method for estimating functional limitations associated with chronic
conditions in the presence of comorbidities. Although diabetes prevalence and physical
functional limitations are strongly correlated, the level of rigor of the studies showing this
correlation is fairly low (Wong & Gregg 2013). Most studies, for example, ignore the
possibility of reverse causality: mobility limitations can increase the risk of diabetes by
making persons more sedentary (Bardenheier, Gregg, Zhuo, Cheng, & Geiss 2014).
6

Studies looking at diabetes presence as a risk factor for mobility limitation also cannot
control for the time-ordering of covariates, even though many personal characteristics can
both cause and result from diabetes (Narayan et al. 2011). Recent advances in propensityscore matching techniques have not been applied to the study of chronic diseases.
Chapter 3 addresses these gaps in the literature by investigating the role of
diabetes incidence, rather than prevalence, in subsequent mobility decline. The long
duration and time-invariance of questions about diabetes presence and functional
limitations in the HRS allows the investigator to observe both incident diabetes cases and
a long subsequent accumulation of mobility limitations. The rich data on socioeconomic
and health backgrounds of subjects also allow for more robust controls for confounding
variables compared to most prior literature. The innovative method of risk-set matching
non-parametrically controls for time-varying onset of diabetes and of time-varying and
time-invariant covariates. Cases and controls not only look similar in the cross-section;
they have similar pre-exposure trajectories. This procedure generates a stronger, lessbiased control group than the extant literature. The chapter illustrates one approach that
can be used to study the contribution of a specific disease to physical functioning
limitations in the presence of multiple comorbidities.
The results show that individuals who developed diabetes subsequently
accumulated more mobility limitations than matched controls. In each pair of case and
control, subjects were followed for the same length of time both before and after diabetes
onset. The magnitude of the association between diabetes and mobility limitations is
smaller than that presented in most of the prior literature; however, there is reason to
7

believe my estimate is less biased. More practically, there is a great deal of room for
better diabetes management to reduce the burden of physical functioning limitations
associated with diabetes.

8

1
1.1

The Cohort Dynamics of Diabetes in the United States

INTRODUCTION
Diabetes is a leading cause of death in the United States (Murphy, Xu, &

Kochanek 2013). A recent meta-analysis estimates that people with diabetes have a 5080% increased risk of disability, including impaired mobility, activities of daily living,
and instrumental activities of daily living, compared to people without diabetes (Wong et
al. 2013). The prevalence of diabetes among adults is approximately 12%, corresponding
to approximately 26.1 million adults with diabetes in 2005-10 (Y. J. Cheng et al. 2013).
The incidence and prevalence of type 2 diabetes, which accounts for over 90% of
diabetes cases (American Diabetes Association 2012), are clearly related to factors in an
individual’s past. In particular, individuals’ own histories of obesity and smoking (Luo et
al. 2013; Yeh, Duncan, Schmidt, Wang, & Brancati 2010) have been shown to affect the
risk of developing diabetes. Of these risk factors, the relationship between obesity history
and diabetes incidence has been studied more extensively. One study found a steep
gradient in the lifetime risk of diabetes based on body mass index (BMI, measured in
kilograms per meters squared) at age 18. Males in the optimal BMI range of 18.5 to 25
kg/m2 at age 18 had a 19.8% lifetime risk of diabetes, while males with BMI in the obese
range of 30 to 35 kg/m2 at age 18 had a 57.0% lifetime risk of diabetes (Narayan et al.
2007). A European cohort study found that the earlier in life that subjects gained weight,
the more likely they were to develop diabetes (Schienkiewitz, Schulze, Hoffmann, Kroke,
& Boeing 2006). Among subjects in the Framingham Heart Study, each additional two
years of obesity were associated with about a 12% increased odds of developing diabetes
9

(Abdullah et al. 2011). In the National Longitudinal Study of Adolescent Health,
persistent obesity was associated with twice the risk of diabetes prevalence compared to
adult-onset obesity (The, Richardson, & Gordon-Larsen 2013). In the CARDIA study,
each additional year a person was obese increased their odds of developing diabetes by
4% (Reis et al. 2013). These and other studies indicate that obesity over the life course is
an important predictor of diabetes incidence.
In this paper, we investigate the rise in diabetes in the United States through the
lens of birth cohorts. Previous studies examining changes in diabetes prevalence over
time have compared one calendar-year period to another (Bullard et al. 2013; Y. J. Cheng
et al. 2013). However, like other chronic diseases, type 2 diabetes is the result of
cumulative processes that develop over a lifetime. A full understanding of the prevalence
of diabetes at a moment in time requires reference to the past, a past that is embodied in
the birth cohorts alive during that period. Because histories in a birth cohort are persistent
– characteristics of a birth cohort established at age 25 remain the age-25 characteristics
of that cohort as it ages – we expect to find “cohort effects” that differentiate one birth
cohort from another as they age.
Birth cohorts not only embody a history of exposures, they are also the
appropriate vehicle for calculating disease incidence. We take advantage of this
opportunity to present new estimates of the age-pattern of diabetes incidence in the
United States. These are the first estimates of incidence that use measured data in a
nationally representative sample. Previous national estimates of diabetes incidence used

10

retrospective reports of individuals rather than biological indicators and provided little
age detail (Geiss et al. 2006; Narayan et al. 2003).

1.2

METHODS

Population and data collection
In order to investigate the dynamics of diabetes in the United States, we use data
from the National Health and Nutrition Examination Surveys (NHANES). We employ
data from NHANES III, conducted in two phases, 1988 to 1991 and 1991 to 1994; and
from the Continuous NHANES that began in 1999, for which data are released in twoyear cycles. We pool adjacent data-release cycles of Continuous NHANES to obtain
three observation periods from Continuous NHANES: 1999 to 2002, 2003 to 2006, and
2007 to 2010. NHANES is a complex, multi-stage probability sample of the U.S. civilian
non-institutionalized population. Participants complete a home interview and are then
examined in a mobile examination center, which includes sampling participants’ blood
for laboratory tests. Participants are randomized into morning or afternoon examinations,
and the morning examinees are asked to fast for at least nine hours prior to the
examination. Whenever possible, NHANES uses consistent laboratory procedures over
time to facilitate analysis of trends in population health. The National Center for Health
Statistics (NCHS) provides extensive documentation of NHANES survey, examination,
and laboratory procedures on its website (National Health and Nutrition Examination
Survey 2012). The characteristics of the NHANES study sample are reported elsewhere
(Bullard et al. 2013; Y. J. Cheng et al. 2013).
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There were 88,224 individuals examined during our study periods. We exclude
individuals below age 20 (n=40,899), above age 80 (n=3,558), or who were pregnant
(n=1,510). We also exclude individuals who were exactly 20 years old when surveyed in
2010 (n=105) because these individuals would not comprise a complete birth cohort, as
described below. We also exclude subjects with missing HbA1c values (n=2,022). The
final analytic sample for HbA1c-based measures consists of 40,130 observations, with
7,011 observations from Phase 1 of NHANES III, 7,427 from Phase 2 of NHANES III,
7,778 from NHANES 1999-2002, 7,755 from NHANES 2003-2006, and 10,159 from
NHANES 2007-2010.

Definition of diabetes
We rely on laboratory results, rather than self-reported diagnoses, because the
latter fails to capture the considerable number of individuals in the US population with
undiagnosed diabetes. A 2010 study estimated that 3.9 million individuals above age 20
had undiagnosed diabetes, representing 19% of the diabetic population (Cowie et al.
2010). Furthermore, intertemporal comparisons based on self-reported diagnosis are
complicated by the fact that criteria for diagnosing diabetes in the clinical setting have
changed (Gregg et al. 2004; Stokes & Mehta 2013).
Our primary definition of diabetes is based on HbA1C, which was first measured
in NHANES III. This measure reflects average glycemia over a prolonged period and
thus has more intra-subject stability than the leading alternative, a measure of fasting
plasma glucose (FPG) (Bonora & Tuomilehto 2011). Furthermore, HbA1c-based
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measures of diabetes are more strongly associated with cardiovascular disease and death
than are FPG-based measures (Selvin et al. 2010). Finally, only 54% as many
observations of diabetes status are available in NHANES using FPG as using HbA1c. A
sensitivity analysis defined diabetes presence as FPG ≥ 126 mg/dL.
Several changes in laboratory measurement of HbA1C occurred over the course
of Continuous NHANES (detailed elsewhere (Bullard et al. 2013)), but we follow the
NCHS recommendation and the methods of recent studies and used HbA1C data without
any corrections or adjustments (Bullard et al. 2013; Y. J. Cheng et al. 2013). Individuals
are considered diabetic if they had HbA1c ≥ 6.5% (48 mmol/mol) (American Diabetes
Association 2012). Because diabetes medication is expected to reduce glycemia, the
HbA1c values of medicated persons might not capture their diabetes status correctly;
therefore, all individuals who reported taking diabetes medication are considered
diabetic. In our sample, there were 4,678 individuals who met our definition of having
diabetes. There were 896 individuals, or 19.2% of the group with diabetes, who reported
taking diabetes medication and who had HbA1c < 6.5%.

Cohort assignment
Birth cohorts must be constructed from repeated cross-sections because NHANES
does not repeatedly sample the same individuals over time. We calculate each
individual’s birth year using the equation Birth cohort = Period - Age. For the purpose of
calculating birth cohorts, Period is defined as the midpoint of the NHANES wave or
phase: April 21, 1990 for Phase 1 of NHANES III, April 23, 1992 for Phase 2 of
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NHANES III, and January 1 of the second year of each data release cycle of Continuous
NHANES. In a recent study of cohort obesity patterns that used NHANES data and the
same procedure for calculating birth years, results were robust to alternative
specifications of period (J. M. Lee et al. 2010). Age is the age of the individual, in
completed years, at the time of the survey. To ensure large enough age-cohort cells, we
analyze cohorts born in ten-year-wide intervals (1910 to 1919, 1920 to 1929, etc.). Using
this approach, we obtain a total of 8 ten-year birth cohorts between 1910-1919 and 19801989. This method involves assuming that upon reaching age 20, diabetes prevalence is
not affected by migration. We test the sensitivity of our results to this assumption by
excluding foreign-born individuals from the sample.

Statistical methods
Prevalence is calculated as the proportion of individuals in the given age-period or
age-cohort cell with diabetes as defined above. Calculations are adjusted for complex
survey design using strata and primary sampling units provided by the National Center
for Health Statistics (NCHS), along with survey weights. For HbA1c, we use the final
examination weight provided by NCHS; because we pool adjacent data release cycles of
Continuous NHANES, we divide the examination weights in Continuous NHANES by 2,
as recommended by NCHS (National Health and Nutrition Examination Survey 2006).
We use least squares to model the age-, cohort- and period-patterns of diabetes
prevalence in the U.S. population, using the following regression models:
Age/Cohort model:

ln(Yia) = α +βaXa + βiXi
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[1]

In this equation, Yia is the proportion of the population in cohort i at age a with diabetes,
Xa is a dummy variable indicating that the observation pertains to age a, and Xi is a
dummy variable indicating that the observation pertains to cohort i.
Age/Period model:

ln(Yia) = α +βaXa + βpXp

[2]

Here, Yia and Xa are defined as in Equation 1 and Xp is a dummy variable indicating that
the observation pertains to period p.
Age/Period/Cohort model: ln(Yia) = α +βaXa + βpXp + γCoh_ob

[3]

Yia, Xa, and Xp are defined as in Equation 2 and Coh_ob is a continuous variable
representing the prevalence of obesity at age 25 in the cohort corresponding to the given
age and period. We use age 25 because NHANES inquired about weight at that specific
age. Obesity at age 25 serves as a measure of a cohort’s history of obesity. The use of a
continuous variable to represent birth cohort influences avoids the identification problem
that any two of age, cohort, and period indicators can be linearly combined to produce the
third (Mason & Fienberg 1985).
Each prevalence estimate is weighted by the number of observations that gave rise
to it in order to give more weight to values estimated with greater precision. The log
specification implies that cohort membership affects an age-pattern of prevalence
multiplicatively; a simple additive specification would suggest implausibly that the agepattern of prevalence is shifted up or down by the same amount at each age, with no
cohort effect on prevalence beyond the earliest age.
Birth-cohort obesity prevalence is estimated using age-25 weight and height recall
data in Continuous NHANES waves 1999-2008. Height recall was only asked of
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participants aged 50 and over; for younger individuals we used self-reported current
height. We identify birth cohorts by subtracting age from survey year, using the
beginning of the second year of each of the waves (e.g., 2000.0 for 1999-2000) and
aggregate them into five-year wide intervals. The earliest and most recent birth cohorts
for whom cohort obesity is calculated are the 1920-1924 and 1975-1979 birth cohorts,
respectively. Thus, the age-period-cohort model excludes prevalence estimates that drew
exclusively from the oldest or youngest birth cohorts (born 1910-1919 and 1980-1989).
Appendix A.1.1 shows a table of the cohort-obesity prevalence values used in this study.
The examination of diabetes prevalence within birth cohorts allows us to estimate
the age-specific incidence of diabetes. In essence, this estimate is made by dividing the
prevalence of non-diabetes in a birth cohort at one age interval (e.g. 50 to 54) by the
prevalence of non-diabetes in the same birth cohort in the adjacent, younger age interval
(e.g. 45 to 49) and adjusting for the fact that people without diabetes die at lower rates
than the general population. The prevalence estimates used in this calculation are based
upon the age coefficients estimated from the age/cohort model, presented in Figure 3B.
These summarize the age-pattern of prevalence revealed within eight birth cohorts,
adjusting for cohort-specific effects. Life tables for individuals without diabetes and for
the general population are estimated using pooled data from NHANES III and
Continuous NHANES (1999-2004 waves) cohorts linked to deaths in the National Death
Index through 2006 (National Health Interview Survey (1986-2004) 2009). A discrete
hazards model on a person-month file is employed to generate the underlying risks for
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predicting mortality rates. The model is implemented on baseline ages 20-74. There were
2,903 deaths among 25,971 respondents.

Derivation of formula for diabetes incidence in a cohort
Suppose that 20% of a cohort has diabetes at age 30 and 25% of that cohort has
diabetes at age 35. Then the incidence of diabetes (number of new cases per diabetes-free
member of the population) between ages 30 and 35 is approximately .05/.80=.0625. That
figure refers to incidence over a five-year period, whereas incidence is normally
measured annually. An annualized rate would be .0625/5=.0125. This figure is based on
the number who are free of diabetes at the beginning of the interval, whereas incidence is
typically measured using a denominator measured at the middle of the interval. So the
corrected figure is (.05/.775)/5=.0129.
This calculation makes three basic assumptions: (1) Migration does not affect
birth cohort prevalence; (2) Those with diabetes at age 30 do not become diabetes-free by
age 35, and (3) Those with diabetes at age 30 have the same probability of dying by age
35 as those who were diabetes-free at age 30. In constructing our estimates of the
incidence of diabetes, we retain assumption 1 and 2, that migration does not affect
prevalence and that those who enter the diabetic state leave it only by death (see
Discussion section for analysis of remission). To check the sensitivity of our results to
Assumption 1, we excluded foreign-born individuals from our sample, and results were
not substantially altered (see Appendix A.1.6). We address Assumption 2 in the
Discussion section below. However, Assumption 3 is demonstrably untenable (Stokes &
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Mehta 2013). Accordingly, our estimates of diabetes incidence adjust for the higher
mortality of those with diabetes.
We develop the estimation formula first by referring to the population at exact
ages and then substituting equivalent formulas for the population at discrete age intervals.
Under our assumptions, the diabetes-free population is subject to two sources of
decrement, incident diabetes and death (Preston et al. 2001).
0
5𝑝𝑥

= exp(−5(𝜇𝑥0 + 𝛿𝑥0 )) ,

[4]

where
5

p xO

= probability of surviving in the disease-free state from age x to age x+5 for a

person free of diabetes at age x,

 xO = death rate at age x for a person free of diabetes,
 xO

= rate of acquiring diabetes (incidence rate) at age x for a person free of diabetes.
5𝑝𝑥

= exp(−5𝜇𝑥 ),

[5]

where
5

px

= probability of surviving from age x to age x+5 for a randomly-chosen member of

the population

x =

death rate at age x for a randomly-chosen member of the population.
Equations 4 and 5 assume that death rates and the incidence rate of diabetes are

constant in the age interval x to x+5, producing the exponential functional form.
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Call the non-diabetes population at age x N xO and the total population at age x 𝑁𝑥 .
Then the prevalence of non-diabetes at age x is
N xO
x 
Nx .

The prevalence of non-diabetes in the same cohort at age x+5 is
 x 5 

N xO5 N xO exp[ 5(  xO   xO )]

N x 5
N x exp[ 5 x ]

= Π𝑥 exp(−5𝛿𝑥0 ) exp(−5(𝜇𝑥0 − 𝜇𝑥 )).

[6]

Rewriting equation 6 gives
exp(−5𝛿𝑥0 ) =

Π𝑥+5 exp(−5𝜇𝑥 )
Π𝑥 exp(−5𝛿𝑥0 )

or
1

Π𝑥+5 ∗ 5𝑝𝑥

5

Π𝑥 ∗ 𝑀5𝑝𝑥0

𝛿𝑥0 = − ln(

),

[7]

where
M
5

p xO

= probability of surviving the risk of death from x to x+5 for a diabetes-free person

at age x.
Equation 7 shows that the incidence rate of diabetes between ages x and x+5 can
be derived from the ratio of non-diabetes prevalence at x and x+5 and from differences in
the survival probabilities between the entire population and the diabetes-free population
over that age span. It also shows why a moving average of incidence estimates made
using this equation is appropriate: errors in prevalence estimates at any particular age will
19

appear in the numerator of one age-specific incidence estimate and in the denominator of
the adjacent incidence estimate.
Substituting expressions for discrete five-year intervals into the equivalent terms
in Equation 7 gives
O

10

1
5

 x   ln[ 5

 x 5
5x

5
M
5

Lx 5
LOx5

L
]
L ,

5 x
M O
5 x

[8]

where
O

10

 x = rate of developing diabetes for a non-diabetic person in the age interval x to x+10,

5

x

5

Lx

M
5

= prevalence of non-diabetes at ages x to x+5

= person-years lived between ages x and x+5 in a life table for the population

LOx

= person-years lived between ages x and x+5 in a life table for persons free of

diabetes.
O

We interpret

10

 x as pertaining to the age interval x+2.5 to x+7.5, i.e. the five-

year age span at the middle of the ten-year age interval x to x+10. We use equation 8 for
our incidence estimates in this study, assuming the incidence rate and differential
mortality are constant within the five-year age intervals used. Values of 5Π𝑥 are
calculated from fitted values in the age-cohort model of prevalence. Values of 5L𝑥 and
𝑀 𝑂
5L𝑥 come

from the life tables as described above in the Statistical Methods section.

All statistical analysis was performed using Stata version 11 (StataCorp, College
Station, TX). Standard errors were estimated using first-order Taylor series linearization.
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1.3

RESULTS

Prevalence Estimates and Modeled Age and Cohort Patterns
Figure 1-1 plots estimates of age-specific diabetes prevalence during the four
observation periods under study. The underlying values and their standard errors are
reported in Appendix Tables A.1.2a and A.1.2b. As reported elsewhere (Y. J. Cheng et
al. 2013), there is a general upward trend in prevalence at each age.
Figure 1-1 shows a pattern in which the prevalence of diabetes declines at some
set of ages above 60-64 in each of the four periods. Such a decline could be produced by
higher mortality rates among those with diabetes than among those without. However, we
show below that this pattern of decline with age is not present when prevalence rates are
arrayed by birth cohort. In other words, the declines in prevalence with age in Figure 1-1
result from the increasing prevalence of diabetes among later-born cohorts.
Figure 1-2 presents estimates of diabetes prevalence among birth cohorts. It is
clear that prevalence is rising from one birth cohort to the next, even at younger ages
where prevalence is low. Furthermore, prevalence continues to rise even at the oldest
ages, which is consistent with a continued positive incidence of diabetes as cohorts age.
Declining prevalence with age, a pattern suggested by period data, is not observed among
real birth cohorts as they age.
The age-pattern of diabetes, as well as changes in diabetes prevalence from birth
cohort to birth cohort, are summarized by our statistical model. Figure 1-3 plots the
coefficients for each birth cohort in the age/cohort regression model. That the coefficients
are monotonically increasing shows that more recent birth cohorts have higher diabetes
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prevalence than older cohorts. The increase is exceptionally rapid among cohorts born
after 1950-59. The implication of the cohort coefficients is that the prevalence of diabetes
at any age for the cohort born 1980-89 will be nearly triple that of the cohort born in
1950-59 and 4.9 times that of the cohort born in 1910-19 (derived from Appendix Table
A.1.3a).
Just as the age/cohort model produces rapidly increasing cohort effects, the
age/period model produces rapidly rising period effects. This nearly straight-line increase
in prevalence across periods is shown in Figure 1-4 (see Appendix Table A.1.3b for
actual values). By themselves, there is nothing in Figures 1-3 and 1-4 that would indicate
which model is preferred. Both models produce R2 values above 0.94. But when we add a
cohort variable to the age/period model, the prevalence of obesity at age 25, the period
effects nearly disappear, as shown in Figure 1-4 (Appendix Table 3c). They also become
statistically insignificant.
Figure 1-5 compares the age-patterns of diabetes prevalence that are produced by
the age/cohort model, the age/period model, and the age/period/cohort model. By far the
most level age pattern is produced by the age/period model. As argued earlier, that age
pattern is misleading because it fails to account for the rise in diabetes prevalence from
one birth cohort to the next. As was suggested by a comparison of Figures 1-1 and 1-2,
the age pattern of diabetes prevalence in a birth cohort is steeper than that in a period.
The age-pattern in the age/period model becomes much steeper when birth-cohort obesity
is introduced, as shown in Figure 1-5. The age-pattern identified in the age/period/cohort
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model is very similar to that in the age/cohort model. The same pattern of results holds
when FPG rather than HbA1c is used to define diabetes (Appendix A.1.4).

Incidence estimates
Based on Equation 8 above, Figure 1-6 shows the age pattern of diabetes
incidence that is implied by the age pattern of prevalence that we have uncovered. The
values on the graph apply to the cohort born 1950-1959, but the shape of the curve is the
same for all birth cohorts. The age-pattern of incidence rises to a peak in the age interval
55 to 64 (centered at age 60) and then declines slowly. At its peak from ages 55 to 64, for
the cohort born 1950-1959, approximately 1.1% of the diabetes-free population will
develop diabetes each year. Appendix A.1.5 presents numerical details of our incidence
estimates. As shown in Appendix A.1.6, the age pattern of diabetes incidence is similar
when foreign-born subjects are removed from the sample, suggesting that our results are
not sensitive to the assumption that migrants experience the same relevant rates as nativeborn individuals.

Sensitivity of results to threshold choice
To examine the sensitivity of results to the choice of the HbA1c threshold, we
adopt a threshold of HbA1c levels ≥ 6.0%. Recent guidelines from the American
Diabetes Association consider individuals at this level to be at “very high risk” of
incident diabetes (American Diabetes Association 2012). See Appendix A.1.7 for a
discussion of this choice of threshold. Using this lower threshold, we estimate the
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prevalence of being “at least at high risk” of diabetes over time and across birth cohorts,
as shown in Appendix Figures A.1.7a and A.1.7b. 7,370 individuals in our sample met
the more inclusive criterion. A comparison of Figure 1-2 to Appendix Figure A.1.7b
shows that the increase across birth cohorts in age-specific prevalence of “at least highrisk” is even more striking than that using the higher cut-off. In particular, the higher
prevalence seen in more recent birth cohorts appears at earlier ages in “at least high-risk”
than it does in diabetes itself.
We also estimate age/period, age/cohort, and age/period/cohort models of “at least
high-risk” prevalence. The patterns described above are largely replicated using the lower
cut-off. Consistent with the higher level of prevalence, the rise in prevalence across ages
and birth cohorts is greater when HbA1c ≥ 6.0% is used. However the introduction of
obesity at age 25 into the age/period model has much the same effect as when HbA1c ≥
6.5% is used; it steepens the age effects and reduces the period effects, though a
significant period effect remains in the most recent period (see Appendix Figures
A.1.7c-7e and Figure 1-4). Once again, this result places the spotlight on birth cohort
influences in the rise of diabetes in the United States. Appendix Tables A.1.7a-7c
present numerical details of the results of our modeling of the prevalence of HbA1c ≥
6.0%.

1.4

DISCUSSION
Birth cohorts are an attractive vehicle for investigating changes in the prevalence

of diabetes because prevalence at any age is a cumulative product of influences in the
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past. These influences manifest themselves over the lifetime of birth cohorts, creating
close associations in the prevalence of diabetes across age within a cohort.
We show that the prevalence of diabetes in the United States is rapidly increasing
from one birth cohort to the next. We demonstrate this increase graphically and by means
of an age/cohort model. The increase is especially rapid across cohorts born after 195059.
Our results also reveal that the pattern of increase with age in the prevalence of
diabetes is considerably faster within a birth cohort than it is across ages in a particular
period. The increase with age during any particular period is too mild, or even negative,
because it does not account for the higher levels of diabetes evident among more recent
birth cohorts.
An additional suggestion of the importance of birth cohort influences on diabetes
prevalence is supplied by our age/period/cohort model. While an age/period model shows
sharply increasing period effects, the addition of a term measuring birth cohort obesity at
age 25 renders the period effects small and insignificant. This result indicates that birth
cohort influences – in particular, birth cohort obesity levels – are important determinants
of diabetes prevalence.
An innovation of our approach is that we convert estimates of birth cohort
diabetes prevalence to estimates of incidence. Such estimates cannot be made using
period data alone without the extreme assumption that no population rates are changing
(Greenland & Rothman 2008). This assumption is clearly not warranted in the case of
diabetes, as shown in Figure 1-1. But such calculations of incidence can be made by
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comparing prevalence at different ages for the same birth cohort since any changes in
prevalence within a birth cohort must be attributed to some combination of new
diagnoses (incidence), differential mortality by diabetes status, and recovery (if any). To
estimate incidence, we use the age effect coefficients from the age/cohort model, which is
based on observations across eight birth cohorts. We demonstrate that the incidence of
diabetes among diabetes-free persons rises steadily to a peak at ages 55 to 64 and then
declines slowly.
To the best of our knowledge, these are the first estimates of the age-pattern of
diabetes incidence that are based on measured data in a nationally-representative sample.
Other estimates of age-patterns of diabetes incidence are few and inconsistent. Age
patterns of diabetes incidence that peak and then decline are found in some populations
(Berger, Stenström, & Sundkvist 1999; Khan et al. 2011; McDermott, Li, & Campbell
2010; Pavkov et al. 2007). Other studies find that incidence continues to rise with age
(Thunander et al. 2008; Wilson, Anderson, & Kannel 1986) or levels off at older ages
(Geiss et al. 2006; Monesi et al. 2012). Annual estimates of incidence in the U.S. from
the Centers for Disease Control and Prevention (CDC), which are based on retrospective
self-reports, show a peak in the age interval 45-64 in some years and at ages 65-79 in
other years (Centers for Disease Control and Prevention 2012). Experimental evidence
suggests a biological mechanism for increasing incidence with age at the individual level
(H.-Y. Lee et al. 2010). One possible explanation for the peak and decline in diabetes
incidence in a birth cohort is population heterogeneity in vulnerability to diabetes, with

26

the most vulnerable individuals being successively selected out of the diabetes-free
population as birth cohorts age.
Our study has several limitations. We assume that migration does not affect the
prevalence of diabetes in birth cohorts. When we removed foreign-born respondents from
the sample, however, the pattern of our results was essentially unchanged (e.g. Appendix
A.1.6). We also assume no age-cohort interactions. We tested this assumption by
including interactions between a continuous variable for age and indicators for the three
birth cohorts that provided the most prevalence estimates; coefficients on these
interaction terms were not statistically significant (p>.15 in all cases).
The small sample sizes in NHANES required us to use ten-year wide birth cohorts
and assume homogeneity within those birth cohorts. As a specification check, we divided
the birth cohorts into different ten year intervals than reported in this paper (1915 to
1924, 1925 to 1934, etc.). Resulting patterns of prevalence were similar to the results
presented here (e.g. Appendix A.1.8).
The NHANES data do not permit distinguishing between type 1 and type 2
diabetes. However, because type 2 accounts for about 90-95% of all diabetes cases
(American Diabetes Association 2012), this was not a serious limitation.
We categorized as diabetic individuals below the 6.5% HbA1c threshold who reported
taking medication for diabetes. On the other hand, we did not categorize as diabetic
individuals below the 6.5% threshold with self-reported diabetes because we assume that
the large majority of this group was assessed using alternative diagnostic criteria, such as
FPG or Oral Glucose Tolerance Test. Prior research indicates that relative to these
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measures, the HbA1c test identifies as diabetic a smaller group of high-risk individuals
(Cowie et al. 2010). For this reason, we did not assume that individuals with self-reported
diabetes were ever above the HbA1c threshold for diabetes.
Our method for estimating diabetes incidence assumes that mortality differences
between people with and without diabetes have been constant; the literature on this
question is unresolved (Gregg et al. 2012; Gregg, Gu, Cheng, Narayan, & Cowie 2007;
Stokes & Mehta 2013). Our calculations also assume that there is no remission once the
diabetes-defining threshold is reached (i.e. one can only exit the diabetic state through
death). Remissions would offset new cases and produce an underestimate of the
incidence rate. The principal source of remission of diabetes is bariatric surgery.
According to the American Society for Metabolic and Bariatric Surgery (ASMBS), the
number of procedures reached 103,000 in 2003 (National Institute of Diabetes and
Digestive and Kidney Diseases 2011). There were approximately 21,708,000 Americans
aged 20+ with HbA1c values of 6.5% or greater in that year (Y. J. Cheng et al. 2013; U.S.
Census Bureau 2005). Assuming that all those who had the surgery had diabetes, the
annual rate of surgery among people with diabetes was .00497 in 2003. Two recent
randomized clinical trials investigated the efficacy of bariatric surgery among those with
diabetes. One found a one-year success rate in reducing HbA1c below 6.0% of 42%
(Schauer et al. 2012) and the other a two-year rate of success of reducing HbA1c below
6.5% of 75% (Mingrone et al. 2012). If we assume that the higher figure applies to the 5year success rate required in our calculations, bariatric surgery would produce a
remission rate of (.75)(.00497) = .00373 among people with diabetes in 2003. Since the
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ratio of people without diabetes to people with diabetes in that year was 9.12 (Y. J.
Cheng et al. 2013), the rate of flow into the non-diabetic population as a result of
successful bariatric surgery was .00373/9.12 = .00041. This value compares to an
incidence rate above age 50 of about .010 in our calculations. So the incidence rate above
age 50 would be perhaps higher by the factor 1.04 if allowance were taken of remission
from bariatric surgery.
There are other sources of remission, of course, but in these two randomized
clinical trials the remission rates for very intensive non-surgical medical treatment was
only 12% (Schauer et al. 2012) and 0% (Mingrone et al. 2012). Due to the intensive
nature of the medical treatment, these findings can be considered an upper bound on
remission rates in the diabetic population at large. It is worth noting that projections of
future diabetes prevalence assume the cure rate for diabetes is zero (Boyle, Thompson,
Gregg, Barker, & Williamson 2010), and clinical guidelines imply that people who have
been diagnosed with diabetes are considered diabetic even if their blood glucose is under
control (Ali et al. 2013).
Two recent studies of individuals in NHANES found that secular changes in timeof-survey BMI explained some but not all of the secular increase in the prevalence of
diabetes and prediabetes (Bullard et al. 2013; Y. J. Cheng et al. 2013). Our findings also
implicate the rise in obesity for increases in diabetes but we use aggregate data on birth
cohorts and an historical rather than contemporary indicator of obesity. That both current
and past levels of obesity affect an individual’s risk of developing diabetes has been
demonstrated in prior research (Abdullah et al. 2011). Thus, our results are consistent
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with other analyses that identify increases in the prevalence of obesity as an important
factor in the rise in diabetes.
The prevalence of obesity has increased dramatically across recent US birth
cohorts. We have shown that birth-cohort prevalence of diabetes is associated with birthcohort levels of obesity at age 25. Because cohort effects persist as cohorts age, our
results suggest that diabetes prevalence is likely to continue increasing despite an
apparent plateauing of obesity in recent years (Flegal et al. 2012). Additional analyses
should investigate the implications of the birth cohort trends identified here for future
diabetes prevalence in the United States.
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Figure 1-1. Diabetes Prevalence across NHANES Waves
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Data: National Health and Nutrition Examination Surveys (NHANES), United States,
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking
diabetes medication. Values are weighted to reflect the contemporary U.S. population.
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Figure 1-2: Age-Specific Prevalence, by Decadal Birth Cohort
300

Prevalent cases per 1,000 persons

250

200

150

100

50

0
20

25

30

35

40

45

50

55

60

65

70

75

80

Age
1910-1919

1920-1929

1930-1939

1940-1949

1950-1959

1960-1969

1970-1979

1980-1989

Data: National Health and Nutrition Examination Surveys (NHANES), United States,
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking
diabetes medication. Values are weighted to reflect the contemporary U.S. population.

32

Prevalence as a Multiple of 1910-1919 Birth Cohort Prevalence

Figure 1-3: Age-Adjusted Diabetes Prevalence in Birth Cohorts Relative to those
born 1910-19
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The graph shows the age-adjusted prevalence of diabetes in each birth cohort as a
multiple of the age-adjusted prevalence for the 1910-1919 birth cohort.
Data: National Health and Nutrition Examination Surveys (NHANES), United States,
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking
diabetes medication. Estimates are weighted to reflect the contemporary U.S. population.
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Figure 1-4: Age-Adjusted Prevalence as a Multiple of 1988-94 Prevalence
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This figure shows age-adjusted prevalence as a multiple of age-adjusted prevalence in the
reference 1988-1994 period for the Age/Period model (diamonds) and Age/Period/Cohort
model (squares). Data: National Health and Nutrition Examination Surveys (NHANES),
United States, 1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least
6.5% or taking diabetes medication. Values are weighted to reflect the contemporary U.S.
population.
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Figure 1-5: Age Pattern of Diabetes Prevalence in Different Models
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This figure shows age-specific prevalence as a multiple of the prevalence at age 20-24 in
the Age/Cohort model (triangles), Age/Period model (diamonds), and Age/Period/Cohort
model (squares). Data: National Health and Nutrition Examination Surveys (NHANES),
United States, 1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least
6.5% or taking diabetes medication. Values are weighted to reflect the contemporary U.S.
population.
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Figure 1-6: Smoothed Age Pattern of Diabetes Incidence Using Prevalence Values
from Age/Cohort Model
Annual Incidence: New Cases of Diabetes Per 1,000 DiseaseFree Person-Years
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Incidence estimated from Age/Cohort model of diabetes prevalence and differential
mortality estimates, detailed in Statistical Methods section. Three-term moving average
of incidence is plotted. For graphical purposes, incidence values are plotted for the cohort
born 1950-1959, but the shape of the curve is the same for all birth cohorts. Data:
National Health and Nutrition Examination Surveys (NHANES), United States, 19881994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking
diabetes medication. Values are weighted to reflect the contemporary U.S. population.
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2
2.1

Lifetime risk of dementia in the United States

INTRODUCTION
Dementia is increasingly recognized as a major source of disease burden in the

United States (Murray 2013). A national study estimated that 3.4 million American adults
over 70 had dementia, corresponding to a prevalence of approximately 13.9% (Plassman
et al. 2007). Dementia imposed a financial cost of over $40,000 per affected person per
year, comparable to the financial costs of heart disease and cancer (Hurd et al. 2013).
Americans over 60 reported fearing dementia more than any other disease, including
cancer (Alzheimer’s Association 2014). As the U.S. population ages, the number of
Americans with dementia is very likely to increase in the coming decades (He & Larsen
2014; Kasper et al. 2015). Using nationally representative, longitudinal data, this study
will estimate the probability that an average dementia-free person will develop dementia
in the course of life.
An approach that incorporates the competing risks of death and dementia
incidence in a prospective cohort allows one to estimate the risk that the average
dementia-free individual will develop dementia in the future. It can also provide an
estimate of the related measures of dementia-free life expectancy and life expectancy
with dementia. These quantities are important for individuals, businesses, and
governments as they plan for retirement, save and contribute to pensions, and assess
future health care costs and caregiving needs. For demographers and epidemiologists,
these quantities provide meaningful insight into the question of whether long-run gains in
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survivorship are being experienced in healthy or unhealthy states (Crimmins & BeltránSánchez 2010; Crimmins et al. 2009).
Data from the Framingham Heart Study and from a national Canadian sample
have been used to report the lifetime risk of developing dementia using a competing-risks
framework (Carone, Asgharian, & Jewell 2014; Seshadri & Wolf 2007; Seshadri et al.
1997). Dementia-free life expectancy was reported for a large cohort in the Pacific
Northwest, known as the Adult Changes in Thought study (ACT) (Tom et al. 2015).
Though informative, the Framingham, Canadian, and ACT cohorts are not representative
of the U.S. population. For example, these cohorts had a larger proportion of subjects
who were white than did the U.S. as a whole. Studies have generally found that African
Americans have higher age-specific rates of mild cognitive impairment and of dementia
than whites (Katz et al. 2013; Sheffield and Peek 2011). As the nation gets more racially
and ethnically diverse, these cohorts are decreasingly representative of the U.S. elderly
population. Therefore, there is a need for estimates of lifetime risk of dementia from
nationally representative data.

2.2

METHODS

Sample and definitions
This study uses the Aging, Demographics, and Memory Study (ADAMS), a
nationally representative, longitudinal study of cognitive health and dementia conducted
in four waves from 2001 to 2009 (Langa et al. 2005). ADAMS, a probability subsample
of the Health and Retirement Study (HRS), examined adults aged 70 and older with a
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series of cognitive, psychological, and neurological tests, and conducted an extensive
medical history, an inventory of current prescription medications, a neurology-focused
physical exam, and a family/caregiver questionnaire. The testing was conducted in person
by trained technicians and nurses and supervised by neuropsychologists (Langa et al.
2005). Diagnostic criteria were based on the Diagnostic and Statistical Manuals of
Mental Disorders, DSM-III-R and DSM-IV, and final diagnosis of dementia was made by
a consensus expert panel of physicians (Heeringa et al. 2009; Langa et al. 2005). Detailed
descriptions of the ADAMS sample and assessment tools have been previously published
(Heeringa et al. 2009; Langa et al. 2005; Plassman et al. 2007).
According to the DSM, the essential feature of dementia is the development of
multiple cognitive deficits that include memory impairment and at least one of aphasia
(language deficit), apraxia (movement deficit), agnosia (deficit in recognition of objects
or senses), or executive functioning deficit (American Psychiatric Association 2000). The
cognitive deficits must represent a decline from past abilities and must be severe enough
to cause impairment in occupational or social functioning (American Psychiatric
Association 2000). The most common type of dementia is Alzheimer’s disease (AD),
which accounts for 60% to 80% of dementia cases. The next most common type is
vascular dementia, which alone accounts for about 10% of cases but which is often found
together with AD (Alzheimer’s Association 2014).
The initial wave of ADAMS, 2001-2003, examined 856 subjects to generate
baseline estimates of dementia prevalence in the U.S. (Plassman et al. 2007). The
subsequent waves followed 456 dementia-free individuals for dementia incidence
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(Plassman et al. 2011). The second wave focused on subjects whose baseline status was
“cognitively impaired, no dementia”; this second wave assessed subjects 16 to 18 months
after their baseline assessment. For the third and fourth waves, all living subjects who
were dementia-free at baseline were in the sampling frame. Subjects in the third wave
averaged 3.7 years since their most recent assessment, and subjects in the fourth wave
averaged 1.8 years since their most recent assessment (Plassman et al. 2011). Despite the
relatively long intervals between assessments, ADAMS investigators could determine,
based on informant reports, medical records, and clinical assessment, that a subject
experienced the onset of dementia at any time since the previous assessment. For
example, if a 72 year old subject was deemed dementia-free at baseline and then assessed
at age 76 and found to have dementia, investigators could determine that his age at the
onset of dementia was 73. The assignment of ages at dementia onset during the interassessment interval allows for the estimation of dementia incidence rates, rather than
probabilities. Thus the ADAMS data can be used to calculate age-specific incidence of
dementia, an essential ingredient in making estimates of lifetime risk.
Incidence rates in large age categories (below 80, 80 to 89, and 90+) have been
published in a prior study (Plassman et al. 2011). In that study, incidence was measured
as follows. First, the number of incident cases in the ADAMS sample, by age group, was
counted. This number was converted to a comparable figure for the U.S. population using
the sampling weights. Then, the number of person-years at risk for each ADAMS subject,
by age group, was determined as the number of years from the first ADAMS assessment
to the first of the following events: (1) dementia onset, (2) death, or (3) completion of the
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final ADAMS assessment. Finally, the number of person-years at risk in the sample was
converted to a comparable figure for the population using the sampling weights, and the
number of new cases in the population was divided by the number of person-years at risk
in the population (Plassman et al. 2011). Mortality rates were not specifically reported in
that study.
Mortality data for the current investigation come from ADAMS’ link to the
Health and Retirement Study’s mortality tracking via the National Death Index (NDI),
which provides vital status and, if deceased, month of death, as of December 2011. The
856 ADAMS subjects constitute the individuals at risk of mortality. I use the mortality
data to generate estimates of the age-specific ratio of mortality rates between those with
and those without dementia. Mortality rates for the entire U.S. population come from the
Social Security Administration (SSA) cohort life tables (Bell & Miller 2005).

Demographic methods
In a stationary population subject to a given life table, any two parameters among
disease incidence, prevalence, and differential mortality between those with and those
without the disease imply the third parameter (Preston, Heuveline, and Guillot 2001,
chapter 4). The ADAMS data allow for the estimation of all three parameters, as
discussed above; they therefore enable one to assess the stationary population
assumptions of the constancy of age-specific incidence rates and differential mortality
over time. Alternatively, if there is a strong basis for assuming the constancy of rates, one
can use estimates of two of the parameters along with the assumption of constancy of
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rates to derive the third parameter. I will use ADAMS incidence and prevalence estimates
and the assumption of stationarity to derive an estimate of differential mortality and to
estimate lifetime risk of dementia. Then I will relax the assumption of stationarity and
estimate differential mortality directly from the ADAMS data, producing a second set of
lifetime-risk estimates.
In the context of ADAMS and dementia, differential mortality is the parameter
about which there is least agreement in the literature on age patterns and functional form
(Guehne, Riedel-Heller, & Angermeyer 2005). Existing estimates of the ratio of mortality
among women age 75 to 84 with dementia to mortality among same-age women without
dementia vary from 4.07 in Canada (Ostbye, Hill, & Steenhuis 1999) to 2.59 in Spain
(Villarejo et al. 2011). Although this ratio is consistently found to decline with age, the
pace of decline varies widely across studies (James et al. 2014; Ostbye et al. 1999;
Tschanz, Corcoran, & Skoog 2004; Villarejo et al. 2011), making estimates of the age
pattern of differential mortality subject to strong parametric assumptions. The ADAMS
team has published estimates of age-specific prevalence and incidence to which I can
benchmark my own estimates (Plassman et al. 2007, 2011), but no comparable ADAMSbased estimates of differential mortality exist.
In this study, where ADAMS data go to 2009 and mortality data go to 2011, an
additional challenge in estimating differential mortality relates to censoring. Individuals’
dementia status is known as of their last ADAMS assessment, but mortality follow-up
continues for several additional years, during which time new cases of dementia go
unobserved. Thus the question arises of when to censor individuals whose last ADAMS
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assessment categorized them as without dementia. If one follows them as long as the
mortality follow-up allows, one will misclassify many deaths as deaths without dementia.
If one censors these individuals too early, one under-counts deaths and person-years
without dementia. In either case, the distortions to the estimated differential mortality are
potentially severe. The results will show that estimated differential mortality has the
largest standard error among the three parameters, and given underlying questions about
functional form and the censoring of individuals not diagnosed with dementia, it is likely
that standard errors of estimates of differential mortality do not capture all the uncertainty
associated with those estimates.
The difficulties in directly estimating differential mortality motivate the use of the
stationarity assumption of constancy of rates, and there is considerable evidence
suggesting that age-specific dementia incidence has been constant over the last decades
(Asgharian, Wolfson, & Zhang 2006; Ewbank 2004; Rocca et al. 2011). Since my
estimates cover only ages 70 and above, the time interval during which I would assume
constancy of incidence rates is relatively short. Given the evidence for stationarity and
the difficulties directly estimating relative risks of death, I will begin with a method that
assumes that age-specific dementia incidence and differential mortality have been
constant over time, deriving differential mortality from stationary-population relations
rather than estimating it directly.
Other studies do find declines over time in prevalence of moderate or severe
cognitive impairment (Langa et al. 2008; Manton & Ukraintseva 2005). Declines in
prevalence could be consistent with constant incidence if average duration of dementia
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declines, but these contrary findings provide some evidence against the stationarity
assumption. I will therefore conduct additional analyses using differential mortality I
estimate directly from the ADAMS data – despite the limitations of such estimation – and
not assuming a stationary population. Comparing the prevalence estimated at baseline in
ADAMS to that implied by my estimated incidence and differential mortality provides an
informal test of the stationarity assumptions: if the two prevalence series are concordant,
then the incidence and differential mortality that gave rise to baseline prevalence closely
aligns with the incidence and differential mortality observed longitudinally.

Approach 1: Assume constancy of incidence rates over time (stationary-population
approach)
Because of the small sample size in ADAMS, I fit simple models to generate
smooth age patterns of dementia prevalence (P) and incidence (h):
𝑙𝑜𝑔𝑖𝑡(𝑃𝑥 ) = 𝛼 + 𝛽𝑥,

[1]

𝑙𝑜𝑔𝑖𝑡(ℎ𝑥 ) = 𝛼′ + 𝛽′𝑥,

[2]

where x is exact age. This model broadly conforms to the functional form of the age
pattern of Alzheimer’s disease rates, and Alzheimer’s prevalence and incidence rates
have been shown to have similar functional forms (Brookmeyer & Gray 2000;
Brookmeyer et al. 2011; Ziegler-Graham, Brookmeyer, Johnson, & Arrighi 2008). For
prevalence, I fit the model using logistic regression on the baseline ADAMS sample
(n=856). Baseline age was provided in completed years (“last birthday”), so exact age (x)
was the reported age plus 0.5.
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For incidence, I fit the model using a discrete-time logistic regression on a personyear data file (Allison 1984), using the 456 subjects followed longitudinally. Age of
dementia onset was reported in completed years, so, for incident cases, the exact age at
incidence was set at the reported age (last-birthday) of onset plus 0.5. Subjects who never
received a diagnosis of dementia from ADAMS investigators, including those who died
without a dementia diagnosis, were censored. Among the censored subjects, those whose
status at the end of the ADAMS study period was “alive, dementia-free” contributed
dementia-free person-years up to and including their exact age (in months) at their last
assessment. Censored subjects whose status at the end of ADAMS was “died without
dementia” contributed dementia-free person years until their exact age at death. For
example, if a subject’s status at the end of ADAMS was “died without dementia,” and
she died at age 78 and 5 months, then she contributed person-years of exposure until she
was 78.41666. Her death would be assigned to the interval between exact ages 78.0 and
79.0. The approach of carrying the last assessment of deceased individuals forward until
death is consistent with previous ADAMS reports (Plassman et al. 2011) and
recommendations based on simulations of censored time-to-dementia data (Leffondré,
Touraine, Helmer, & Joly 2013). It is based on the idea that if the deceased individuals
had survived and developed dementia, the investigators could have been able to observe
their dementia onset; decedents were therefore at risk of dementia onset until their deaths.
A sensitivity analysis will treat these two forms of censoring – death without dementia
and survival without dementia to the end of the study period – in a more consistent
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fashion by censoring surviving dementia-free subjects at the end of the ADAMS study
period rather than at their last assessment.
There is considerable evidence in the literature suggesting that age-specific
incidence rates of dementia do not vary by sex (Chêne et al. 2015; Plassman et al. 2011;
Ruitenberg, Ott, & Swieten 2001). When a sex term was included in Equation 2, its
coefficient was statistically insignificant (p>0.20).
Call the fitted prevalence vector (𝑛 𝑃𝑥 ), and the incidence vector (𝑛 ℎ𝑥 ); these are
the same for males and females. The 1920 birth cohort would have been aged 81 to 88
over the study period of ADAMS, making this cohort’s life table a good approximation
of the overall level of mortality in the population the ADAMS cohort represents. The
SSA life table for this cohort provides mortality rates (𝑛 𝑚𝑥 ), survivors to exact age x
(𝑙𝑥 ), and person-years lived in each age interval in the entire population (𝑛 𝐿𝑥 ); these
values are sex-specific. In other words, the level of mortality varies by sex, which will
generate sex-specific estimates of lifetime risk, but the other input quantities are constant
across sex. Employing the Sullivan method (Mathers & Robine 1997; Sullivan 1971) and
using single-year age intervals, the number of person-years lived without and with
dementia, respectively, in the age interval (x, x+1) are:
𝐷𝐹
1𝐿𝑥

= 1𝐿𝑥 (1 − 1𝑃𝑥 )

𝐷
1𝐿𝑥

= 1𝐿𝑥 ∗ 1𝑃𝑥 .

The assumptions of stationarity are sufficient for the Sullivan method to generate
unbiased and consistent estimates of person-years lived in each state (Imai & Soneji
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[3]
[4]

2007). Taking 𝑙70 as the radix for the entire population, I estimate the population with
dementia at exact age 70 as
𝐷
𝑙70
= 𝑙70 ∗ 𝑃70.0

[5]

𝐷𝐹
𝑙70
= 𝑙70 ∗ (1 − 𝑃70.0 ).

[6]

and dementia-free (DF) population as

I fill the life table as follows, assuming events occur on average halfway through
intervals. For survivors:
𝐷
𝑙𝑥+1
= (2 ∗ 1𝐿𝐷𝑥 ) − 𝑙𝑥𝐷 ,

[7]

𝐷𝐹
𝐷𝐹
𝑙𝑥+1
= (2 ∗ 1𝐿𝐷𝐹
𝑥 ) − 𝑙𝑥 .

[8]

The number of new dementia cases is
𝑑𝑒𝑚 𝐷𝐹
1𝑑𝑥

= 1𝐿𝐷𝐹
𝑥 ∗ 1ℎ𝑥 .

[9]

In Approach 1, I assume that individuals do not develop dementia and die in the same
single-year age interval. Therefore, the number of deaths from the dementia-free
population is
𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑑𝑥

𝐷𝐹
= 𝑙𝑥𝐷𝐹 − 𝑙𝑥+1
− 𝑑𝑒𝑚1𝑑𝑥𝐷𝐹 .

[10]

The death rate among the dementia-free population is
𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑚𝑥

=

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑑𝑥

⁄

𝐷𝐹
1𝐿𝑥

.

[11]

To derive the death rate among those with dementia, I first decompose the
mortality rate in the entire population into a weighted average of the mortality rates of the
population with and the population without dementia, where the weights are the
prevalence of dementia and its complement:
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1𝑚𝑥

= 1𝑚𝑥𝐷 ∗ 1𝑃𝑥 + 𝑑𝑒𝑎𝑡ℎ1𝑚𝑥𝐷𝐹 ∗ (1 − 1𝑃𝑥 ),

[12]

[ 1𝑚𝑥 − 𝑑𝑒𝑎𝑡ℎ1𝑚𝑥𝐷𝐹 ∗ (1 − 1𝑃𝑥 )]
⁄

[13]

which can be rearranged as
𝐷
1𝑚𝑥

=

1𝑃𝑥

.

Then the ratio of mortality rates (with dementia vs. without dementia) as implied by the
prevalence, incidence, and stationary population assumption is
1𝑅𝑅𝑥

=

𝐷
1𝑚𝑥
𝑑𝑒𝑎𝑡ℎ𝑚𝐷𝐹
1 𝑥

.

[14]

The primary quantity of interest is the lifetime risk of dementia for an age-a person
without dementia:
𝐿𝐹𝑇𝑀𝑎 =

𝑤 𝑑𝑒𝑚 𝐷𝐹
Σ𝑥=𝑎
1𝑑𝑥 ⁄
𝑙𝑎𝐷𝐹 ,

[15]

where w is the highest age interval. Also of interest is dementia-free life expectancy, the
average number of years a randomly chosen person age a can expect to live free of
dementia, under current rates:
𝐷𝐹𝐿𝐸𝑎 =

𝑤
𝐷𝐹
Σ𝑥=𝑎
1𝐿𝑥 ⁄ .
𝑙𝑎

[16]

Total life expectancy is as in a single-decrement life table:
𝐿𝐸𝑎 =

𝑤
Σ𝑥=𝑎
1𝐿𝑥⁄ ,
𝑙𝑎

[17]

and by construction, unconditional life expectancy with dementia – that is, the average
number of years an age-a person randomly chosen from the population can expect to live
with dementia, under current rates, is
𝐷𝐿𝐸𝑎 = 𝐿𝐸𝑎 − 𝐷𝐹𝐿𝐸𝑎 .
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[18]

We can also define conditional life expectancy without dementia as the average number
of years a dementia-free person of a given age can expect to live free of dementia:
𝐷𝐹𝐿𝐸𝑎′ = 

𝑤
𝐷𝐹
Σ𝑥=𝑎
1𝐿𝑥 ⁄
𝑙𝑎𝐷𝐹 .

[19]

This quantity is valuable because the number of dementia-free person-years lived above
age a for someone who already has dementia at age a is zero, and the people contributing
these zeros are counted in the denominator of Equation 16; they are not counted in the
denominator of Equation 19. The conditional DFLE is estimable using this method
because all person-years lived in a dementia-free state above age a are experienced by
people who were dementia-free at age a; the numerator and denominator therefore match.
𝑤
𝐷
𝐷𝐹
In contrast, (Σ𝑥=𝑎
1𝐿𝑥 )⁄𝑙𝑎 is not equal to the average number of years a dementia-free

person age a can expect to live with dementia, because some of the person-years lived
with dementia above age a – years contributing to the numerator – are experienced by
people who already had dementia at age a and who thus do not contribute to the
denominator.

Approach 2: No assumption of stationarity; estimate differential mortality directly from
ADAMS data
Disease prevalence at a point in time embodies a history of disease incidence and
differential mortality. Therefore, age-specific prevalence and incidence estimated in a
stationary population – that is, one in which incidence and differential mortality have not
changed over time – imply a unique pattern of differential mortality. If the population is
non-stationary, then past incidence and differential mortality embodied in current
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prevalence estimates do not necessarily convey information about current incidence and
differential mortality.
To estimate a current age pattern of differential mortality directly from the
ADAMS data, without assuming the population is stationary, I use a Gompertz-type
model of death rates as a function of an indicator for dementia presence, exact age x, and
their interaction, fit with a Poisson regression on a person-year data file (Loomis 2005).
Dementia status is modeled as a time-varying indicator to incorporate both baseline
prevalent cases and incident cases (Palloni & Thomas 2013). The model is:
ln(𝑚𝑥,𝑑𝑒𝑚 ) = 𝛼 + 𝛽1 𝑥 + 𝛽2 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎 + 𝛽3 𝑥 ∗ 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎.

[20]

As with the estimation of dementia incidence discussed above, subjects who died
without a dementia diagnosis during the ADAMS study period contribute dementia-free
person years until their exact age at death, and subjects who survived ADAMS without a
dementia diagnosis contributed dementia-free person years until their last ADAMS
assessment. Mortality data for the period after ADAMS (2009 to 2011) was used only for
those with a dementia diagnosis, whose state could not change until death. Not using
mortality data from the post-ADAMS period for individuals without a dementia diagnosis
avoids large misclassification errors whereby persons who develop dementia subsequent
to ADAMS would wrongly contribute deaths without dementia and person-years without
dementia to the calculations.
Based on Equation 20, the ratio of the mortality rate among persons with
dementia to that among persons without dementia – also known as the risk ratio, rate
ratio, or relative risk (RR) – is
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𝑅𝑅𝑥 =

exp(𝛼 + 𝛽1 𝑥 + 𝛽2 + 𝛽3 𝑥)
⁄exp(𝛼 + 𝛽 𝑥) = exp(𝛽2 + 𝛽3 𝑥). [21]
1

In this way, the ratio of the two mortality rates is estimated from the ADAMS sample,
but the actual values of the mortality rates can be adjusted to match national data with
many more deaths using the SSA 1920 cohort life tables. Consistent with most of the
literature, the ratio of mortality rates between those with and those without dementia were
held constant across sex (Agüero-Torres, Fratiglioni, & Guo 1999; Garcia-Ptacek et al.
2014; Johnson, Brookmeyer, & Ziegler-Graham 2007; Lönnroos, Kyyrönen, Bell, van
der Cammen, & Hartikainen 2013; Meller, Fichter, & Schroppel 1999; Villarejo et al.
2011; Witthaus, Ott, Barendregt, Breteler, & Bonneux 1999). When a sex term and a sexby-dementia-status interaction term were included in Equation 2, the coefficient on the
sex-by-dementia term was not statistically significant (p>0.30), providing additional
justification for keeping differential mortality constant across sex. As with the modeling
of incidence rates, pooling males and females to estimate differential mortality is useful
with a small sample size such as in ADAMS. In this model, the only quantity that
differed by sex was the overall level of age-specific mortality in the entire U.S.
population.
The inclusion of the interaction term with the coefficient β3 implies that the
excess risk of death associated with having dementia declines (assuming β3 is negative)
with age (Helmer, Joly, Letenneur, Commenges, & Dartigues 2001). This decline arises
from two related but distinct forces. The first is the aging of all the individuals in the
cohort: as the underlying risk of death rises with age for everyone, the excess risk of
death associated with dementia declines. The second force is heterogeneity in frailty
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within each group (Vaupel, Manton, & Stallard 1979). Heterogeneity within population
groups selects out the frailest individuals first. This force acts more strongly on the
higher-mortality group (people with dementia), leaving heartier individuals remaining. In
the context of dementia, heterogeneity could arise from changes with age in the average
duration of dementia or changes in the prevalence of the APOE e4 allele in the dementia
population relative to that in the non-dementia population (Ewbank 2004). This process is
similar to the consistent finding of black-white mortality differentials, which decline at
older ages (Eberstein, Nam, & Heyman 2008).
In a sensitivity analysis, subjects who survived ADAMS without a dementia
diagnosis were censored at the end of the ADAMS observation period, rather than at their
last ADAMS assessment, in parallel with the sensitivity analysis for incidence estimates.
By increasing the number of person-years lived without dementia and not changing the
number of deaths without dementia, the sensitivity analysis will reduce the estimated
mortality rate among the non-dementia population, raising the estimated mortality rate
ratio.
For a given age, the mortality rate for the entire population can be decomposed
into a weighted average of mortality rates of the diseased and disease-free populations,
weighted by the age-specific prevalence of the disease, as in Equations 12 to 14 above:
1𝑚𝑥

=

= 1𝑚𝑥𝐷 ∗ 1𝑃𝑥 + 𝑑𝑒𝑎𝑡ℎ1𝑚𝑥𝐷𝐹 ∗ (1 − 1𝑃𝑥 )

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1 𝑚𝑥

∗ 1𝑅𝑅𝑥 ∗ 1𝑃𝑥 + 𝑑𝑒𝑎𝑡ℎ1𝑚𝑥𝐷𝐹 ∗ (1 − 1𝑃𝑥 ).

The terms can be rearranged to solve for the mortality rate in the dementia-free
population:
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[22]

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑚𝑥

=

1𝑚𝑥⁄

( 1𝑃𝑥 ∗ 1𝑅𝑅𝑥 + 1 − 1𝑃𝑥 )

[23]

and in the population with dementia:
𝐷
1𝑚𝑥

=

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑚𝑥

∗ 1𝑅𝑅𝑥 ,

[24]

where the overall mortality rate vector 1𝑚𝑥 comes from the SSA life table, the agespecific prevalence is described below (see Equation 39), and the mortality rate ratio
(𝑅𝑅𝑥 ) is as above in Equation 21.
I then construct a multiple-decrement life table for the population without
dementia, incorporating elements of the increment-decrement life table to keep track of a
model population with dementia (Preston, Heuveline, & Guillot 2001). As with Approach
1, I use single-year age groups and assume no recovery from dementia. The overall rate
of decrement from the dementia-free population is the dementia incidence rate, which
comes from Equation 2, plus the mortality rate for the dementia-free population:
𝐷𝐹
1𝑚𝑥

=

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑚𝑥

+ 1ℎ𝑥 ,

[25]

and the probability of exiting the dementia-free population at a given age, assuming
decrements occur on average halfway through each age interval, is
𝐷𝐹
1𝑞𝑥

=

𝐷𝐹
1𝑚𝑥 ⁄

(1 + 0.5 1𝑚𝑥𝐷𝐹 )

.

[26]

The probabilities of exiting the dementia-free population as a result of dementia onset or
death, respectively, are:
𝐷𝑒𝑚 𝐷𝐹
1𝑞𝑥

𝑖𝑛𝑐𝑖𝑥
= 1𝑞𝑥𝐷𝐹 ∗ ( 1
⁄
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𝐷𝐹
1𝑚𝑥

),

[27]

𝐷𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑞𝑥

= 1𝑞𝑥𝐷𝐹 ∗ (

𝑑𝑒𝑎𝑡ℎ 𝐷𝐹
1𝑚𝑥

⁄

𝐷𝐹
1𝑚𝑥

).

[28]

Define 𝑙𝑥𝐷𝐹 as the number of dementia-free survivors to the xth birthday, so that the
number of exits from the dementia-free population, by type of exit, is
𝑖 𝐷𝐹
1𝑑𝑥

= 𝑙𝑥𝐷𝐹 ∗ 1𝑖𝑞𝑥𝐷𝐹 , 𝑖 = 𝐷𝑒𝑚, 𝐷𝑒𝑎𝑡ℎ.

[29]

The number of dementia-free survivors to the next age is
𝐷𝐹
𝑙𝑥+1
= 𝑙𝑥𝐷𝐹 − 𝐷𝑒𝑚1𝑑𝑥𝐷𝐹 − 𝐷𝑒𝑎𝑡ℎ1𝑑𝑥𝐷𝐹 .

[30]

For an approximation of the prevalence of dementia at age 70, I use the fitted
𝐷𝐹
value of prevalence for age 70.0 from Equation 1 in the life table, obtaining 𝑙70
as in

Equation 6. After age 70, the population with dementia is tracked as follows. The only
way to exit the population with dementia is death, so the probability of death with
dementia is
𝐷
1𝑞𝑥 =

𝐷𝑒𝑎𝑡ℎ 𝐷
1𝑞𝑥

=

𝐷
1𝑚𝑥⁄

(1 + 0.5 1𝑚𝑥𝐷 )

.

[31]

The size of the population reaching the xth birthday with dementia is defined as 𝑙𝑥𝐷 , so the
number of deaths is
𝐷𝑒𝑎𝑡ℎ 𝐷
1 𝑑𝑥

= 𝑙𝑥𝐷 ∗ 𝐷𝑒𝑎𝑡ℎ1𝑞𝑥𝐷

[32]

However, those who develop dementia while age x are subject to the risk of death 𝑚𝑥𝐷
once they develop dementia. If they develop dementia halfway through the age interval
on average, then the probability of death with dementia for these new cases in that
interval is
𝐷𝑒𝑎𝑡ℎ 𝐷
𝑛𝑒𝑤𝑞𝑥

=

𝐷
1𝑚𝑥⁄

(2 + 0.5 1𝑚𝑥𝐷 )
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[33]

and the number of deaths among new dementia cases is
𝐷𝑒𝑎𝑡ℎ 𝐷
𝑛𝑒𝑤𝑑𝑥

=

𝐷𝑒𝑚 𝐷𝐹
1𝑑𝑥

𝐷
∗ 𝐷𝑒𝑎𝑡ℎ
𝑛𝑒𝑤𝑞𝑥 .

[34]

The size of the population with dementia at the subsequent (exact) age is
𝐷
𝐷
𝑙𝑥+1
= 𝑙𝑥𝐷 + 𝐷𝑒𝑚1𝑑𝑥𝐷𝐹 − 𝐷𝑒𝑎𝑡ℎ1𝑑𝑥𝐷 − 𝐷𝑒𝑎𝑡ℎ
𝑛𝑒𝑤𝑑𝑥 .

[35]

Person-years lived in the dementia-free state are calculated assuming exits occur linearly
within age intervals:
𝐷𝐹
1𝐿𝑥

𝐷𝐹
𝐷𝐹 ).
= 𝑙𝑥+1
+ 0.5(𝑙𝑥𝐷𝐹 − 𝑙𝑥+1

[36]

Person-years lived in a state of dementia are simply
𝐷
1𝐿𝑥

= 1𝐿𝑥 − 1𝐿𝐷𝐹
𝑥 .

[37]

Filling in the table for the subsequent age (x+1) requires an approximation of the
proportion of survivors with dementia in the middle of the age (x+1, x+2) interval,
because the mortality rates in Equations 22-24 pertain to age intervals rather than exact
ages. My approximation again uses the assumption that the number of survivors declines
linearly over each one-year interval. I assume that half the attrition recorded from exact
ages x to x+1 will occur from exact age x+1 to the middle of the (x+1, x+2) interval. I
denote approximated number of persons in state i in the middle of the age (x+1, x+2)
interval as

̂𝑖
1 𝐿𝑥+1 ,

while I assume that the L column for the entire population (from

SSA) records all survivors in the middle of the given age interval:
̂𝐷
1 𝐿𝑥+1

𝐷𝐹
𝐷𝐹
𝐷𝐹
= 1𝐿𝑥+1 − 1𝐿̂𝐷𝐹
𝑥+1 = 1𝐿𝑥+1 − [𝑙𝑥+1 − 0.5(𝑙𝑥 − 𝑙𝑥+1 )]
[38]
𝐷𝐹
= 1𝐿𝑥+1 − [1.5𝑙𝑥+1
− 0.5𝑙𝑥𝐷𝐹 ].

Prevalence of dementia at the subsequent age is estimated as the proportion of midinterval survivors living in a state of dementia:
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1𝑃𝑥+1

=

̂𝐷
1𝐿𝑥+1⁄

1𝐿𝑥+1

,

[39]

which is used to solve for the mortality rate in the dementia-free population for the age
x+1 interval, using Equations 22 and 23.
Because I use narrow (one-year) age intervals, the resulting 𝐿̂𝑖𝑥 columns from
Equation 38 will be close to the 𝐿𝑖𝑥 columns from Equations 36-37. (The similarity of
the two columns is shown in Appendix A.2.4). The age schedule of prevalence as
calculated in Equation 39 can be compared to that estimated in baseline ADAMS in
Equation 1 as an informal test of stationarity, under the assumption that the model of
differential mortality is correct.
Once the multiple-decrement life table is completed, the summary quantities of
interest – lifetime risk of developing dementia, unconditional expectancies, and certain
conditional expectancies – can be calculated as in Equations 15 through 19.

Simulated reductions in mortality, and simulated delays or reductions in dementia
incidence
Approach 2, which does not assume the constancy of rates over time, lends itself
to simulations of future lifetime risk based on changes in mortality or dementia incidence.
To assess lifetime risk for younger, lower-mortality cohorts, a secondary analysis used
values for 1𝑚𝑥 from the 1940 cohort life tables from SSA. The results estimate lifetime
risk using current incidence rates and mortality rate ratios as estimated in ADAMS,
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isolating the role of declines in the overall level of mortality in changing lifetime risk of
dementia.
I also estimate the lifecycle effects of an intervention that delays the onset of
dementia. I consider interventions that vary along two parameters: δ, the length of the
delay of dementia onset in years, and π, the proportion of the population at risk for whom
the intervention is effective. I model these interventions by splitting the model dementia𝐷𝐹
𝐷𝐹
free population into groups of size 𝑙70
(1 − 𝜋) and 𝑙70
(𝜋), subjecting the first group to

the dementia incidence rates as modeled in Equation 2, and subjecting the second group
to the dementia incidence rates as modeled by
𝑙𝑜𝑔𝑖𝑡(ℎ𝑥′ ) = 𝛼 + 𝛽(𝑥 − 𝛿),

[40]

where δ is the number of years of delay of dementia onset induced by the intervention.
This equation assigns what had been the age-70 incidence rate to age 70+ δ, what had
been the age-71 incidence rate to age 71+ δ, and so forth.
Another type of intervention would reduce the risk of dementia at every age,
rather than delaying its onset. Such an intervention generates an incidence equation such
as:
𝑙𝑜𝑔𝑖𝑡(ℎ𝑥′′ ) = 𝛼 + (𝛽𝑘)𝑥,

[41]

where k is a value between 0 and 1 that represents the extent to which dementia incidence
rises less steeply with age due to the intervention. The closer k is to zero, the more
effective is the intervention in the sense of reducing the acceleration of dementia
incidence. I simulate an intervention where k = 0.9, to reduce the (logit of) acceleration of
dementia incidence with age by 10%.
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Both the dementia-free and with-dementia populations are subject to the same
mortality rates as before (Equations 23-24); the changing sizes of these two populations
resulting from the simulated intervention are assumed to change the overall mortality rate
(Equation 12).

Estimation of standard errors and confidence intervals
To generate standard errors and confidence intervals around the lifetimeprobability and life expectancy estimates, I considered as stochastic the parameter
estimates generating the age-specific dementia incidence schedules (the fitted values of
[α’ β’] in Equation 2) and either prevalence (for Approach 1 – the fitted values of [α β]
in Equation 1) or differential mortality (for Approach 2 – the fitted values for [α β1 β2 β3]
in Equation 20). Total mortality, derived from the SSA cohort life tables, was treated as
deterministic (i.e. having zero variance) (Abatih, Van Oyen, Bossuyt, & Bruckers 2008;
Loukine, Waters, Choi, & Ellison 2012), and the life table assumptions, such as linearity
of survival within age intervals, were also considered not to contribute any additional
variance.
For dementia incidence, I used the estimates of [α’ β’] in Equation 2, along with
their associated variance-covariance matrix, as the parameters of a bivariate Normal
distribution to draw 1,000 independent values of [α’ β’], generating 1,000 incidence
schedules (Salomon, Mathers, Murray, & Ferguson 2001). Separately, I used an
analogous procedure with the estimated parameters and variance-covariance matrix from
Equation 1 or Equation 20 to generate 1,000 age schedules of prevalence (Approach 1)
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or the mortality rate ratio between those with and those without dementia (Approach 2).
Each incidence schedule was paired with one schedule of the second parameter
(prevalence or mortality rate ratios) and run through the life table operations, producing
1,000 lifetime-probability and expectancy estimates. In figures, the median of the 1,000
estimates is shown as the point estimate, and the 2.5th and 97.5th percentiles are shown as
the confidence bounds (Fishman 2015; Mooney 1997; Salomon et al. 2001). Tables show
the means and standard errors (square roots of variances) of the 1,000 estimates. A
deterministic result using the estimated parameters of incidence, prevalence, and
differential mortality as fixed quantities will also be presented.
Parameters from Equations 1, 2, and 20 were estimated using Stata version 14
(StataCorp, College Station, TX), using first-order Taylor Series linearization for
variance estimation with the svy routine (Heeringa et al. 2009). Random sampling for the
estimation of standard errors was conducted in R using the mvrnorm command in the
MASS package (Venables & Ripley 2002), and life table operations were conducted
using base R (R Core Team, Vienna, Austria). The HRS and ADAMS data are available
to the public after a registration procedure (Health and Retirement Study 2013).

2.3

RESULTS
There were 308 cases of dementia at baseline out of 856 unweighted sample

members. All baseline sample members were at risk of death, generating 519 deaths in
3,520 person-years at risk. Among the 456 individuals without dementia at baseline who
were followed longitudinally, 106 developed dementia in 2,142 person-years at risk. The
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estimates of the regression parameters in Equations 1, 2, and 20, along with the
variance-covariance matrices used to sample the 1,000 simulated incidence, prevalence,
and mortality rate-ratio schedules for the confidence intervals, are shown in Appendix
A.2.1.
Table 2-1 shows the estimated age schedule of dementia prevalence, which aligns
closely with published estimates from ADAMS (Plassman et al. 2007), at 6.1% for age
75, 22.7% for age 85, and 38.4% at age 90. The fitted age-specific dementia incidence
rates are also shown in Table 1, with 16 new cases per 1,000 person-years at age 75, 37
new cases per 1,000 person-years at age 85, and 56 to 86 new cases per 1,000 personyears at ages 90-95. The incidence rates shown here are close to those from the previous
ADAMS incidence study, which reported incidence rates of 18.9 (95% CI: 10.1, 27.8)
new cases per 1,000 person-years for ages below 80, 42.2 (95% CI: 26.0, 58.5) for ages
80 to 89, and 82.1 (95% CI: 39.9, 124.3) for ages 90 and above (Plassman et al. 2011).
The small differences between the current incidence estimates and those from the prior
study are attributable to the parametric model fit to the data in this study.
The age pattern of mortality rate ratios shown in Table 2-1, showing a rapid
decline in differential mortality with age, is largely consistent with that found in other,
non-national and non-U.S. samples; however, as mentioned previously, the pace of
decline of differential mortality with age varies widely in the literature (Guehne et al.
2005; Ostbye et al. 1999; Tschanz et al. 2004; Villarejo et al. 2011). The estimated
mortality rate ratio (RR) at age 70 of 13.3 is highly unreliable, as shown by its high
standard error, arising from the low number of deaths at age 70; the true RR is probably
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not quite that high. Since the prevalence of dementia is very low at age 70, results are not
sensitive to the RR estimate at that age. The RR implied by estimated incidence, baseline
prevalence, and the stationary population assumption is around 1 for ages above 85,
which is plausible given the high level of mortality in the general population at those
ages. The close correspondence between the point estimates using stochastic inputs
(Table 2-1) and the deterministic estimates (Appendix Table A.2.2a), with the exception
of the highly unreliable age-70 estimate of RR, suggest that the resampling strategy used
to generate the stochastic estimates was on target.
Using Approach 1, Table 2-2 shows calculations of the various life table
quantities of interest: total life expectancy, dementia-free life expectancy and life
expectancy with dementia (for a randomly chosen person in the population), and, of most
interest, the probability that a currently dementia-free person will develop dementia later
in life. It also shows conditional dementia-free life expectancy (DFLE’) – dementia-free
life expectancy for a dementia-free person at the given ages. About 23.7% (SE: 2.9%) of
dementia-free 70 year old males are expected to develop dementia later in the course of
life, compared to 31.8% (SE: 3.6%) of dementia-free females age 70. The lifetime
probability remains roughly constant with age for males, meaning the force of dementia
incidence increases about as quickly as the force of male mortality. For females, lifetime
probability declines to 25.2% at age 95, indicating that the force of female mortality
increases more quickly than the force of dementia incidence. Lifetime probability is
higher for females than males because females have lower overall mortality, the only
input that varies by sex. Appendix Table 2.2.2b again shows concordance between the
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stochastic point estimates of expectancies and lifetime risk and the deterministic
calculations.
For both sexes at ages 70 to 85, the vast majority of remaining life for a randomly
chosen person is expected to be dementia-free, as shown by the high ratio of DFLE to
DLE at these ages. However, at the oldest ages, 90 and above, DFLE and DLE are about
equal – with DLE even greater than DFLE at age 95 – because mortality, incidence, and
prevalence are all high at these ages. Dementia-free life expectancy for a dementia-free
person (DFLE’) is slightly higher than unconditional DFLE because the latter includes
people with dementia, whose DFLE is zero. The gap between DFLE’ and DFLE widens
with age because the prevalence of dementia rises with age.
Table 2-3 (with Appendix Table A.2.2c for deterministic quantities) shows the
same quantities as Table 2-1 – prevalence, incidence, and the mortality rate ratio (RR) –
but uses estimated incidence and RR to infer prevalence (i.e. Approach 2), rather than
using estimated incidence and prevalence to infer RR. For all except the youngest and
oldest ages, estimated RR is higher than that implied by stationary-population incidence
and prevalence in Table 2-1. For example, 80-year-olds with dementia are estimated to
die at 4.6 times the rate of 80-year-olds without dementia, whereas the stationary
population implied a multiplier of just 1.8 times. A higher estimated RR implies a lower
prevalence, also shown in Table 2-3, because exits from the population with dementia
(relative to the population without) occur more quickly when RR is higher. Figure 2-1
shows that the prevalence series implied by the estimated RRs is not even within the
confidence bands of the prevalence from baseline ADAMS for ages 80 and above.
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There are several possible explanations for the discordant results shown in Figure
2-1. If the estimated RRs are correct, then the figure implies a departure from stationarity,
i.e. a change in dementia incidence rates, such that the rates that produced baseline
prevalence were higher than the rates observed longitudinally in ADAMS. Another
possible, though less likely, departure from stationarity consistent with Figure 2-1 is that
RR has increased over time, since a higher RR implies a lower prevalence. However, if
we are confident that dementia incidence rates and differential mortality have not
changed, then the figure implies a misspecification of the RR function (Equations 2122). A final possibility is that the discrepancy arises from differences in the ascertainment
of dementia status between the baseline study and the longitudinal follow-up study.
Although the assessments of subjects were similar across waves of ADAMS, the baseline
study by definition did not have access to the results of prior dementia examinations by
the ADAMS team. To obtain a cognitive history of the subject (that is, measures of
cognition prior to the baseline examination), the baseline study used medical records and
interviews of knowledgeable informants. These methods have high reliability and validity
(Langa et al. 2005; Plassman et al. 2007), but they are not the same as observing the
person’s cognitive performance in detail over time, as was done for the longitudinal
ADAMS incidence sample.
When using the non-stationary approach, estimated lifetime risk of dementia is
higher by about 3 to 5 percentage points than when using stationary population relations.
For example, Table 2-4 (with Appendix Table A.2.2d for deterministic quantities)
shows that at age 70, the lifetime risk for males without dementia was 26.9% and for
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females 34.7%. However, there is considerable overlap in the confidence intervals around
the estimated-RR and stationary-population estimates of lifetime risk (Figure 2-2),
suggesting statistical concordance in the results of the two approaches. In other words,
the lifetime-risk estimates shown in Table 2-2 are robust to the possible departures from
stationarity implied by Figure 2-1. The higher estimate of differential mortality
employed in Approach 2 means the competing risk of death without dementia is lower,
raising lifetime risk of developing dementia.
Using the 1940 cohort life table rather than that of 1920 (with Approach 2) raises
lifetime risk at all ages (Table 2-5). The increase is between 3 and 4 percentage points
for both males and females. The probability that a dementia-free 70 year old male from
this cohort develops dementia later in life is about 28.9%; for a dementia-free 70 year old
female it is 34.9%. The increase in lifetime risk results from population-wide reductions
in mortality between the two birth cohorts, reducing the competing risk of death and
allowing a larger proportion of the population to survive to ages of high dementia
incidence. The changes in the results based on the choice of an input life table do not
negate the results for the older cohort, nor do they cast doubt on Approach 1, which
requires only that incidence and differential mortality be constant over time. Rather, the
1940 results simply illustrate that individuals in younger, lower-mortality cohorts face
higher age-specific lifetime risks of dementia than individuals in older, higher-mortality
cohorts. The percentage increase in lifetime risk across the two cohorts is larger for males
than females because females have lower mortality than males to begin with (a larger
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base leads to smaller percentage change), and/or because mortality declined less for
females than for males between these two cohorts (Preston & Wang 2006).
Table 2-6 shows the lifetime-risk estimates under a series of alternative scenarios
where dementia incidence is reduced, again using Approach 2. Appendix A.2.3 shows
the age pattern of incidence under the alternative scenarios. In the first two scenarios, an
intervention delays the risk of dementia by one year; in Scenario 1 the intervention
affects 50% of dementia-free 70-year-olds, and in Scenario 2 it affects 90%. The
estimates for Scenarios 1 and 2 in Table 2-6 indicate that this intervention would reduce
lifetime risk at age 70 by only one to two percentage points, with similar reductions at
older ages. The small difference between Scenarios 1 and 2 shows that the proportion of
the age-70 population for which this intervention is effective has a small effect on
lifetime risk estimates. Extending the reach from 50% to 90% of dementia-free 70-yearolds reduces lifetime risk by less than one percentage point.
A larger reduction in lifetime risk is achieved by an intervention that delays
dementia onset by five years and reaches 50% of the dementia-free population age 70
(Scenario 3) – now the reduction is 3.7 percentage points for males and 4.5 for females. If
this five-year delay affected 90% of dementia-free 70 year olds (Scenario 4), it would
reduce lifetime risk at age 70 by 6.7 percentage points for males and 8.1 percentage
points for females, a 25% reduction in lifetime risk for males and a 23% reduction for
females. Similar reductions in lifetime risk are achieved by an intervention that reduces
the rate of acceleration of dementia incidence with age, as in Scenario 5. This
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intervention achieves a 5.6 percentage-point reduction in lifetime risk for males and 7.1
percentage-point reduction for females.

Sensitivity analysis
To test the sensitivity of the results to the choice of censoring subjects who
survived ADAMS without dementia at their last assessment, a secondary analysis
censored these subjects at the end of the ADAMS study period. This approach treats the
two forms of not experiencing dementia onset – dying without developing dementia and
surviving without developing dementia – in roughly the same way, following both groups
until the end of ADAMS. This secondary approach increased the number of person-years
at risk of death to 4,191 and the number of person-years at risk of dementia onset to
2,350. Because this sensitivity analysis only changed the treatment of subjects who were
not observed as having experienced either event (dementia onset or death), estimates both
of dementia incidence rates and of the mortality rate among the dementia-free population
are lower than in the main analysis.
Appendix Table A.2.5a shows the estimated incidence rates under this
alternative censoring strategy. They are in much less alignment than the main incidence
rates (Table 2-1) with incidence rates previously published (Plassman et al. 2011).
Furthermore, the relative risks implied by the incidence rates in Appendix Table 9
suggest the unlikely result that, for those aged 85 to 95, individuals with dementia died at
a lower rate than individuals without dementia.
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A comparison of Appendix Table A.2.5b to Table 2-2 shows that lifetime risk of
dementia is lower using the alternative censoring approach, by about 2 to 4 percentage
points at younger ages and 5 to 6 percentage points at older ages. The lower incidence
rates under this censoring strategy generate lower lifetime risks. Furthermore, the lower
RR implied by imposing lower incidence rates on constant prevalence values raises
competing risk of death without dementia.
Appendix Table A.2.5c also uses this alternative method of censoring but uses
Approach 2, not assuming a stationary population and estimating relative risks of death
directly from the data. Directly-estimated relative risks of death are higher using this
method of censoring than when using the original method of censoring (Table 2-3)
because this method of censoring counts more person-years lived without dementia,
reducing the estimated mortality rate in the population without dementia and raising the
RR. Incidence is again lower than in the main approach to censoring, with the same
incidence estimates as in Appendix Table A.2.5a. In Appendix Table A.2.5c, the low
estimates of incidence combine with the high estimates of RR to produce implausibly low
estimates of dementia prevalence at old ages.
Lower incidence would imply lower lifetime risk of dementia than that estimated
using the main approach to censoring, while higher RR would imply higher lifetime risk.
Appendix Table A.2.5d shows that lifetime risk of dementia under this alternative
censoring strategy is indeed lower than that estimated using the main censoring strategy
(compare to Table 2-4), by about 2 to 4 percentage points for both sexes. Appendix
Table A.2.5e is parallel to Table 2-5, showing results with Approach 2 (non-stationary
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population) with the 1940 cohort life tables, but censoring those who survive ADAMS
without dementia at the end of ADAMS rather than at their last assessment. As with the
main results, using the 1940 life table raises lifetime risk of dementia by reducing the
competing risk of mortality at ages of low dementia incidence, surviving a larger fraction
of the population into ages of higher dementia incidence rates. The increase in lifetime
risk due to the transition from 1920 to 1940 cohort mortality is about 3 to 4 percentage
points at each age, similar in magnitude to the increase when using the main censoring
strategy.
The discordance between the incidence rates in the sensitivity analysis and those
in Plassman et al. 2011, and the implausibility of the implied RRs (Appendix Table
A.2.5a) or the implied prevalence values (Appendix Table A.2.5c) cast doubt on the
appropriateness of the censoring strategy employed in the sensitivity analysis and thus
strengthen the validity of the approach taken in the main analysis.
2.4

DISCUSSION
This study provides, to my knowledge, the first nationally representative estimates

of the lifetime probability of developing dementia in the U.S. These estimates suggest
that about 23% to 27% of dementia-free 70 year-old males and about 31% to 35% of
dementia-free 70-year-old females in the 1920 birth cohort will develop (or have
developed) dementia before they die. For the 1940 birth cohort, these estimates rise to
about 31% for males and 37% for females. The expected number of years that a randomly
chosen individual at age 70 could expect to live with dementia is only about one to 1.5
years for males and two years for females, but given the high care needs of people with
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dementia, this estimate still implies a large need for individuals and families to plan for a
life stage with dementia.
A recent study, known as Adult Changes in Thought (Tom et al. 2015), reported
dementia-free life expectancy for dementia-free cohort members (what I call DFLE’) age
70, estimating 14.3 years for males and 15.7 years for females. My estimates were 11.1
years for males and 13.4 years for females (Table 2-2). The ACT population was clearly
at lower baseline risk of mortality than the 1920 birth cohort in the U.S. as a whole, as the
ACT cohort had a total life expectancy at age 70 of 16.0 years for males and 18.0 years
for females, in contrast to the national cohort’s 12.3 and 15.3 years. Since the ACT
cohort had much longer life expectancy overall, it is not surprising that it also had longer
conditional dementia-free life expectancy.
Another past study of an individual’s lifetime risk of dementia that incorporated a
competing-risks framework used Framingham data from 1975-1995 (Seshadri et al.
1997). It estimated that a dementia-free male age 65 had a 14.3% probability of
developing dementia at some point in his remaining life, and a dementia-free female age
65 had 21.7% probability of developing dementia at some point in her remaining life
(Seshadri & Wolf 2007).
There are several reasons why my estimates of the probability of developing
dementia are considerably higher than the Framingham-based estimates. First, overall
mortality during ADAMS was lower than overall mortality during Framingham. The agestandardized mortality rate (ASMR) in the U.S. population age-65+ in 2005, the middle
of the ADAMS study period, was 4,804 deaths per 100,000 person-years lived; this rate
69

was much lower than the ASMR in Massachusetts for age 65+ in 1985, the middle of
Framingham’s study period, which was 5,679 deaths per 100,000 person-years lived
(Centers for Disease Control and Prevention 2014). The comparison of the 1920 SSA
cohort table to that of 1940 shows that lower mortality levels imply higher lifetime risks
of dementia. Second, the mortality rate ratios I use could be higher than the differential
mortality in the Framingham study, which was not specifically reported (Seshadri &
Wolf 2007; Seshadri et al. 1997). A higher mortality rate ratio would reduce the
competing risk of death without dementia and thus raise the estimated lifetime risk of
developing dementia. Additionally, the authors of the Framingham study noted that
because the Framingham sample was disproportionately white, it might not generalize to
the U.S. population, due to known differences in incidence across racial and ethnic
groups in the U.S. (Seshadri & Wolf 2007). ADAMS included a larger proportion of
African American subjects, who are at higher risk of developing dementia at any given
age (Plassman et al. 2011). Racial disparities in mortality also narrow with age (Eberstein
et al. 2008; Preston, Elo, Rosenwaike, & Hill 1996). The higher incidence rates among
African Americans could certainly contribute to higher estimates of lifetime risk of
developing dementia. My estimates – especially those using the 1940 cohort life table
from SSA – are closer to those estimated for a national sample from Canada, where the
authors estimated that slightly over 40% of 70-year-olds in Canada would develop
dementia before death (Carone et al. 2014).
A recent simulation study using ADAMS and HRS found that an intervention that
delayed the onset of Alzheimer’s Disease (AD) for five years would result in a 41%
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lower prevalence of AD in 2050 among those aged 70+ than if onset had not been
delayed (Zissimopoulos, Crimmins, & St.Clair 2014). Setting aside possible differences
between AD and other dementias, a 41% decline in AD prevalence could be consistent
with my estimate of a 25% decline in lifetime risk of dementia (Scenario 4 in Table 2-6),
if the average duration of AD fell substantially as a result of the delayed onset of AD. In
the literature, average duration of dementia among those who get it varies from 4.4 to 9.9
years depending on the age of diagnosis (Treves & Korczyn 2012). Additionally, since
the average duration of AD is longer than that of vascular dementia (Treves & Korczyn
2012), an intervention reducing the duration of AD could have a larger effect on AD
prevalence than an intervention reducing the duration of all types of dementia could have
on all-dementia prevalence. Further research can use increment-decrement methods to
estimate age-specific average duration of dementia under different possible interventions.
There are several other possible explanations for the difference between the
potential reduction in prevalence obtained in the aforementioned simulation study and the
potential reduction in lifetime risk estimated here. First, the prior study used a model
incorporating changes in risk factors for dementia and death across real (not synthetic)
cohorts, whereas I just used age and sex and a national life table. Second, they assumed
that any intervention would be effective for 100% of the population at risk, while I only
allowed up to 90% effectiveness. Additionally, it is unclear how they operationalized a
five-year delay in onset of AD. They might have done so as I did, pushing age-specific
incidence rates back five years and “filling in” the younger ages with lower rates
consistent with the functional form of the model age pattern of dementia incidence. But
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they might have set incidence to zero in the first five years and then continued five years
of age later with the initial set of rates. Or perhaps they reestimated a different equation
entirely. If they used a different operationalization of a “five year delay in onset,” they
could produce different results.
Another direction for future research is the estimation of quantities associated
with family members of persons with dementia, such as the risk of having a parent who
develops dementia. The estimates of lifetime risk presented here imply that informal care
givers will face an increasing burden in the near future (Kasper et al. 2015). Because of
the generally advanced age of persons with dementia, spouses are often not available to
provide care, with daughters picking up the lion’s share of the load (Friedman, Shih,
Langa, & Hurd 2015). The lower parity of cohorts born in the 1940s and 1950s, relative
to cohorts born in the 1920s and 1930s, implies that fewer aging Baby Boomers will have
daughters who can take care of them than members of older generations have had
(Human Fertility Database 2015). Research has found that middle-aged and young adults
consistently underestimate their future need for personal care (Henning-Smith & Shippee
2015; Kemper, Komisar, & Alecxih 2005; Spillman & Lubitz 2002). The results shown
here suggest that a large fraction of current and near-future elderly will develop dementia
in their lifetimes, even if treatments delaying or reducing dementia risk become
widespread.
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Table 2-1: Dementia Prevalence, Incidence, and Differential Mortality – Stationary
Population Approach
Fitted prevalence & incidence
Implied
Age Prevalence
(SE) Incidence
(SE)
RR
(SE)
70
0.030 (0.007)
0.010 (0.003) 13.313 (12.999)
75
0.061 (0.009)
0.016 (0.003) 4.395 (2.107)
80
0.121 (0.012)
0.024 (0.003) 1.846 (0.121)
85
0.227 (0.022)
0.037 (0.005) 1.108 (0.300)
90
0.384 (0.043)
0.056 (0.011) 1.024 (0.295)
95
0.569 (0.061)
0.086 (0.023) 1.037 (0.271)
100
0.734 (0.064)
0.130 (0.042) 1.259 (0.346)
RR = Relative risk of death, with dementia vs. without dementia; SE = standard error.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort. Mortality by dementia status
data from Health and Retirement Study (HRS), United States, 2001-2011.
Parametric models were fitted to prevalence and incidence data to generate single-year
age-specific estimates. RR was implied by the fitted prevalence and incidence estimates
along with stationary-population relations.
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Table 2-2: Life Cycle Quantities for Dementia – Stationary Approach
A. Males
Age
70
75
80
85
90
95
100

LE
12.31
9.65
7.26
5.20
3.64
2.61
2.02

DFLE
10.83
8.04
5.54
3.43
1.91
0.96
0.47

DLE
1.48
1.61
1.72
1.76
1.74
1.64
1.55

(SE)
(0.129)
(0.142)
(0.162)
(0.182)
(0.187)
(0.163)
(0.123)

Lifetime
Risk
0.237
0.233
0.226
0.215
0.208
0.213
0.246

(SE)
(0.029)
(0.027)
(0.032)
(0.041)
(0.052)
(0.067)
(0.089)

DFLE'
11.14
8.53
6.25
4.37
3.01
2.15
1.71

(SE)
(0.119)
(0.134)
(0.143)
(0.135)
(0.109)
(0.078)
(0.039)

(SE)
(0.190)
(0.205)
(0.227)
(0.249)
(0.251)
(0.220)
(0.167)

Lifetime
Risk
0.318
0.304
0.286
0.267
0.253
0.252
0.277

(SE)
(0.036)
(0.037)
(0.044)
(0.054)
(0.067)
(0.081)
(0.102)

DFLE'
13.41
10.19
7.41
5.17
3.53
2.47
1.90

(SE)
(0.191)
(0.205)
(0.209)
(0.190)
(0.149)
(0.102)
(0.061)

B. Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.17
9.77
6.74
4.25
2.41
1.26
0.63

DLE
2.08
2.14
2.16
2.12
2.00
1.83
1.69

LE = total life expectancy for a randomly chosen person in the population of given age,
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities calculated using fitted values of dementia incidence and prevalence and
implied relative risk of death (with dementia vs. without) shown in Table 1.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort. Mortality by dementia status
data from Health and Retirement Study (HRS), United States, 2001-2011.

74

Table 2-3: Dementia prevalence, incidence, and differential mortality – nonstationary approach
Implied
Estimated
Estimated
Age Prevalence
(SE) Incidence
(SE)
RR
(SE)
70
0.030 (0.173)
0.010 (0.003) 8.86
(3.344)
75
0.058 (0.241)
0.016 (0.003) 6.37
(1.761)
80
0.093 (0.304)
0.024 (0.003) 4.63
(0.896)
85
0.137 (0.371)
0.037 (0.005) 3.41
(0.513)
90
0.196 (0.443)
0.056 (0.011) 2.54
(0.447)
95
0.286 (0.535)
0.086 (0.023) 1.91
(0.479)
100
0.453 (0.673)
0.130 (0.042) 1.48
(0.472)
RR = Relative risk of death, with dementia vs. without dementia
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
Parametric models were fitted to incidence and mortality data from ADAMS to generate
single-year age-specific estimates. Prevalence in the cohort arises from the life table
relations as described in the Methods section, under Approach 2.
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Table 2-4: Life Cycle Quantities – Non-Stationary Approach
A. Males
Lifetime
Age
LE DFLE
DLE
(SE)
Risk
(SE)
70
12.31
11.55
0.76 (0.220)
0.269 (0.032)
75
9.65
8.90
0.75 (0.228)
0.271 (0.032)
80
7.26
6.51
0.76 (0.223)
0.267 (0.036)
85
5.20
4.47
0.73 (0.211)
0.257 (0.044)
90
3.64
2.93
0.72 (0.200)
0.247 (0.056)
95
2.61
1.85
0.76 (0.200)
0.244 (0.072)
100
2.02
1.10
0.92 (0.207)
0.255 (0.091)

DFLE'
11.91
9.35
7.04
5.04
3.49
2.43
1.77

(SE)
(0.190)
(0.154)
(0.123)
(0.094)
(0.080)
(0.082)
(0.084)

DFLE'
13.93
10.88
8.15
5.84
4.02
2.76
1.97

(SE)
(0.278)
(0.213)
(0.172)
(0.133)
(0.101)
(0.088)
(0.086)

B. Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.51
10.21
7.34
4.99
3.21
1.97
1.13

DLE
1.74
1.69
1.56
1.38
1.21
1.12
1.19

(SE)
(0.292)
(0.303)
(0.300)
(0.285)
(0.262)
(0.243)
(0.228)

Lifetime
Risk
0.347
0.341
0.329
0.312
0.293
0.281
0.284

(SE)
(0.037)
(0.038)
(0.043)
(0.052)
(0.064)
(0.079)
(0.097)

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities calculated using fitted values of dementia incidence and relative risk of death
(with dementia vs. without) shown in Table 3.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
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Table 2-5: Life Cycle Quantities Using 1940 Cohort Life Table – Non-Stationary
Approach
A. Males
Age
70
75
80
85
90
95
100

LE
13.64
10.65
7.96
5.70
4.05
2.95
2.30

DFLE
12.54
9.57
6.93
4.74
3.13
1.97
1.15

DLE
1.10
1.08
1.03
0.96
0.93
0.97
1.14

(SE)
(0.262)
(0.272)
(0.268)
(0.253)
(0.239)
(0.233)
(0.227)

Lifetime
Risk
0.308
0.306
0.298
0.286
0.276
0.273
0.285

(SE)
(0.034)
(0.035)
(0.040)
(0.049)
(0.063)
(0.080)
(0.099)

DFLE'
12.93
10.13
7.59
5.44
3.82
2.68
1.96

(SE)
(0.237)
(0.192)
(0.156)
(0.121)
(0.101)
(0.098)
(0.095)

(SE)
(0.332)
(0.343)
(0.340)
(0.324)
(0.301)
(0.277)
(0.248)

Lifetime
Risk
0.374
0.370
0.359
0.342
0.325
0.313
0.316

(SE)
(0.038)
(0.041)
(0.047)
(0.057)
(0.070)
(0.087)
(0.105)

DFLE'
14.44
11.38
8.62
6.23
4.35
3.02
2.16

(SE)
(0.315)
(0.252)
(0.209)
(0.166)
(0.129)
(0.109)
(0.101)

B. Females
Age
70
75
80
85
90
95
100

LE
15.99
12.62
9.57
6.93
4.89
3.49
2.63

DFLE
14.01
10.67
7.73
5.26
3.40
2.09
1.18

DLE
1.97
1.95
1.84
1.66
1.49
1.40
1.46

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities calculated using fitted values of dementia incidence and relative risk of death
(with dementia vs. without) shown in Table 3. Mortality rates for total population come
from Social Security Administration, 1940 birth cohort life tables.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
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Table 2-6: Lifetime risk of dementia under intervention scenarios – non-stationary approach
A. Males
Age
70
75
80
85
90
95
100

Scenario 1
Estimate
SE
0.261 (0.032)
0.263 (0.031)
0.259 (0.034)
0.249 (0.042)
0.240 (0.054)
0.236 (0.069)
0.247 (0.088)

Scenario 2
Estimate
SE
0.255 (0.032)
0.256 (0.031)
0.253 (0.033)
0.243 (0.041)
0.234 (0.052)
0.231 (0.068)
0.242 (0.087)

Scenario 3
Estimate
SE
0.232 (0.032)
0.233 (0.029)
0.229 (0.030)
0.219 (0.035)
0.209 (0.044)
0.205 (0.057)
0.213 (0.074)

Scenario 4
Estimate
SE
0.202 (0.032)
0.203 (0.028)
0.199 (0.026)
0.192 (0.029)
0.184 (0.038)
0.182 (0.051)
0.193 (0.068)

Scenario 5
Estimate
SE
0.213 (0.031)
0.212 (0.028)
0.205 (0.026)
0.194 (0.029)
0.181 (0.035)
0.171 (0.043)
0.170 (0.052)

Scenario 1
Estimate
SE
0.338 (0.036)
0.331 (0.037)
0.320 (0.042)
0.303 (0.050)
0.285 (0.062)
0.273 (0.077)
0.277 (0.094)

Scenario 2
Estimate
SE
0.330 (0.036)
0.324 (0.036)
0.312 (0.041)
0.296 (0.049)
0.278 (0.060)
0.267 (0.075)
0.271 (0.093)

Scenario 3
Estimate
SE
0.302 (0.035)
0.296 (0.034)
0.284 (0.036)
0.268 (0.042)
0.251 (0.052)
0.239 (0.064)
0.240 (0.080)

Scenario 4
Estimate
SE
0.266 (0.034)
0.260 (0.032)
0.250 (0.032)
0.236 (0.036)
0.222 (0.045)
0.214 (0.058)
0.218 (0.074)

Scenario 5
Estimate
SE
0.276 (0.034)
0.268 (0.031)
0.255 (0.031)
0.237 (0.035)
0.217 (0.041)
0.200 (0.049)
0.192 (0.057)

B. Females
Age
70
75
80
85
90
95
100

Lifetime Risk = probability that a dementia-free person of given age will develop dementia later in life. Scenario 1: Dementia incidence delayed by 1 year,
effective for 50% of dementia-free population age 70. Scenario 2: Dementia incidence delayed by 1 year, effective for 90% of dementia-free population age 70.
Scenario 3: Dementia incidence delayed by 5 years, effective for 50% of dementia-free population age 70.
Scenario 4: Dementia incidence delayed by 5 years, effective for 90% of dementia-free population age 70. Scenario 5: Acceleration of dementia incidence with
age reduced by 10%. Original incidence shown in Table 3.

78

Figure 2-1: Baseline fitted prevalence vs. prevalence implied by non-stationary
approach

Notes: Baseline fitted prevalence from Aging, Demographics, and Memory Study
(ADAMS) Wave A, United States, 2001-2003, n=856.
Estimated relative risks of death, used in Non-Stationary Approach, are from ADAMS
and Health and Retirement Study, longitudinal follow-up 2001-2011, n=856 with 519
deaths. Prevalence implied by non-stationary approach arises from life table relations
described in Methods section under Approach 2.
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Figure 2-2: Lifetime risk of dementia, stationary approach vs. non-stationary
approach
A) Males

B) Females

Notes: Lifetime risk = probability that a dementia-free person will develop dementia later
in life. Stationary approach used baseline dementia prevalence and longitudinal dementia
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incidence along with life-table relations and 1920 U.S. birth cohort life tables. Nonstationary approach used longitudinal dementia incidence and differential mortality
estimates with the 1920 cohort life tables.
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3

3.1

Incident diabetes and mobility limitations: reducing bias with risk-set matching
INTRODUCTION
Diabetes was estimated to account for $176B in annual medical costs and an

additional $69B in lost productivity in the U.S. in 2012 (American Diabetes Association
2013). Population aging, increased age-specific diabetes incidence, and improved
survival among people with diabetes are projected to cause the prevalence of diabetes in
the U.S. among adults to increase from about 12% in 2010 (Y. J. Cheng et al. 2013) to
between 21% and 33% by 2050 (Boyle et al. 2010). If the strong cross-sectional
association between diabetes and disability (Wong et al. 2013) persists in the future, that
projected prevalence of diabetes implies a massive burden of disability and medical costs
on individuals, businesses, and government.
The cross-sectional associations between diabetes and physical functioning
outcomes – the subject of most prior studies (Wong et al. 2013) – reflect causal pathways
that can run in both directions: diabetes can cause mobility limitations and disability
(Bianchi, Zuliani, & Volpato 2013), but mobility limitations among non-diabetic
individuals can cause reductions in physical activity and other lifestyle changes that raise
the risk of developing diabetes (Bardenheier et al. 2014). The latter pathway is a type of
reverse causality that biases prevalence-based estimates of the association between
diabetes and mobility limitations. Using incident, rather than prevalent, diabetes as the
exposure of interest would reduce the strength of reverse causal pathways that plague
previous studies of this topic. This paper will using risk-set matching, a type of
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propensity score matching, to estimate the relationship between incident diabetes and
subsequent mobility limitations, using data from the Health and Retirement Study (HRS).
The inability of prevalence-based estimates to identify the time-ordering of
covariates can also create bias due to confounding. In prevalence-based studies, including
longitudinal studies of the association between baseline diabetes prevalence and
subsequent functional limitations (Chiu & Wray 2011; Cigolle et al. 2011), the values of
common control variables such as body mass index (BMI), income, and comorbidities
could actually have resulted from, rather than contributed to, the person’s diabetes status
(Bertoni & Goff 2011; Brown, Pagán, & Bastida 2005; Caruso, Silliman, Demissie,
Greenfield, & Wagner 2000; C. Cheng et al. 2014). In estimating the association between
prevalent diabetes and functional limitations, the investigator can either leave these
covariates out of the model, raising the likelihood of confounding, or include them,
running the risk of conditioning on a mediator. This study will provide a more accurate
estimate of the relation between diabetes and functional limitation by controlling for
factors known to precede diabetes diagnosis, including time-varying characteristics that
change between baseline and diagnosis, and not for behaviors or conditions that follow it.
Propensity-score methods are often preferred for reducing bias due to confounding
(Rosenbaum & Rubin 1983; Rosenbaum 2010), and risk-set matching in particular is a
preferred method for controlling for time-varying covariates when the exposure is timevarying (Rosenbaum 2010). A propensity-score based assessment has not been applied in
the study of the relationship between incident diabetes and mobility limitations.
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3.2

METHODS

Study population
HRS is an ongoing longitudinal study representative of the U.S. population aged
50 and older, with biennial interviews collecting data on health status, demographics,
health behavior, health care use, income and wealth (Health and Retirement Study 2013).
Details on HRS are reported elsewhere (Heeringa & Connor 1995). A standardized data
file made available by the RAND corporation was used (RAND 2011), confined to the
original HRS cohort, born 1931 to 1941, and the “War Babies” cohort, born 1942 to
1947. The baseline observation for the original HRS cohort is 1992, and for the War
Babies 1998. Each biennial interview of cohort members is called a wave and
corresponds to a discrete date.
Response rates in the initial wave of each cohort were calculated as the number
who responded divided by the number of eligible sample members. For subsequent
waves, response rates were defined as the number who responded divided by the number
of initial-wave respondents still alive. The original HRS cohort had an initial sample size
(in 1992) of 12,652, representing an 81.6% overall response rate. Each subsequent wave
had over an 85% response rate. The War Babies cohort had an initial sample size (in
1998) of 2,529, for a 69.9% response rate. Response rates in subsequent waves were
always at least 87% (Health and Retirement Study 2011). Spouses of target respondents
were included in the sample by HRS; I excluded spouses whose actual birth cohort did
not align with their survey cohort, e.g. a spouse born in 1948 who was included in the
War Babies survey cohort. Individual respondent weights are provided for each year a
84

subject is observed to make each sample cohort representative of the U.S. population
born during the given years.
There were 12,230 subjects in the appropriate survey and birth cohorts. 501 were
excluded because they did not respond to the baseline survey (1992 for HRS, 1998 for
War Babies) but had been added to the dataset later. An additional 1,094 subjects
reported having diabetes at baseline. The 987 subjects who provided fewer than three
survey responses over the course of the study period were excluded, and two additional
subjects had zero values for sampling weights, indicating their responses were valid for
individual-level analysis (Health and Retirement Study 2010). The analytic sample size
was thus 9,646. Time between first and last observation averaged 14.7 years and ranged
from 4 to 18 years.

Measures
Disability is a gap between personal capacity and environmental demand
(Verbrugge & Jette 1994). Rather than being synonymous with diseases or impairments,
disability is best viewed as a late stage in a pathway that begins with pathologies or
diseases, such as diabetes, goes through impairments, such as neuropathy, then follows
with functional limitations, such as pain or numbness in the lower extremities, and finally
restrictions on a person’s ability to function in society, such as the inability to get from
place to place. Impairments affect organs or systems in the body; functional limitations
refer to basic bodily or mental actions irrespective of the social context; and participation
restrictions are about the person’s interaction with society (Nagi 1976). The last category,
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participation restrictions, is what the disabilities literature refers to as “disability”
(Verbrugge & Jette 1994). Therefore, impairments and functional limitations are properly
measured objectively, while disabilities are best understood subjectively. However, many
activities, such as walking a specified distance or climbing stairs, the outcomes examined
in this paper, fall on the boundaries between functional limitations and disabilities.
The outcome under study is lower-extremity mobility limitation, because of the
biological link between diabetes and lower extremity impairments (Laditka & Laditka
2006). HRS asks, “Because of a health or memory problem, do you have any
difficulty…?”. The outcome variable can take values 0 through 5 because five lowerextremity mobility activities were measured: walking one block, walking several blocks,
walking across a room, climbing one flight of stairs, and climbing several flights of stairs.
Diabetes status is determined by self-reported diagnosis. HRS asks, “Has a doctor
ever told you that you have diabetes or high blood sugar?”. Incident diabetes is defined as
not reporting a diabetes diagnosis at one wave and reporting a diagnosis in the subsequent
wave. An individual is considered to have diabetes for every wave subsequent to his/her
initial report of diabetes diagnosis. There were 2,000 incident cases of diabetes during the
years of data collection. The number of mobility limitations at the time of diagnosis is
assumed to be the number of limitations at the last wave prior to diagnosis, to avoid
possibly adjusting for limitations that follow from diabetes. A sensitivity analysis defined
the number of mobility limitations at the time of diagnosis as the number of mobility
limitations at the subject’s first report of a diagnosis.
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All covariates were self-reported. The following time-invariant covariates were
used in the analysis: parents’ years of education, self-rated health in childhood, gender,
race/ethnicity (white, black, Hispanic), whether foreign born, and own years of education.
The time-varying covariates were: age, marital status, region of residence (Northeast,
Midwest, South, West), health insurance, employment status, income, wealth, smoking
(current, former, never), BMI (kg/m2), self-rated current health; the presence of high
blood pressure, heart diseases, and arthritis; a history of stroke; and number of mobility
limitations prior to diabetes diagnosis. A recent study showed that mobility limitations
were associated with subsequent diabetes incidence, emphasizing the need to control for
mobility limitations that precede it (Bardenheier et al. 2014). The rich set of
socioeconomic variables, including parents’ education and total wealth, distinguish this
study from most of the literature on this topic (Wong et al. 2013).
Only four covariates had a large number of missing values: BMI (70 to 120 cases
missing per wave), mother’s education (845 missing cases, time-invariant), father’s
education (1,246 missing cases, time-invariant), and childhood health (355 missing cases,
time-invariant – all individuals who were last observed in 1996). Missingness of a
parent’s education variable is likely correlated with own education, race, and income,
which are likely correlated with both diabetes onset and disability accumulation. Single
random imputation was used to assign values of parents’ education to missing cases,
under the assumption, known as “missing at random,” that whether parents’ education is
missing is independent of its true value, conditional on observed variables. This is a much
weaker assumption than the “missing completely at random” assumption employed by
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other standard methods of dealing with missing data (Allison 2002). The parent’s
education variable was regressed onto sociodemographic covariates (age, gender,
race/ethnicity, nativity, education, region, income). The observations missing parent’s
education take a value equal to the fitted value based on the regression plus a randomly
generated error (Allison 2002).
For the missing BMI values, linear interpolation was used to assign a value based
on the values the individual supplies in other waves: If the subject’s BMI is 28 kg/m2 in
1998 and 32 in 2002 and missing in 2000, their assigned BMI in 2000 is 30. All subjects
had a valid baseline BMI value. Linear interpolation was unable to fill in BMI values for
534 person-observations. The individuals missing values for childhood health were all
last observed in 1996, before the question was asked. In other words, missingness of the
childhood health variable is a function of attrition from the study. Individuals last
observed in 1996 were assigned the average childhood health value among individuals
who died or were dropped from the study sample prior to 2010 but had nonmissing
childhood health values; this average value was 1.80 with 1=best health, 5=worst health.
All other covariates have fewer than 20 missing values per wave, negligible in a sample
size of thousands.

Matching method
When an exposure might occur at different times, risk-set matching can be used to
ensure that exposed individuals – those who report incident diabetes – and control
individuals look similar prior to exposure while avoiding matching on characteristics
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occurring after exposure (Rosenbaum 2010; Sylvestre, Huszti, & Hanley 2006). By
matching individuals with similar characteristics up to the time of diabetes diagnosis,
risk-set matching ensures that exposed and control units have been observed for the same
amount of time, respecting the temporal structure of the data and avoiding so-called
“immortal time bias” (Sylvestre et al. 2006), in which assignment to exposed or control
groups requires using information obtained after the exposure. This bias applies when
treated units have a built-in health advantage because they must have survived up to the
point of treatment, whereas control units could have died at any time, or, as in the case of
this study, when control units have a built-in health advantage because they must have
survived until the end of the study period without exposure (Rosenbaum 2010).
A time-dependent propensity score was constructed using a discrete-time hazard
model fit with logistic regression (Singer & Willett 1993). The propensity score is the
predicted probability that the individual will develop diabetes in the given period,
conditional on the values of the person’s covariates. The observation period for the
estimation of the propensity scores extends from baseline until the individual develops
diabetes or is censored, whichever comes first.
Individuals are matched to minimize the total within-pair distance between
exposed and control individuals, with “distance” defined as the rank-based Mahalanobis
distance with a propensity-score caliper penalty function (Rosenbaum 2010; Silber et al.
2009). The variables included in the calculation of the Mahalanobis distance were the
time-invariant covariates, the time-varying covariates measured at the wave prior to
initial report of diabetes, and baseline BMI and self-rated health. Matching based on the
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Mahalanobis distance minimizes the total within-pair distance between the exposed
group’s covariate matrix and the control group’s covariate matrix, while the propensity
score-based penalty ensures that the distance between any two matched individuals
within a single pair is not too large (Rosenbaum 2010). Covariate balance is assessed by
comparing standardized exposed-control differences in covariates, with standardized
differences below 0.1 considered good balance and below 0.2 considered acceptable
(Rosenbaum & Rubin 1985; Silber et al. 2001), and with significance tests for differences
in means.
To be matched as an exposed unit, an individual needed to provide complete data
– a full vector of independent variables and diabetes status – for both the first wave where
diabetes is reported (i.e. when diabetes incidence is ascertained) and the wave
immediately preceding it (when covariates are measured). If some information was
missing, and especially if the individual had missing data for the wave immediately
preceding the first report of diabetes, and thus the period of onset of their diabetes was
uncertain, the individual was only eligible to be matched as a control unit. (See (Lu 2005)
for details about data requirements in risk-set matching.)
At each wave, each incident diabetes case is matched to a diabetes-free individual.
Cases are matched to controls separately for the original HRS and War Babies cohorts.
Each control individual can only be matched to one case; see Figure 3-1 for an
illustration of the matching procedure. The matching was implemented using the
pairmatch command in the optmatch package (Hansen & Klopfer 2006) in R (R Core
Team, Vienna, Austria).
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Analysis of outcome
The dependent variable is first defined as the difference between an individual’s
mobility limitations at censoring and the individual’s average number of mobility
limitations prior to diabetes diagnosis (Lu 2005). Censoring time is the last wave in
which both individuals in the pair were observed, ensuring the same length of follow-up
within pairs. A one-sided Wilcoxon signed rank test is applied to the dependent variable
to test the null hypothesis of no effect of incident diabetes on mobility limitations, and an
asymmetric confidence interval is constructed by inverting the Wilcoxon test
(Rosenbaum 2003). A rejection of the null hypothesis would imply the following: Under
the assumption of no unmeasured confounding, incident diabetes increases the number of
mobility limitations a person accumulates.
Then, a right-censored Poisson model was fit (Winkelmann 2003), with the
dependent variable defined as the number of limitations at censoring time, accounting for
length of follow-up. The independent variables are an indicator exposure status and the
matched pair’s total number of mobility limitations at censoring time (Lachin 2011).
Because the matched pairs in this regression model are made using risk-set matching, the
regression retains the useful properties of risk-set matching: time ordering is respected,
and covariates are balanced both at baseline and just prior to exposure. The exponentiated
coefficient, or rate ratio, for the exposure variable estimates the expected proportionate
number of mobility limitations at study exit for a person who develops diabetes, relative
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to a matched individual who does not. The model was fit using the rcpoisson command
(Raciborski 2011) in Stata 13.1 (StataCorp, College Station, TX).

3.3

RESULTS

Descriptive statistics
The average age of participants who reported no diabetes at study entry was 54.48
(SD: 3.04) and average number of mobility difficulties was 0.78 (SD: 1.22) (Table 3-1).
A comparison of individuals excluded from the analytic sample, due to having
diabetes at baseline, to those included (Appendix Table A.3.1a) reveals that the
excluded individuals tended to be more socioeconomically disadvantaged and less
healthy at baseline than included individuals. Excluded individuals were more likely to
be high school dropouts and to have had a history of smoking. They were less wealthy on
average, and they reported more chronic conditions (high blood pressure, arthritis, and
stroke) and more disabilities. Individuals who had diabetes at baseline had an average
BMI more than 3 kg/m2 higher than included individuals, over twice the prevalence of
high blood pressure, and over four times the prevalence of having had a stroke.
Appendix Table A.3.1b shows the progression of each cohort through time. I
observe 1,699 incident cases of diabetes in the HRS cohort and 301 in the War Babies
cohort. In each cohort, the number of incident cases (and the implicit incidence rate,
though this rate is subject to assumptions about mortality and attrition between the two
data collection times) generally rise with age, but not monotonically. The number of
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incident cases observed in a given wave is the maximum number of individuals who can
be matched as “exposed” units for the period (interval) that precedes the given wave.

Covariate balance
Table 3-2 shows the results of the matching procedure. 1,602 individuals who
developed diabetes were matched to 1,602 controls who had not been diagnosed with
diabetes as of the wave of matching. There were 136 individuals who reported diabetes
during the study period but whose period of onset was uncertain, of which 9 were
matched as controls and 127 were left unmatched. Additionally, to be included in
analysis of the outcome, both units in a matched pair had to provide nonmissing data on
mobility limitations at baseline, at the last wave prior to first diabetes report, and at
censoring time. Since censoring time is defined as the last wave in which both individuals
in a matched pair are observed, censoring time is unknown prior to matching. That raises
the possibility that some matched pairs will have to be dropped following matching, if
they have missing values for mobility limitations at censoring time. Nine such pairs were
matched and then dropped, leaving 1,593 case-control pairs for analysis.
An approach to estimating the relation between incident diabetes and mobility
limitations that does not use risk-set matching might take a sample of individuals who are
non-diabetic at baseline and compare those who developed diabetes at any point during
data collection to those who never developed diabetes. In the non-risk set matching
approach, the difference in the mean number of mobility limitations at last wave prior to
incident diabetes between the exposed group and the control group was 0.446 of a
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limitation, or 62.7% of the mean in the never-diabetic group (Table 3-2). Comparisons of
subsequent mobility limitations using the non-risk set matching approach would not
control for this pre-exposure difference. An estimate of the diabetes-mobility limitation
relationship using this approach would thus be biased upwards. In contrast, when using
risk-set matching, the exposed-control group difference in means was 0.112 of a
limitation, or 10.9% of the control group mean (Table 3-2), and in standard deviation
units, the difference declined from 0.239 to 0.060.
Table 3-2 also shows that, without matching, the exposed and control groups
were statistically significantly different in terms of other key covariates, including BMI at
baseline (exposed mean: 29.86 kg/m2 vs. control mean: 26.31) and self-rated health just
prior to diagnosis (3.031 vs. 2.568 where 1=excellent health). In all cases, the covariate
differences between exposed and control groups prior to matching imply that the exposed
group was both more likely to develop diabetes (see Appendix Table A.3.2a) and more
likely to experience mobility limitation even without diabetes. Thus, a failure to balance
exposed and control groups on these variables would bias estimates of the diabetesmobility limitation relationship upward. Table 3-2 shows that these variables were
balanced after risk-set matching; for example, the difference in mean BMI at baseline
between exposed individuals and matched controls was only 0.25 kg/m2. See Appendix
Table A.3.2b for a complete accounting of covariate differences before and after
matching.

Outcome analysis
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Table 3-3 tests the null hypothesis that there was no difference in the change in
mobility limitations between exposed individuals and their matched controls. At the
median, individuals who developed diabetes experienced a 0.25-unit larger increase in
mobility limitations than their matched controls (sign-rank P=0.0001). A 0.25-unit larger
increase among cases than controls is substantively important, considering that the
average number of limitations reported at baseline was only 0.79. The average postdiagnosis increase in self-reported mobility limitations in the exposed group was 0.55 of
a mobility limitation, and in the matched control group 0.37 of a limitation (sign-rank
P=0.0001).
The estimated rate ratio of 1.249 (Table 3-4, column 2) implies that people in the
sample who developed diabetes had, on average, 24.9% more mobility limitations at
study exit than matched individuals who did not develop diabetes, when both individuals
were followed for the same post-exposure period. A comparison of the two columns in
Table 4 shows a similar association between diabetes and mobility limitations regardless
of the total number of mobility limitations in the matched pair.

Sensitivity Analyses and Subgroup Analyses
To test the sensitivity of the results to the use of self-reported diagnosis, similar
analysis was performed excluding matched pairs in which the control unit would later
develop diabetes. Such controls are most likely to have had undiagnosed diabetes at the
time of matching. Results were similar when dropping matched pairs in which the control
individual would later be diagnosed with diabetes (271 pairs; Appendix Table A.3.3a).
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Appendix Table A.3.3b shows that results were also robust to an alternative
parameterization of the number of mobility limitations at diabetes diagnosis.
In Appendix A.3.4, the sensitivity of the results to possible unmeasured
confounding are examined, following Rosenbaum (Rosenbaum 1987, 2002). Suppose
there exists an unmeasured confounder that is positively associated with the development
of mobility limitations, such as a genetic predisposition toward development of diabetes
after age 50. Such a variable would have to raise the probability of developing diabetes
by 15% for one subject in each matched pair in order to explain the associations
discussed above.
Finally, examining the association between diabetes incidence and mobility
limitations among obese individuals could shed light on the complex relationships among
obesity, diabetes, and mobility limitations. On the one hand, obesity could exacerbate the
disabling consequences of diabetes; on the other hand, if obesity on its own exerts a
strong negative effect on mobility, then it could mute the estimated effect of diabetes on
mobility limitations. To explore the role of obesity, I analyze the outcome for the 466
matched pairs in which both the exposed and control units were obese at baseline.
The average mobility decline in the exposed group was 0.63 of a limitation and in
the control group was 0.43 of a limitation, close to the results found for all matched pairs
(Appendix Table A.3.5a). Similarly, Appendix Tables A.3.5b and A.3.5c show that the
nonparametric test of significance and sensitivity of the results to unmeasured
confounding produce very similar results when looking only at pairs in which both units
were obese at baseline as when looking at all the matched pairs: a significant difference
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in mobility decline, an estimated median difference of 0.25 of a limitation, and results
that are somewhat sensitive to unmeasured confounding.

3.4

DISCUSSION
This study uses risk-set matching to estimate the association between incident

diabetes and subsequent mobility limitations. Individuals who developed diabetes
experienced significantly larger increases in mobility limitations than matched controls;
the median difference in the change in mobility limitations was 0.25 limitations, out of a
maximum of five. This is a fairly large difference, given that the average number of
mobility limitations at baseline was 0.78 (Table 3-1). At study exit, people in the sample
who developed diabetes reported an estimated 24.9% more limitations than were reported
by matched controls. These results were robust to a number of alternative specifications.
The study reduces many of the potential biases found in prior estimates of the
relationship between diabetes and physical function limitations. In particular, by
including only individuals who were diabetes-free at baseline and examining incident
diabetes, bias from unobserved underlying health is reduced and factors that precede
diabetes diagnosis are controlled without “controlling” for factors that follow it. Results
show that the incident-diabetes and matched-control groups were balanced on measured
confounders prior to diabetes onset.
The increased risk of physical functioning difficulties associated with diabetes as
estimated in this study is lower than previous estimates (Cigolle et al. 2011; Dhamoon,
Moon, Paik, Sacco, & Elkind 2014; Gregg et al. 2002; Kalyani, Saudek, Brancati, &
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Selvin 2010; P. G. Lee et al. 2013; Wong et al. 2013; Wray, Ofstedal, Langa, & Blaum
2005). One difference between this and past investigations is that the current study
controlled for a richer set of background socioeconomic and health conditions than most
of the literature has done (Haas 2008; Herd, Goesling, & House 2007; Wong & Gregg
2013). Another important difference is that this study focuses on incident diabetes as the
measure of exposure while prior studies focus on prevalent diabetes. As discussed in the
introduction, prevalence-based estimates incorporate the effects of diabetes on
functioning difficulties and the effects of functioning difficulties on the risk of
developing diabetes. This study avoids incorporating the latter pathway, which is a source
of bias.
Prevalence-based estimates also incorporate the effect of the duration of diabetes
on functioning limitations, while the incidence-based estimates presented in this paper do
not account for duration (see Appendix A.3.6). Since the duration of diabetes likely
increases the risk of limitations, due to the progression of peripheral neuropathy and
accumulation of comorbidities (Bruce, Davis, & Davis 2005; Stenholm et al. 2014), the
estimates presented here might thus be considered a “lower bound” of the overall effect
of diabetes on physical functioning limitations.
The study is subject to several limitations. First, because diabetes status was
ascertained based on self-report, undiagnosed individuals are treated as non-diabetic. An
alternative specification (Appendix Table A.3.3a) that excluded pairs in which the
control individual later developed diabetes suggests that this limitation might not be
severe, but it does not address the possibility that exposed individuals might have
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developed diabetes years before they were diagnosed. Second, although missing data
were addressed using recommended techniques, they could still create selection bias in
the matching process. Third, the focus on mobility limitations ignores the many other
types of functional limitations to which diabetes could contribute, such as limited vision
(Cigolle et al. 2011). Examining other outcomes would provide a more comprehensive
picture of the association between diabetes and physical limitations and would likely
increase the estimated magnitude of the association (Cigolle et al. 2011).
An assumption used throughout the analysis is that whether and when a person is
censored from the study – through death or attrition – does not provide information on
their accumulation of mobility limitations. Censoring by death may be informative;
however, in theory, informative censoring could bias the results in either direction, and it
is difficult to determine which direction is more likely. Finally, because the analysis
focuses only on individuals born 1931 to 1947, it might not generalize to younger
cohorts.
Although the results might be sensitive to unmeasured confounding (see
Appendix A.3.4), the confounding would have to be of a fairly specific type.
Unmeasured confounding that is positively associated with mobility limitation would
have to raise the probability of developing diabetes, conditional not only on the host of
early-life and current conditions this analysis controls for, but also on being diabetes-free
at study entry. Those with diabetes at study entry were substantially sicker than the
average sample individual on a range of measures. Unmeasured confounders that make
people’s underlying health poor – and thus increase the probability of both diabetes and
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mobility limitation – are likely strongest among the people who already had diabetes at
entry into the study. Because these individuals were excluded, general, unmeasured
underlying health is less likely to confound the results.
As the U.S. population ages and the prevalence of chronic diseases such as
diabetes increases, increasing our knowledge of the relationships between specific
diseases and physical functioning difficulties will enhance our understanding of barriers
to healthy aging among older Americans. The methods used in this paper reduce the bias
in estimates of the effect of diabetes on increased mobility limitation. Given the high
prevalence of mobility limitations and disabilities at older ages (Freedman et al. 2013),
the rate ratios estimated in this paper amount to a large number of people whose mobility
limitations result from diabetes. A randomized trial among people with diabetes showed
that an intensive lifestyle intervention for weight loss improved physical functioning
outcomes (Rejeski et al. 2014), implying considerable potential for improved diabetes
management to reduce the burden of physical functioning limitations in the old-age
population.

100

Figure 3-1: Illustration of Risk-Set Matching

Suppose there are eleven individuals in the cohort when the study begins in 1992,
identified A through K. At the beginning of the study, they are aged 51 to 61 last
birthday, respectively. In 1996, Subject A first reports having diabetes. At this point,
Subject A is matched with someone in the risk set. The risk set consists of everyone who
is still in the study, does not yet have diabetes, and has not yet been matched prior to
1996 (represented by solid life lines up to 1996). In this cohort, all subjects are in the risk
set in 1996. Based on the similarity of their covariate matrices (characteristics observed
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in 1992 and 1994), Subject C is matched as a control to Subject A. The pair is followed
until the end of the study, represented by the dotted life lines. Subject C remains a control
for Subject A even though Subject C reports having diabetes in 2000. The vertical dashed
line at 1996 is the first “post-exposure” wave, i.e. the first wave after Subject A was
diagnosed with diabetes. The change in disability from 1996 to 2010 for Subject A is
compared to the change in disability from 1996 to 2010 for Subject C.
In 2006, subject F first reports having diabetes. Subject F is now matched with
someone in the risk set, which consists of all the subjects with solid life lines up to 2006.
Subjects A and C have already been matched, and subject K has died, so those three
subjects are not in the risk set for 2006. Subject I is matched as a control to subject F. The
pair is followed through 2008, which is the last time subject I is observed in the data set.
The change in disability between from 2006 to 2008 for Subject F is compared to the
change in disability from 2006 to 2008 for Subject I.
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Table 3-1: Weighted means (SDs) or percentages at study entry for individuals
included in propensity score matching
Mean (SD) or
Variable type
Variable
Percentage
Time-invariant
Mother's education (years)
9.82 (3.59)
Father's education (years)
9.46 (3.94)
Childhood health (1=excellent) 1.76 (0.96)
Female (%)
50.55
Black (%)
9.65
Hispanic (%)
6.57
Foreign born (%)
8.70
Education (years)
12.77 (2.95)
Time-varying: demographic
Age
54.48 (3.04)
Married (%) a
80.51
a
Not Married (%)
19.48
Northeast (%)
19.42
Midwest (%)
24.79
South (%)
37.23
West (%)
18.55
Time-varying: economic
No health insurance (%)
17.32
Works full-time (%)
62.15
Works part-time (%)
10.02
Unemployed (%)
1.98
Retired (%)
12.97
Not in labor force (%)
9.35
On work disability (%)
3.52
Income per household member
($)
27,119 (40,401)
Wealth ($)
230,037 (489,000)
Time-varying: health
Smokes now (%)
26.12
Ever smoked (%)
62.23
2
BMI (kg/m )
27.09 (5.07)
Self-rated health (1=excellent)
2.39 (1.13)
High blood pressure (%)
28.04
Heart problems (%) b
7.70
Stroke (%)
1.75
Arthritis (%)
30.27
# Mobility limitations (max=5) 0.78 (1.22)
0 (%)
53.70
1 (%)
24.14
2 (%)
10.07
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3 (%)
4 (%)
5 (%)
Missing (%)

5.18
4.15
2.72
0.04

# subjects
9646
Notes: Health and Retirement Study, United States, 1992-2010.
a
Marital status groups: married, partnered, widowed = “Married”; divorced, separated,
never married = “Not married”.
b
Heart problems: heart attack, coronary heart disease, angina, congestive heart failure, or
“other heart problems” (RAND 2011).
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Table 3-2: Covariate balance without vs. with risk-set matching, selected variables
No risk-set matching
With risk-set matching
StandarStandarExposed Control
dized
P for Exposed Control
dized
P for
a
b
a
When measured Variable
mean
mean
diff
diff
mean
mean
diff
diff b
Female
0.500
0.532
-0.046
0.010
0.501
0.514
-0.019
0.458
Time-invariant Own educ (yrs)
11.7
12.5
-0.181 <0.001
11.8
11.9
-0.010
0.914
Black
0.215
0.140
0.138 <0.001
0.209
0.180
0.053
0.040
c
Self-rated health
2.730
2.379
0.216 <0.001
2.699
2.642
0.035
0.246
2 d
Study entry
BMI (kg/m )
29.86
26.31
0.497 <0.001
29.62
29.37
0.035
0.082
# mobility lims e
1.203
0.822
0.202 <0.001
1.200
1.082
0.063
0.017
c
Self-rated health
3.031
2.568
0.302 <0.001
3.000
2.948
0.034
0.201
Observation
2
d
prior to incident BMI (kg/m )
30.941
30.080
0.106 <0.001
30.640 30.526
0.014
0.410
e
diabetes
# mobility lims
1.156
0.710
0.239 <0.001
1.138
1.026
0.060
0.057
Number of individuals
2,000
7,646
1,602
1,602
Notes:
a
Standardized difference = ((exposed group mean) – (control mean))/(Pooled standard deviation).
b
P-values from Pearson chi-squared tests for binary variables (female, black), Wilcoxon rank-sum tests for numeric variables (e.g.
BMI).
c
Self rated health: 1=excellent, 5=poor.
d
BMI = Body Mass Index.
e
Maximum = 5.

105

Table 3-3: Change in mobility limitations, exposed vs. matched control individuals
Parameter

Estimate

Hodges-Lehman estimate, 95% confidence interval a
Sign-rank P value b
Average change in # mobility limitations c: exposed group
Average change in # mobility limitations c: matched
controls
P-value for difference b

0.25 [0.0001,0.2501]
0.0001
0.554
0.366
0.0001

Notes:
Num. pairs = 1,593.
a
Hodges-Lehman estimate is the median of pairwise Walsh averages (approximately, the
median within-pair difference). Confidence interval is asymmetric because of the highly
discrete nature of the dependent variable.
b
P-value from Wilcoxon signed-rank test for H0: Change in mobility limitations among
exposed = change in mobility limitations among matched controls.
c
Change in mobility limitations = (# limitations at censoring) – ([# limitations just prior
to exposed individual’s diabetes diagnosis] + [# limitations at baseline])/2.
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Table 3-4: Rate Ratios from Censored Poisson Regression of Mobility Limitations
onto Incident Diabetes
Dependent variable = Number of mobility limitations at censoring (maximum=5,
median=1) a
(1)
(2)
Incident diabetes

1.220***
[1.122,1.328]

1.249***
[1.149,1.357]

# limitations in
pair

--

1.362***
[1.341,1.384]

N

3186

3186

Notes:
*
P < 0.05, **P< 0.01, ***P< 0.001 (two-sided tests).
a
Censoring time defined as last wave in which both observations in a matched pair were
observed.
Model (1) regresses the dependent variable onto an indicator for being the “exposed”
individual in the matched pair (i.e. the one who developed diabetes), accounting for
length of follow-up. Model (2) adds a covariate for the total number of mobility
limitations in the matched pair. Robust standard errors used.
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A.1. Appendices to Chapter 1 (Cohort Dynamics of Diabetes)
A.1.1. Cohort Obesity Prevalence
The prevalence of obesity at age 25 in successive cohorts, used in our age/period/cohort
model as a continuous variable, is shown in the following table:
Table A.1.1 a: Prevalence of Obesity at age 25, by birth cohort
Birth Years
Percent
1920-1924
2.00%
1925-1929
2.58%
1930-1934
3.34%
1935-1939
3.46%
1940-1944
3.96%
1945-1949
4.85%
1950-1954
5.99%
1955-1959
6.99%
1960-1964
8.47%
1965-1969
11.32%
1970-1974
14.52%
1975-1979
15.92%
Sources: Calculated from NHANES continuous waves 1999-2008 using the interview
sample.

One limitation of our study is that we used retrospective data on height and
weight to estimate trends in cohort obesity at age 25 for subsequent US birth cohorts.
Recall data may be subject to errors of misreporting. However, prior research using
longitudinal data found a relatively high degree of correspondence between recall and
contemporaneously reported data on BMI (Perry, Byers, Mokdad, Serdula, & Williamson
1995). Validity of recall data over longer intervals of time has not been investigated. A
second limitation is that we were not able to investigate cohort trends in obesity at
younger ages because of lack of data on trends in childhood and adolescence.
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A.1.2. Prevalence Estimates and Confidence Intervals
Results displayed in Figures 1a and 1b are shown in more detail in the following tables.
Table A.1.2 a: Age-Specific Prevalence Across Observation Periods
Period:
1988-1994
1999-2002
2003-2006
2007-2010
Age
Estimate
95% CI
Estimate 95% CI
Estimate 95% CI
Estimate
95% CI
20-24
0.004397 (0,0.009)
0.004269 (-0.001,0.009) 0.00623 (0.002,0.011)
0.005288 (-0.002,0.012)
25-29
0.004864 (0.001,0.009) 0.017177 (0.007,0.027)
0.02294 (0.01,0.035)
0.021857 (0.011,0.033)
30-34
0.008792 (0.004,0.014) 0.026586 (0.008,0.045)
0.02416 (0.013,0.035)
0.028596 (0.018,0.039)
35-39
0.032287 (0.015,0.05)
0.029327 (0.016,0.043)
0.03726 (0.022,0.052)
0.039685 (0.028,0.051)
40-44
0.045436 (0.03,0.06)
0.046697 (0.033,0.061)
0.04710 (0.03,0.064)
0.052208 (0.036,0.069)
45-49
0.050596 (0.036,0.066) 0.070413 (0.045,0.096)
0.0677 (0.048,0.087)
0.085597 (0.061,0.11)
50-54
0.091078 (0.063,0.119) 0.096351 (0.073,0.12)
0.11732 (0.095,0.14)
0.1389 (0.113,0.165)
55-59
0.114349 (0.091,0.138) 0.114759 (0.087,0.142)
0.15295 (0.112,0.194)
0.156262 (0.12,0.192)
60-64
0.153817 (0.129,0.178) 0.178177 (0.146,0.21)
0.16539 (0.138,0.193)
0.192598 (0.151,0.234)
65-69
0.140782 (0.109,0.172) 0.193894 (0.158,0.23)
0.20029 (0.164,0.237)
0.264501 (0.204,0.325)
70-74
0.142179 (0.112,0.173) 0.160267 (0.126,0.194)
0.21140 (0.175,0.247)
0.248475 (0.218,0.278)
75-79
0.186321 (0.148,0.224) 0.160083 (0.113,0.207)
0.18344 (0.145,0.222)
0.230738 (0.182,0.279)
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Table A.1.2 b: Age-Specific Diabetes Prevalence by Birth Cohort
Cohort:
1910-1919
1920-1929
1930-1939
1940-1949
Age
Estimate 95% CI
Estimate 95% CI
Estimate 95% CI
Estimate 95% CI
20-24
25-29
30-34
35-39
40-44
0.0613 (0.031,0.091)
45-49
0.0506 (0.036,0.066)
50-54
0.0743 (0.048,0.1)
0.1043 (0.075,0.134)
55-59
0.1143 (0.091,0.138)
0.1460 (0.119,0.173)
60-64
0.1596 (0.128,0.191)
0.1626 (0.131,0.194)
0.1814 (0.158,0.205)
65-69
0.1408 (0.109,0.172)
0.2059 (0.178,0.234)
0.2430 (0.191,0.295)
70-74
0.1337 (0.098,0.17)
0.1506 (0.119,0.182)
0.2190 (0.198,0.24)
0.2620 (0.13,0.394)
75-79
0.1863 (0.148,0.224)
0.1724 (0.14,0.204)
0.2246 (0.179,0.27)
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(Table A.1.2b, continued)
Cohort: 1950-1959
Age
Estimate 95% CI
20-24
25-29
30-34
0.0051
(0.001,0.009)
35-39
0.0323
(0.015,0.05)
40-44
0.0364
(0.023,0.05)
45-49
0.0733
(0.056,0.09)
50-54
0.1229
(0.106,0.14)
55-59
0.1406
(0.109,0.172)
60-64
0.1721
(0.105,0.24)
65-69
70-74
75-79

1960-1969
Estimate 95% CI
0.0079
(0,0.016)
0.0049
(0.001,0.009)
0.0203
(0.01,0.031)
0.0324
(0.023,0.042)
0.0507
(0.04,0.061)
0.0770
(0.057,0.097)
0.1054
(0.045,0.166)

1970-1979
Est.
95% CI
0.0022 (-0.001,0.006)
0.0211 (0.013,0.03)
0.0257 (0.017,0.034)
0.0403 (0.029,0.052)
0.0497 (0.007,0.092)
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1980-1989
Est.
95% CI
0.0058 (0.002,0.009)
0.0201 (0.009,0.031)
0.0364 (-0.009,0.081)

A.1.3.
Results of Models of Prevalence of Diabetes
Results displayed in Figures 2 and 3 are shown in more detail in the following tables.
Table A.1.3 a: Results of Age-Cohort Model
Dependent Variable = Log Diabetes Prevalence
Indicator
Coefficient SE
t-statistic
Age 25-29
1.080695 0.292925 3.689325
Age 30-34
1.704125 0.314012 5.426944
Age 35-39
2.532282 0.328767 7.702351
Age 40-44
2.96014 0.342128 8.652146
Age 45-49
3.384705 0.367831 9.201791
Age 50-54
3.988511 0.395827 10.0764
Age 55-59
4.232604 0.430616 9.829178
Age 60-64
4.553761 0.435592 10.45419
Age 65-69
4.748697 0.46782 10.15069
Age 70-74
4.791991 0.494981 9.68117
Age 75-79
4.92001 0.536914 9.163504
1920-29 cohort
0.0491136 0.446574 0.109979
1930-39 cohort
0.3153463 0.443356 0.711272
1940-49 cohort
0.4939475 0.492615 1.002704
1950-59 cohort
0.5045705 0.527574 0.956399
1960-69 cohort
0.809644 0.554556 1.459987
1970-79 cohort
1.161477 0.583122 1.991825
1980-89 cohort
1.588968 0.630111 2.521726
constant
-6.687672 0.60934 -10.9753
R-Squared
0.9486
N
41

p-value
0.001283
1.89E-05
1.1E-07
1.57E-08
5.36E-09
1.05E-09
1.65E-09
5.35E-10
9.19E-10
2.17E-09
5.77E-09
0.913423
0.48439
0.326905
0.349263
0.158427
0.058947
0.019422
2.16E-10

95% CI
0.473206 1.688185
1.052904 2.355346
1.85046 3.214103
2.25061 3.669669
2.62187 4.14754
3.167616 4.809406
3.33956 5.125647
3.650399 5.457124
3.778497 5.718897
3.765464 5.818518
3.806519
6.0335
-0.87702 0.975251
-0.60412 1.234809
-0.52767 1.515569
-0.58955 1.598691
-0.34043 1.959722
-0.04784 2.370798
0.282197 2.895739
-7.95137 -5.42398

Age/Cohort Model: ln(Yia) = α +βaXa + βiXi, where Yia = the proportion of the population
in cohort i at age a with diabetes, Xa is a dummy variable indicating that the observation
pertains to age a, and Xi is a dummy variable indicating that the observation pertains to
cohort i.
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Table A.1.3 b: Results of Age-Period Model
Dependent Variable: Log Diabetes Prevalence
Indicator
Coefficient SE
t-statistic p-value
95% CI
Age 25-29
0.8340861 0.177858 4.689627 4.59E-05 0.472232 1.19594
Age 30-34
1.229262 0.176308 6.972242 5.69E-08 0.87056 1.587963
Age 35-39
1.935714 0.176051 10.99518 1.43E-12 1.577535 2.293892
Age 40-44
2.256934 0.173813 12.98482 1.61E-14 1.903309 2.61056
Age 45-49
2.564451 0.181592 14.12202 1.52E-15 2.194998 2.933903
Age 50-54
3.056156 0.183954 16.61367 1.36E-17 2.681898 3.430414
Age 55-59
3.259276 0.195733 16.65169 1.27E-17 2.861055 3.657497
Age 60-64
3.512932 0.177514 19.78963 7.07E-20 3.151777 3.874086
Age 65-69
3.625526 0.187088 19.37873 1.34E-19 3.244892 4.006159
Age 70-74
3.586429 0.189392 18.93653 2.7E-19 3.201108 3.97175
Age 75-79
3.620085 0.210792 17.17377 5.08E-18 3.191226 4.048944
2001
NHANES
0.2922673 0.108457 2.694766 0.010993 0.071609 0.512926
2005
NHANES
0.4265295 0.108519 3.930467 0.00041 0.205746 0.647313
2009
NHANES
0.5343021 0.100049 5.34043 6.76E-06 0.330752 0.737852
constant
-5.571567 0.133038 -41.8794 3.46E-30 -5.84224
-5.3009
R-Squared
0.9686
N
48
Age/Period model: ln(Yia) = α +βaXa + βpXp, where Yia = the proportion of the population
in cohort i at age a with diabetes, Xa is a dummy variable indicating that the observation
pertains to age a, and Xp is a dummy variable indicating that the observation pertains to
period p.
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Table A.1.3 c: Results of Age-Period-Cohort Obesity Model
Dependent Variable: Log Diabetes Prevalence
Indicator
Coefficient SE
t-statistic p-value
95% CI
Age 25-29
0.9926029 0.155681 6.375895 5.71E-07
0.6742 1.311005
Age 30-34
1.655445 0.18084 9.154213 4.71E-10 1.285587 2.025304
Age 35-39
2.672352 0.22659 11.79378 1.38E-12 2.208924 3.13578
Age 40-44
3.191595 0.25972 12.28859 5.08E-13 2.660407 3.722782
Age 45-49
3.636119 0.288422 12.60695 2.71E-13 3.046231 4.226008
Age 50-54
4.259973 0.314103 13.56235 4.38E-14 3.61756 4.902385
Age 55-59
4.545092 0.333427 13.63146 3.86E-14 3.863158 5.227026
Age 60-64
4.892977 0.345447 14.16418 1.46E-14 4.186459 5.599496
Age 65-69
5.07219 0.360942 14.05265 1.79E-14 4.333981 5.810399
Age 70-74
5.107939 0.392845 13.00242 1.26E-13 4.304481 5.911398
Age 75-79
5.116603 0.416248 12.2922 5.04E-13 4.26528 5.967926
2001
NHANES
0.0517601 0.119307 -0.43384 0.667616 -0.29577 0.192251
2005
NHANES
0.0782829 0.119932 0.652728 0.519073 -0.16701 0.323571
2009
NHANES
0.0561693 0.142336 0.394624 0.696008 -0.23494 0.347279
obesity
13.10013 2.828275 4.631844 7.05E-05 7.315658 18.8846
constant
-7.107672 0.35859 -19.8212 2.09E-18 -7.84107 -6.37427
R-Squared
0.9813
N
45
Age/Period/Cohort model: ln(Yia) = α +βaXa + βpXp + γCoh_ob, where Yia, Xa, and Xp are
defined as in the Age/Period model and Coh_ob is a continuous variable representing the
prevalence of obesity at age 25 in the cohort corresponding to the given age and period.
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A.1.4. Results when using Fasting Plasma Glucose as the Indicator of Diabetes
The figures below (A.1.4a- 4c) are analogous to Figures 1-3, 1-4, and 1-5 in the main
manuscript. The difference is that in the figures below, diabetes is defined as fasting
plasma glucose ≥ 126 mg/dL and not based on HbA1c. Data are from the National Health
and Nutrition Examination Surveys (NHANES) II, III, and Continuous, United States,
1976-2010.
Figure A.1.4 a: Prevalence as a multiple of 1900-1910 birth cohort prevalence
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Figure A.1.4 b: Age-adjusted diabetes prevalence across observation periods
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Figure A.1.4 c: Age patterns of diabetes prevalence

Prevalence as a multiple of age 20-24 prevalence
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A.1.5. Model Age Pattern of Diabetes Incidence
The model age pattern of diabetes incidence (new cases per person-year without diabetes)
shown in Figure 4 in the main text is shown in detail (values for 1950-59 birth cohort) in
the following table:
Table A.1.5 a: Estimates of Diabetes Incidence for 1950-59 birth cohort
Incidence
with no
differential
Age Interval
Incidence
mortality
20-24 to 25-29 0.000994
0.000934
25-29 to 30-34 0.001693
0.001617
30-34 to 35-39 0.002422
0.002303
35-39 to 40-44 0.003611
0.003429
40-44 to 45-49 0.006399
0.00612
45-49 to 50-54 0.007944
0.007516
50-54 to 55-59 0.011015
0.010359
55-59 to 60-64 0.011268
0.010269
60-64 to 65-69 0.010361
0.008846
65-69 to 70-74 0.009888
0.007609
70-74 to 75-79 0.008723
0.006022
Incidence estimates are based on cohort prevalence estimates from age-cohort model and
life-table values by diabetes status (nondiabetic versus entire population); see Methods
section in text for details. Figure 1-6 in the main text plots the values in the “Incidence”
column above. To demonstrate the effect of using mortality differences by diabetes status
on the estimates, the table shows estimates of incidence that would result if we had
ignored mortality differences by diabetes status.
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A.1.6. Incidence with foreign-born excluded from sample
Figure A.1.6 a: Age pattern of diabetes incidence, foreign-born subjects excluded
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This calculation plots the 1950-59 birth cohort, but the shape of the curve is the same for
all decadal birth cohorts. Foreign-born individuals were excluded from the sample. Data
are from the National Health and Nutrition Examination Surveys (NHANES), United
States, 1988 to 2010.
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A.1.7. Results based on “High Risk” of Diabetes, and Discussion of Threshold
Choice
Appendix Figures A.1.7a and A.1.7b show estimates of the prevalence of “at least
high risk” of diabetes, using HbA1c ≥ 6.0% (42 mmol/mol) (American Diabetes
Association 2012), by period and cohort. Appendix Figure A.1.7c shows the cohort
coefficients from the age/cohort model. Appendix Figure A.1.7d shows the period effects
in the age/period and age/period/cohort models discussed in the Statistical Methods
section, as applied to the threshold HbA1c ≥ 6.0%. Appendix Figure A.1.7e shows the
modeled age-pattern of “at least high risk.”
Although the recent ADA guidelines mention 6.0% as a possible threshold, they
note that there is a “continuum of risk for diabetes with all glycemic measures” and did
not formally identify 6.0% as a formal “high risk” threshold (American Diabetes
Association 2012). A recent meta-analysis indicated that there is no clear HbA1c-based
threshold above which the risk of incident diabetes increases dramatically (Gregg, Geiss,
et al. 2013). Nevertheless, using the 6.0% threshold is a useful way to test the sensitivity
of our methods to the choice of threshold. The patterns found using the 6.0% threshold
are similar to the patterns found using the 6.5% threshold.
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Figure A.1.7 a: Prevalence of HbA1c 6.0%+ in Successive NHANES Waves
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Figure A.1.7 b: Prevalence of HbA1c 6.0%+ in Successive Decadal Birth Cohorts
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Figure A.1.7 c: Age-Adjusted Prevalence of HbA1c 6.0%+ in Birth Cohorts Relative
to 1910-1919 Birth Cohort
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Figure A.1.7 d: Prevalence of HbA1c 6.0%+ Relative to that in 1988-1994
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Figure A.1.7 e: Age-Specific Prevalence of HbA1c 6.0%+ Relative to Age 20-24
Prevalence

Prevalence of HbA1c ≥ 6.0% as a Multiple of Prevalence at Age 20-24
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Table A.1.7 a: Results of Age-Cohort Model
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%)
Indicator
Coefficient SE
t-statistic p-value
Age 25-29
0.8303195 0.121278 6.846402 7.07E-07
Age 30-34
1.474147 0.130009 11.33883 1.17E-10
Age 35-39
1.944194 0.136118 14.28316 1.31E-12
Age 40-44
2.33351 0.141649 16.47384 7.35E-14
Age 45-49
2.691181 0.152291 17.67128 1.74E-14
Age 50-54
3.129008 0.163882 19.09303 3.51E-15
Age 55-59
3.4235 0.178286 19.20231 3.11E-15
Age 60-64
3.654953 0.180346 20.26636 1.01E-15
Age 65-69
3.828174 0.193689 19.76451 1.71E-15
Age 70-74
3.876574 0.204934 18.91618 4.26E-15
Age 75-79
4.00686 0.222296 18.02492 1.16E-14
1920-29 cohort 0.0330163 0.184893 0.17857 0.85991
1930-39 cohort
0.240484 0.18356 1.31011 0.203674
1940-49 cohort 0.3391446 0.203955 1.66284 0.110527
1950-59 cohort 0.3927891 0.218429 1.79825 0.085875
1960-69 cohort 0.4955284
0.2296 2.158226 0.042089
1970-79 cohort 0.6965528 0.241427 2.885149 0.008593
1980-89 cohort 0.9089721 0.260882 3.48423 0.002102
constant
-5.280235 0.252282 -20.9299 5.14E-16
R-Squared
0.9878688
N
41
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95% CI
0.578804 1.081835
1.204525 1.743768
1.661903 2.226485
2.039747 2.627273
2.375348 3.007013
2.789137 3.468879
3.053757 3.793242
3.280939 4.028967
3.426487 4.229861
3.451566 4.301582
3.545847 4.467873
-0.35043 0.41646
-0.1402 0.621165
-0.08383 0.762121
-0.0602 0.845782
0.019368 0.971689
0.195864 1.197242
0.367937 1.450008
-5.80344 -4.75703

Table A.1.7 b: Results of Age-Period Model
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%)
Indicator
Coefficient SE
t-statistic p-value
Age 25-29
0.785042 0.089818 8.740355 4.21E-10
Age 30-34
1.382502 0.089036 15.52754 9.9E-17
Age 35-39
1.750047 0.088906 19.68429 8.32E-20
Age 40-44
2.079389 0.087776 23.6898 2.73E-22
Age 45-49
2.381469 0.091704 25.96907 1.53E-23
Age 50-54
2.77329 0.092897 29.85342 1.85E-25
Age 55-59
3.016927 0.098845 30.52183 9.13E-26
Age 60-64
3.201748 0.089644 35.71608 5.92E-28
Age 65-69
3.317046 0.094479 35.10868 1.03E-27
Age 70-74
3.311332 0.095643 34.6218 1.61E-27
Age 75-79
3.376998 0.10645 31.7239 2.66E-26
2001
NHANES
-0.0258708 0.054771 -0.47235 0.639789
2005
NHANES
0.0411817 0.054802 0.751463
0.4577
2009
NHANES
0.4200199 0.050525 8.313196 1.33E-09
constant
-4.683064 0.067184 -69.7048 2.09E-37
R-Squared
0.9897704
N
48
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95% CI
0.602306 0.967778
1.201358 1.563646
1.569167 1.930927
1.900808 2.25797
2.194896 2.568043
2.58429 2.962291
2.815825 3.218028
3.019365 3.384131
3.124826 3.509265
3.116745 3.505919
3.160425 3.593572
-0.1373 0.085562
-0.07031 0.152677
0.317227 0.522813
-4.81975 -4.54638

Table A.1.7 c: results of Age-Period-Cohort Obesity Model
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%)
Indicator
Coefficient SE
t-statistic p-value
Age 25-29
0.9286565 0.087923 10.5622 1.88E-11
Age 30-34
1.61597 0.102132 15.82242 8.41E-16
Age 35-39
2.088447 0.12797 16.31986 3.74E-16
Age 40-44
2.484058 0.146681 16.93516 1.41E-16
Age 45-49
2.834346 0.16289 17.40037 6.89E-17
Age 50-54
3.271163 0.177394 18.44012 1.46E-17
Age 55-59
3.541548 0.188307 18.8073 8.63E-18
Age 60-64
3.757913 0.195096 19.26188 4.54E-18
Age 65-69
3.893697 0.203847 19.1011 5.69E-18
Age 70-74
3.946568 0.221865 17.78819 3.83E-17
Age 75-79
3.984019 0.235082 16.94739 1.39E-16
2001
NHANES
-0.1520016 0.06738 -2.25588 0.031793
2005
NHANES
-0.0857865 0.067733 -1.26654
0.2154
2009
NHANES
0.2139795 0.080386 2.661893 0.012539
obesity
4.388277 1.597306 2.747298 0.010222
constant
-5.274105 0.202519 -26.0426 1.15E-21
R-Squared
0.9925176
N
45
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95% CI
0.748835 1.108479
1.407087 1.824853
1.82672 2.350175
2.184062 2.784053
2.501198 3.167493
2.908352 3.633973
3.156417 3.92668
3.358897 4.156929
3.476784 4.31061
3.492804 4.400332
3.503223 4.464814
-0.28981

-0.01419

-0.22432 0.052743
0.049571 0.378388
1.121419 7.655136
-5.6883 -4.85991

A.1.8. ALTERNATIVE DELINEATION OF BIRTH COHORTS
Figure A.1.8 a: Age-specific diabetes prevalence in successive ten-year birth cohorts,
using alternative delineation of birth cohorts
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Figure A.1.8 b: Age pattern of diabetes prevalence, including alternative delineation
of birth cohorts
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The “alternative cohorts” are born 1915-1924, 1925-1934, etc., rather than 1910-1919,
1920-1929, etc.
Data are from the National Health and Nutrition Examination Surveys (NHANES),
United States, 1988 to 2010.

130

A.2. Appendices to Chapter 2 (Lifetime Risk of Dementia)
A.2.1. Models of dementia incidence, prevalence, and differential mortality
A) Prevalence model: 𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑥 ) = 𝛼 + 𝛽𝑥,
Point estimates:
Term
Coefficient estimate
0.152565
Age (x)
-14.2737
Constant
Variance-covariance:
Age
Constant
Age
0.000295 -0.02424
Constant -0.02424 2.004415
B) Incidence model: 𝑙𝑜𝑔𝑖𝑡(𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒𝑥 ) = 𝛼′ + 𝛽′𝑥,
Point estimates:
Term
Coefficient estimate
Age (x)
0.087151
Constant
-10.6868
Variance-covariance:
Age
Age
0.000407
Constant
-0.03363

Constant
-0.03363
2.793747

C) Differential mortality
Model: ln(𝑚𝑥,𝑑𝑒𝑚 ) = 𝛼 + 𝛽1 𝑥 + 𝛽2 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎 + 𝛽3 𝑥 ∗ 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎.
Point estimates:
Term
Dementia
Age (x)
Age*Dementia
Constant

Coefficient estimate
6.435545
0.110955
-0.06139
-12.2631

Variance-covariance:
Dementia
Age
Age*Dementia
Constant

Dementia
Age Age*Dementia Constant
3.427942 0.027964
-0.03975 -2.35307
0.027964 0.000299
-0.00033
-0.025
-0.03975 -0.00033
0.000464 0.027693
-2.35307
-0.025
0.027693 2.10715
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A.2.2. Deterministic inputs and results
Table A.2.2 a: Deterministic inputs to stationary approach
Estimated Estimated
Implied
Age Prevalence Incidence
RR
70
0.029
0.010
10.213
75
0.060
0.016
4.041
80
0.120
0.024
1.824
85
0.226
0.036
1.062
90
0.385
0.055
0.955
95
0.574
0.083
0.962
100
0.743
0.122
1.150
RR = Mortality rate ratio, with dementia vs. without dementia.
Parametric models were fit to ADAMS baseline data for prevalence, ADAMS
longitudinal data for incidence. Parameters of the models – shown in Appendix Table 1 –
were treated as non-stochastic and run through life table operations as described in the
Methods section under Approach 1.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort.
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Table A.2.2 b: Deterministic life cycle quantities using stationary approach
A. Males
Age
70
75
80
85
90
95
100

LE
12.31
9.65
7.26
5.20
3.64
2.61
2.02

DFLE
10.84
8.05
5.54
3.43
1.90
0.95
0.45

DLE
1.47
1.60
1.72
1.77
1.75
1.66
1.57

Lifetime
Risk
0.233
0.230
0.222
0.209
0.199
0.200
0.228

DFLE'
11.14
8.52
6.24
4.36
3.01
2.14
1.71

DLE
2.21
2.29
2.34
2.32
2.19
2.00
1.81

Lifetime
Risk
0.312
0.298
0.280
0.259
0.241
0.236
0.255

DFLE'
13.40
10.18
7.40
5.16
3.52
2.46
1.89

B. Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.04
9.62
6.57
4.06
2.22
1.09
0.50

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life. DFLE’ = Dementia-free life expectancy for a dementiafree person in the population of given age.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort. Prevalence, incidence, and
mortality rate ratios used in this table are shown in Appendix Table 2.
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Table A.2.2 c: Deterministic inputs to non-stationary approach
Implied
Estimated Estimated
Age Prevalence Incidence
RR
70
0.029
0.010
8.486
75
0.057
0.016
6.243
80
0.090
0.024
4.593
85
0.134
0.036
3.379
90
0.191
0.055
2.486
95
0.277
0.083
1.829
100
0.443
0.122
1.346
Parametric models were fit to ADAMS longitudinal data for incidence and differential
mortality. Parameters of the models – shown in Appendix Table 1 – were treated as nonstochastic and run through life table operations as described in the Methods section.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
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Table A.2.2 d: Deterministic life cycle quantities using non-stationary approach
A. Males
Age
70
75
80
85
90
95
100

LE
12.31
9.65
7.26
5.20
3.64
2.61
2.02

DFLE
11.58
8.93
6.53
4.49
2.95
1.87
1.10

DLE
0.73
0.72
0.73
0.71
0.69
0.73
0.91

Lifetime
Risk
0.267
0.269
0.264
0.253
0.239
0.232
0.234

DFLE'
11.93
9.37
7.05
5.05
3.51
2.44
1.76

DLE
1.70
1.66
1.53
1.35
1.18
1.09
1.18

Lifetime
Risk
0.344
0.338
0.325
0.307
0.285
0.269
0.264

DFLE'
13.95
10.90
8.17
5.86
4.04
2.77
1.95

B. Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.55
10.25
7.38
5.02
3.24
2.00
1.13

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life. DFLE’ = Dementia-free life expectancy for a dementiafree person in the population of given age.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
Prevalence, incidence, and mortality rate ratios used in this table are shown in Appendix
Table 4.
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Table A.2.2 e: Deterministic life cycle quantities using 1940 cohort life table, nonstationary approach
A. Males
Age
70
75
80
85
90
95
100

LE
13.64
10.65
7.96
5.70
4.05
2.95
2.30

DFLE
12.58
9.60
6.96
4.77
3.16
2.00
1.16

DLE
1.06
1.04
1.00
0.93
0.90
0.95
1.14

Lifetime
Risk
0.305
0.303
0.295
0.280
0.268
0.260
0.262

DFLE'
12.95
10.15
7.61
5.46
3.83
2.69
1.94

DLE
1.93
1.91
1.81
1.63
1.45
1.37
1.45

Lifetime
Risk
0.371
0.366
0.355
0.336
0.316
0.300
0.294

DFLE'
14.47
11.41
8.64
6.26
4.38
3.03
2.15

B. Females
Age
70
75
80
85
90
95
100

LE
15.99
12.62
9.57
6.93
4.89
3.49
2.63

DFLE
14.05
10.71
7.76
5.30
3.43
2.11
1.18

Notes: This table uses as inputs the quantities shown in Appendix Table 4, along with
1940 birth cohort life tables from the U.S. Social Security Administration.
LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
Prevalence, incidence, and mortality rate ratios used in this table are shown in Appendix
Table 4.
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A.2.3. Incidence rates under intervention scenarios
New cases per dementia-free person-year lived

Age
70
75
80
85
90
95
100

Scenario
1&2
0.0095
0.0144
0.0220
0.0337
0.0518
0.0794
0.1201

Scenario Scenario
3&4
5
0.00685
0.0058
0.01032
0.0084
0.01566
0.0122
0.02394
0.0178
0.03675
0.0261
0.05648
0.0384
0.08636
0.0565

Scenarios 1 & 2 delay dementia incidence by one year compared to rates estimated from
ADAMS and shown in Table 1. Scenarios 3 & 4 delay dementia incidence by five years.
Scenario 5 reduces the acceleration of dementia incidence with age by 10%.
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A.2.4.
Approximated dementia-free survivors to middle of age interval
versus dementia-free person-years lived in the interval
Males, non-stationary approach, deterministic calculation

Age
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

𝐿̂𝑁𝐷
𝑥
91351.4
87440.3
83361.0
79139.0
74991.4
70708.7
66374.0
62007.1
57592.1
53108.6
48703.9
44329.6
39870.7
35520.1
31251.5
27121.4
23176.1
19469.8
16047.1
12954.2
10216.6
7857.0
5876.3
4262.6
2990.0
2028.6
1327.1
836.8
510.6
298.0

𝐿𝑁𝐷
𝑥
91329.4
87376.9
83292.3
79140.9
74947.0
70676.5
66352.5
61983.9
57561.6
53124.7
48719.4
44306.6
39899.1
35556.9
31309.9
27202.5
23282.8
19599.9
16200.4
13123.7
10399.1
8044.1
6061.0
4437.8
3152.1
2169.3
1444.4
930.6
579.7
348.5

Absolute Diff. as %
Difference
of 𝐿𝑁𝐷
𝑥
22.01
0.02%
63.41
0.07%
68.68
0.08%
1.89
0.00%
44.39
0.06%
32.14
0.05%
21.43
0.03%
23.16
0.04%
30.58
0.05%
16.08
0.03%
15.48
0.03%
23.00
0.05%
28.40
0.07%
36.79
0.10%
58.48
0.19%
81.03
0.30%
106.73
0.46%
130.06
0.66%
153.31
0.95%
169.55
1.29%
182.48
1.75%
187.15
2.33%
184.73
3.05%
175.24
3.95%
162.16
5.14%
140.71
6.49%
117.28
8.12%
93.80
10.08%
69.12
11.92%
50.55
14.51%

𝑁𝐷
The 𝐿̂𝑁𝐷
𝑥 values are approximated dementia-free survivors; 𝐿𝑥 are person-years lived without
𝑁𝐷
dementia in the age interval. The 𝐿̂𝑥 values were used to estimate the dementia prevalence in
each age group using the non-stationary approach and were estimated assuming linearity of
survival within one-year age intervals; see Methods section, under Approach 2, for details.
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A.2.5. Results using alternative censoring strategy
Table A.2.5 a: Incidence, Prevalence, and Differential Mortality, censoring subjects
without dementia at end of ADAMS study period (Stationary Approach)

Age
70
75
80
85
90
95
100

Fitted prevalence & incidence
Implied
Prevalence
(SE) Incidence
(SE)
RR
(SE)
0.030 (0.007)
0.010 (0.003) 13.542 (13.668)
0.061 (0.009)
0.015 (0.003)
3.939 (1.921)
0.121 (0.012)
0.022 (0.003)
1.487 (0.101)
0.227 (0.022)
0.032 (0.005)
0.889 (0.261)
0.384 (0.043)
0.046 (0.009)
0.875 (0.236)
0.569 (0.061)
0.068 (0.019)
0.919 (0.202)
0.734 (0.064)
0.099 (0.035)
1.106 (0.228)

RR = Relative risk of death, with dementia vs. without dementia
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort.
Parametric models were fitted to prevalence and incidence data to generate single-year
age-specific estimates. Subjects who survived ADAMS without a diagnosis of dementia
were censored at the end of the ADAMS study period, rather than at their last assessment.
RR was implied by fitted prevalence, incidence, and stationary-population relations.
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Table A.2.5 b: Life cycle quantities for dementia, stationary approach, censoring
subjects without dementia at end of ADAMS study period
A) Males
Age
70
75
80
85
90
95
100

LE
12.31
9.65
7.26
5.20
3.64
2.61
2.02

DFLE
10.83
8.04
5.54
3.43
1.91
0.96
0.47

DLE
1.48
1.61
1.72
1.76
1.74
1.64
1.55

(SE)
(0.129)
(0.142)
(0.162)
(0.182)
(0.187)
(0.163)
(0.123)

Lifetime
Risk
0.214
0.206
0.194
0.179
0.168
0.166
0.187

(SE) DFLE'
(0.028) 11.14
(0.025)
8.53
(0.028)
6.25
(0.035)
4.37
(0.044)
3.01
(0.056)
2.15
(0.073)
1.71

(SE)
(0.119)
(0.134)
(0.143)
(0.135)
(0.109)
(0.078)
(0.039)

(SE)
(0.190)
(0.205)
(0.227)
(0.249)
(0.251)
(0.220)
(0.167)

Lifetime
Risk
0.283
0.265
0.244
0.221
0.203
0.196
0.210

(SE) DFLE'
(0.034) 13.41
(0.033) 10.19
(0.038)
7.41
(0.047)
5.17
(0.056)
3.53
(0.067)
2.47
(0.085)
1.90

(SE)
(0.191)
(0.205)
(0.209)
(0.190)
(0.149)
(0.102)
(0.061)

B) Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.17
9.77
6.74
4.25
2.41
1.26
0.63

DLE
2.08
2.14
2.16
2.12
2.00
1.83
1.69

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities were calculated using fitted values of dementia incidence and relative risk of
death (with dementia vs. without) shown in Appendix Table 9.
Subjects who survived ADAMS without a diagnosis of dementia were censored at the
end of the ADAMS study period, rather than at their last assessment.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social
Security Administration life tables for 1920 birth cohort.
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Table A.2.5 c: Incidence, Prevalence, and Differential Mortality, censoring subjects
without dementia at end of ADAMS study period (non-stationary approach)

Age
70
75
80
85
90
95
100

Implied
Prevalence
0.030
0.052
0.075
0.098
0.119
0.145
0.206

(SE)
(0.173)
(0.228)
(0.274)
(0.313)
(0.345)
(0.381)
(0.454)

Estimated
Incidence
0.010
0.015
0.022
0.032
0.046
0.068
0.099

(SE)
(0.003)
(0.003)
(0.003)
(0.005)
(0.009)
(0.019)
(0.035)

Estimated
RR
10.56
7.94
6.04
4.67
3.65
2.89
2.33

(SE)
(4.290)
(2.322)
(1.200)
(0.699)
(0.664)
(0.777)
(0.874)

RR = Relative risk of death, with dementia vs. without dementia
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
Parametric models were fitted to incidence and mortality data from ADAMS to generate
single-year age-specific estimates. Prevalence in the cohort arises from the life table
relations as described in the Methods section, under Approach 2.
Subjects who survived ADAMS without a diagnosis of dementia were censored at the
end of the ADAMS study period, rather than at their last assessment.
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Table A.2.5 d: Life cycle quantities for dementia, non-stationary approach,
censoring subjects without dementia at end of ADAMS study period
A) Males
Age
70
75
80
85
90
95
100

LE
12.31
9.65
7.26
5.20
3.64
2.61
2.02

DFLE
11.83
9.21
6.85
4.82
3.31
2.28
1.63

DLE
0.48
0.44
0.42
0.37
0.34
0.33
0.39

(SE)
(0.186)
(0.182)
(0.163)
(0.140)
(0.119)
(0.112)
(0.136)

Lifetime
Risk
0.252
0.249
0.240
0.225
0.211
0.205
0.216

(SE) DFLE'
(0.033) 12.19
(0.033)
9.63
(0.036)
7.28
(0.044)
5.24
(0.054)
3.66
(0.065)
2.59
(0.083)
1.95

(SE)
(0.150)
(0.106)
(0.069)
(0.042)
(0.035)
(0.036)
(0.047)

(SE)
(0.249)
(0.255)
(0.245)
(0.220)
(0.186)
(0.160)
(0.164)

Lifetime
Risk
0.323
0.312
0.295
0.274
0.252
0.238
0.242

(SE) DFLE'
(0.038) 14.27
(0.039) 11.22
(0.044)
8.46
(0.052)
6.10
(0.062)
4.24
(0.073)
2.95
(0.090)
2.18

(SE)
(0.234)
(0.157)
(0.111)
(0.071)
(0.042)
(0.035)
(0.044)

B) Females
Age
70
75
80
85
90
95
100

LE
15.25
11.91
8.91
6.37
4.42
3.10
2.32

DFLE
13.84
10.59
7.76
5.45
3.70
2.51
1.74

DLE
1.41
1.32
1.14
0.92
0.72
0.59
0.57

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities calculated using fitted values of dementia incidence and relative risk of death
(with dementia vs. without) shown in Appendix Table 11.
Subjects who survived ADAMS without a diagnosis of dementia were censored at the
ADAMS study period, rather than at their last assessment.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
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Table A.2.5 e: Life cycle quantities for dementia, non-stationary approach,
censoring subjects without dementia at end of ADAMS study period, 1940 cohort
life table
A) Males
Age
70
75
80
85
90
95
100

LE
13.64
10.65
7.96
5.70
4.05
2.95
2.30

DFLE
12.88
9.95
7.35
5.18
3.59
2.50
1.77

DLE
0.76
0.70
0.62
0.52
0.46
0.45
0.52

(SE)
(0.222)
(0.223)
(0.207)
(0.181)
(0.156)
(0.147)
(0.167)

Lifetime
Risk
0.289
0.282
0.270
0.253
0.239
0.235
0.247

(SE)
(0.036)
(0.036)
(0.041)
(0.050)
(0.062)
(0.076)
(0.096)

DFLE'
13.28
10.47
7.91
5.71
4.05
2.90
2.20

(SE)
(0.193)
(0.139)
(0.097)
(0.061)
(0.047)
(0.049)
(0.061)

(SE)
(0.288)
(0.294)
(0.285)
(0.261)
(0.229)
(0.202)
(0.202)

Lifetime
Risk
0.349
0.340
0.325
0.304
0.283
0.271
0.276

(SE)
(0.040)
(0.043)
(0.049)
(0.059)
(0.070)
(0.084)
(0.103)

DFLE'
14.85
11.80
9.01
6.57
4.65
3.29
2.44

(SE)
(0.269)
(0.194)
(0.145)
(0.098)
(0.063)
(0.051)
(0.058)

B) Females
Age
70
75
80
85
90
95
100

LE
15.99
12.62
9.57
6.93
4.89
3.49
2.63

DFLE
14.41
11.11
8.22
5.80
3.97
2.71
1.88

DLE
1.58
1.51
1.35
1.13
0.91
0.77
0.76

LE = total life expectancy for a randomly chosen person in the population of given age.
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of
given age, DLE = life expectancy with dementia for a randomly chosen person in the
population of given age, Lifetime Risk = probability that a dementia-free person will
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementiafree person of given age.
By construction, DFLE and DLE have the same standard error, and LE has zero variance.
Quantities calculated using fitted values of dementia incidence and relative risk of death
(with dementia vs. without) shown in Appendix Table 11.
Subjects who survived ADAMS without a diagnosis of dementia were censored at the
end of the ADAMS study period, rather than at their last assessment.
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009.
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia
status data from Health and Retirement Study (HRS), United States, 2001-2011.
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A.3. Appendices to Chapter 3 (Diabetes and mobility limitations)
A.3.1. Additional sample characteristics
Table A.3.1 a: Weighted means or proportions of characteristics of individuals who
had diabetes at baseline vs. individuals included in propensity score matching
procedure

Mother's education (years)
Father's education (years)
Childhood health
(1=excellent)
Age (last birthday)
Female
Black
Hispanic
Foreign born
Own education (years)
Less than high school
High school graduate
Some college
College graduate
Northeast
Midwest
South
West
Married
Divorced
Uninsured
Works full time
Works part-time
Unemployed
Retired
Not in labor force
On work disability
HH income per head ($)
Wealth ($)
Smokes now
Ever smoked

Diabetic at baseline All included
(excluded)
individuals
Sig.†
***
8.886
9.837
***
8.367
9.470
**
1.904
1.758
***
55.029
54.483
47.1%
50.6%
***
20.1%
9.7%
***
9.4%
6.6%
9.1%
8.7%
***
11.9
12.8
***
29.3%
18.0%
*
35.1%
37.1%
**
19.4%
22.1%
***
16.2%
22.7%
18.6%
19.4%
26.1%
24.8%
***
41.7%
37.2%
***
13.6%
18.6%
*
75.7%
80.5%
*
24.1%
19.5%
17.4%
17.3%
***
44.4%
62.2%
**
7.4%
10.0%
2.6%
2.0%
***
23.5%
13.0%
10.5%
9.4%
***
11.5%
3.5%
***
18088
27119
***
128368
230037
**
22.0%
26.1%
*
67.0%
62.2%
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***
BMI (kg/m2)
30.89
27.09
Self-rated health
***
(1=excellent)
3.572
2.392
***
Has high blood pressure
60.0%
28.0%
***
Has had stroke
7.4%
1.7%
***
Has arthritis
46.2%
30.3%
# Mobility limitations
***
(max=5)
1.697
0.784
Number of subjects
1094
9646
Source: Author’s calculations from Health and Retirement Study (United States, 19922010).
† Significance tests: Pearson Chi-Squared test for differences between groups
(proportions); Wilcoxon rank-sum test for differences between groups (sample means):
*p<0.05, **p<0.01, ***p<0.001.

145

Table A.3.1 b: Diabetes incidence and survival in Original HRS and War Babies cohorts
Original HRS cohort (born 1931-1941)
New
Year Wave Respondents
Diabetic
At risk New cases
deaths
Censored
1992
1
8006
0
8006
0
0
0
1994
2
7639
0
7639
135
0
0
1996
3
7575
129
7446
168
0
0
1998
4
7235
269
6966
154
134
135
2000
5
6865
379
6486
190
187
240
2002
6
6590
521
6069
227
249
314
2004
7
6317
687
5630
225
189
254
2006
8
5994
833
5161
214
248
407
2008
9
5712
961
4751
180
262
299
2010
10
5225
1006
4219
206
367
402

No
response
0
367
431
771
1141
1416
1689
2012
2294
2781

War Babies cohort (born 1942-1947)
Year Wave Respondents
1998
4
1642
2000
5
1583
2002
6
1593
2004
7
1534
2006
8
1482
2008
9
1441
2010
10
1369

Diabetic
0
0
30
83
116
159
194

At risk
1642
1583
1563
1451
1366
1282
1175

New cases
0
31
60
39
54
51
66
146

New
deaths
0
0
0
12
26
25
27

Censored
0
0
0
12
27
27
29

No
response
0
59
49
108
160
201
273

Diabetic = Number of subjects who had already reported having diabetes in a previous wave.
At risk = Number of subjects at risk of incident diabetes this wave.
New cases = Number of diabetes cases first observed this wave.
New deaths = Number of new deaths reported this wave.
Censored = Number of subjects censored this wave = Number of new deaths + Number newly dropped from survey.
No response = Number of subjects who did not respond to survey this wave.
Source: Author’s calculations from Health and Retirement Study (United States, 1992-2010).
Number of incident cases in row for wave w equals the number of diabetes cases first observed at wave w, i.e. the number of incident
cases that occurred between wave w-1 and wave w. Number already diabetic in wave w is approximately the sum of all incident cases
prior to wave w. Without sample attrition, nonresponse, and mortality, it would be exactly equal. Data were collected every two years;
calculating an incidence rate requires additional knowledge or assumptions about when in the interval people died or were lost to
follow-up. # censored = # who died since previous wave + # dropped from sample since previous wave. In general, individuals who
did not respond in a given wave remained in the sample, and the HRS data collection team attempted to reach them in subsequent
waves. Individuals who died before their cohort was observed three times were excluded from the sample because they did not
provide enough data to identify an effect of incident diabetes on subsequent disability.
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A.3.2. Propensity score model fit and matching results
Table A.3.2 a: Propensity score model fit
Dependent variable = Diagnosed with diabetes
Independent variable
Odds ratio

95% Conf.
Int.

Mother’s education (years)
Father’s education (years)
Childhood health b
Age (last birthday)
Female
Black
Hispanic
Foreign born
Own education (years)
Midwest
Northeast
West
Divorced
Uninsured
Works full-time
Wealth (Z-score) a
Household income per head (Z-score) a
Current smoker
Former smoker
BMI (kg/m2)
Self-rated health b
High blood pressure
Heart problems
Stroke
Arthritis
Number mobility limitations (max=5)

0.988
0.994
0.971
1.010
0.765***
1.231
1.452**
0.995
0.987
0.924
0.928
0.999
0.915
1.197
1.130
0.949
0.511*
1.034
0.977
1.101***
1.177***
1.641***
1.254**
1.071
0.923
0.980

[0.968,1.009]
[0.974,1.015]
[0.916,1.031]
[0.996,1.024]
[0.677,0.864]
[0.996,1.523]
[1.167,1.806]
[0.753,1.314]
[0.968,1.006]
[0.765,1.116]
[0.816,1.055]
[0.868,1.149]
[0.769,1.089]
[0.972,1.473]
[0.976,1.308]
[0.847,1.064]
[0.267,0.977]
[0.859,1.245]
[0.827,1.155]
[1.086,1.116]
[1.101,1.259]
[1.477,1.823]
[1.077,1.460]
[0.833,1.378]
[0.778,1.094]
[0.927,1.036]

1994-1996 interval
1996-1998 interval
1998-2000 interval
2000-2002 interval
2002-2004 interval
2004-2006 interval
2006-2008 interval
2008-2010 interval
N (person-waves)
(Continued on next page)

1.327*
1.270
1.330*
2.060***
1.776***
2.088***
1.953***
2.429***
64776

[1.047,1.682]
[0.936,1.722]
[1.066,1.659]
[1.675,2.533]
[1.381,2.284]
[1.555,2.804]
[1.427,2.673]
[1.735,3.401]
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Notes: Author's calculations from Health and Retirement Study (United States, 19922010).
*
p < 0.05, ** p < 0.01, *** p < 0.001.
a
Household wealth and income per head were measured in standard-deviation units, so
their odds ratios show the proportionate increased odds of developing diabetes associated
with a one-standard-deviation increase in wealth or income per head, respectively.
Sample mean wealth across all person-observations was $333,774 with standard
deviation $1,285,870. Income per head sample mean was $30,359 with standard
deviation $227,406.
b
Childhood health (self-rated) and current self-rated health were measured on a scale
from 1 to 5, with 1 indicating the best health.
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Table A.3.2 b: Balance of covariates before and after risk-set matching

When
measured

Variable
Mother's education (yrs)
Father's education (yrs)
Childhood health
female
Timeinvariant Own education (yrs)
Black
Hispanic
Foreign born

Std diff
Std diff
Exposed Control
before
after
mean
mean
matching matching before
before
-0.171
-0.008
8.695
9.6
-0.147
0.010
8.378
9.2
0.048
0.047
1.868
1.800
-0.046
-0.019
0.500
0.532
-0.181
-0.010
11.7
12.5
0.138
0.053
0.215
0.140
0.126
0.081
0.128
0.074
0.062
0.090
0.121
0.094

(Table continues on next three pages.)
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P
before
<0.001
<0.001
0.010
0.010
<0.001
<0.001
<0.001
<0.001

Exposed Control
mean
mean
after
after
P after
8.8
8.8
0.980
8.5
8.4
0.607
1.865
1.799
0.240
0.501
0.514
0.458
11.8
11.9
0.914
0.209
0.180
0.040
0.120
0.086
0.001
0.115
0.076 <0.001

When
measured

Std diff before
matching

Std diff after
matching

Exposed
mean before

Control
mean before

P
before

Exposed
mean after

Control
mean after

P after

-0.014

-0.020

54.95

55.01

0.541

54.97

55.06

0.280

South

0.066

-0.067

0.451

0.405

<0.001

0.440

0.487

0.008

West

-0.028

0.070

0.153

0.167

0.120

0.156

0.120

0.003

Midwest

-0.020

-0.010

0.235

0.247

0.252

0.232

0.238

0.677

Northeast

-0.036

0.032

0.162

0.181

0.046

0.172

0.155

0.198

Married

-0.016

-0.118

0.816

0.824

0.354

0.808

0.873

<0.001

Variable
Age

Baseline
(study entry)

Divorced

0.016

0.118

0.185

0.176

0.254

0.192

0.127

<0.001

Household income ($)

-0.151

-0.037

18,480

24,441

<0.001

18,767

20,239

0.025

Wealth ($)

-0.137

-0.025

143,552

224,561

<0.001

145,068

159,926

0.002

Works full time

-0.045

0.005

0.570

0.601

0.011

0.571

0.567

0.830

Works part time

-0.017

-0.046

0.097

0.104

0.336

0.094

0.114

0.073

Unemployed

0.008

0.006

0.025

0.023

0.651

0.026

0.024

0.821

Retired

0.020

0.000

0.149

0.139

0.252

0.151

0.151

1.000

On disability

0.050

0.014

0.047

0.033

0.003

0.046

0.042

0.607

Not in labor force

0.031

0.024

0.114

0.100

0.080

0.112

0.101

0.330

BMI (kg/m2)

0.497

0.035

29.86

26.31

<0.001

29.62

29.37

0.082

Smokes now

0.006

0.088

0.271

0.267

0.735

0.272

0.217

<0.001

-0.004

-0.037

0.354

0.357

0.814

0.358

0.383

0.143

Uninsured

0.061

0.047

0.223

0.188

0.001

0.215

0.188

0.058

Self-rated health

0.216

0.035

2.730

2.379

<0.001

2.699

2.642

0.246

High blood pressure

0.254

-0.006

0.437

0.267

<0.001

0.423

0.426

0.830

Heart disease

0.060

0.014

0.101

0.077

<0.001

0.100

0.094

0.591

Stroke

0.014

0.061

0.021

0.018

0.420

0.024

0.012

0.013

Former smoker
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When
measured
Baseline

Variable

Std diff before
matching

Arthritis

0.079

(Study entry)

# Mobility limitations
Age

Just before
diabetes onset

Std diff after
matching

Exposed
mean before

Control
mean before

P
before

Exposed
mean after

Control
mean after

P after

-0.017

0.355

0.303

<0.001

0.352

0.363

0.507

0.202

0.063

1.203

0.822

<0.001

1.200

1.082

0.017

0.033

-0.014

61.98

61.74

0.637

62.34

62.44

0.687

South

0.128

-0.075

0.452

0.363

<0.001

0.454

0.506

0.003

West

-0.004

0.079

0.148

0.150

0.826

0.157

0.117

0.001

Midwest

0.008

-0.010

0.220

0.215

0.644

0.226

0.232

0.705

Northeast

0.005

0.032

0.152

0.149

0.765

0.162

0.146

0.203

Married

0.115

-0.124

0.799

0.730

<0.001

0.814

0.888

<0.001

Divorced

0.045

0.140

0.171

0.148

0.010

0.184

0.112

<0.001

Household income ($)

-0.121

0.007

21661

33022

<0.001

22285

21660

0.108

Wealth ($)

-0.113

0.001

203585

339099

<0.001

216712

215473

0.008

Works full time

0.006

0.003

0.319

0.315

0.722

0.320

0.318

0.909

Works part time

-0.018

-0.018

0.058

0.064

0.329

0.058

0.064

0.461

Unemployed

0.020

0.019

0.011

0.008

0.247

0.011

0.009

0.477

Retired

0.091

-0.014

0.443

0.379

<0.001

0.466

0.476

0.571

On disability

0.062

0.040

0.051

0.033

<0.001

0.052

0.041

0.132

Not in labor force

0.030

0.002

0.092

0.080

0.085

0.092

0.092

0.951

BMI (kg/m )

0.106

0.014

30.941

30.080

<0.001

30.640

30.526

0.410

Smokes now

-0.021

0.051

0.181

0.193

0.251

0.180

0.152

0.033

Former smoker

0.086

0.003

0.435

0.375

<0.001

0.454

0.452

0.915

Uninsured

0.070

0.067

0.136

0.104

<0.001

0.130

0.100

0.007

Self-rated health

0.302

0.034

3.031

2.568

<0.001

3.000

2.948

0.201

High blood pressure

0.318

-0.017

0.614

0.395

<0.001

0.610

0.622

0.490

2

152

When
measured
Just before
diabetes onset

Variable

Std diff before
matching

Std diff after
matching

Exposed
mean before

Control
mean before

P
before

Exposed
mean after

Control
mean after

P after

0.070

0.215

0.136

<0.001

0.220

0.182

0.008

Heart disease

0.148

Stroke

0.042

0.098

0.053

0.040

0.016

0.059

0.030

<0.001

Arthritis

0.104

-0.021

0.554

0.481

<0.001

0.553

0.568

0.393

# Mobility limitations

0.239

0.060

1.156

0.710

<0.001

1.138

1.026

0.057

Std diff = Standardized difference = ((exposed group mean) – (control mean))/(Pooled standard deviation). BMI = Body Mass Index.
Childhood health and self rated health: 1=excellent, 5 is the worst possible health.
Household income is household income per person living in the household.
P-values are from Pearson chi-squared tests for binary variables (e.g. “smokes now”), and Wilcoxon rank-sum tests for numeric
variables (e.g. household income per head). Small P-values indicate a statistically significant difference in means between the exposed
and control group.
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A.3.3. Results using alternative specifications
To test the sensitivity of the results to the restriction that only diagnosed diabetes
is observed, matched pairs in which the control unit was diagnosed with diabetes in some
later wave, after being matched, were dropped. Individuals subsequently diagnosed with
diabetes are probably more likely than those who are never diagnosed to have had
undiagnosed diabetes when matched as controls. Because those with undiagnosed
diabetes might experience some of the disabling effects of the disease, removing pairs
with control units who later got diabetes could increase the within-pair differences in
disability accumulation, increasing the magnitude of the estimated association between
incident diabetes and mobility limitation. In fact, as shown in Appendix Table 5, the
results are almost identical when these pairs are excluded, which suggests that ignoring
undiagnosed diabetes does not produce a major bias in either direction.
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Table A.3.3 a: Signed-rank test results, excluding pairs with control individual who
later developed diabetes
(Number of pairs = 1323)
Hodges-Lehman estimate
0.25
95% CI for H-L estimate
[0.000009, 0.25001]
p-value for H0: No difference between
0.0001
exposed and matched-controls
Notes: Author’s calculations from Health and Retirement Study (United States, 19922010).
Hodges-Lehman estimate is the median of pairwise Walsh averages; it can be interpreted
roughly as the median within-pair difference between an exposed and control unit.
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Table A.3.3 b: Comparing mobility change among incident cases of diabetes to
mobility change among matched controls, defining number of mobility limitations at
diagnosis as number of mobility limitations at first report of diabetes diagnosis
(Number of pairs = 1559)
p-value for H0: No difference
between exposed and
matched-controls
Hodges-Lehman estimate:
median of pairwise Walsh
averages (approximately, the
median within-pair
difference)
95% CI for H-L estimate

0.000001557

0.2499

[0.2499, 0.2500]

Source: Author’s calculations from Health and Retirement Study (United States, 19922010).
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A.3.4. Sensitivity to unmeasured confounding
The Wilcoxon signed-rank test and its associated Hodges-Lehman estimate
represent a test and estimate of the effect of incident diabetes on subsequent mobility
limitation, under the assumption of no unmeasured confounding (Rosenbaum 2002). By
observing incident diabetes and subsequent disabilities and ensuring balance between
exposed (incident-diabetes) and control groups prior to diabetes onset, this paper reduces
the potential confounding found in other studies. However, there could still be
unmeasured forces that affect both diabetes onset above age 50 and subsequent mobility
limitation. This appendix estimates the magnitude of unmeasured confounding (also
called hidden bias) that would be needed to explain any observed association between
incident diabetes and subsequent mobility limitation.
The claim underlying matched-sets inference is that within matched sets, i.e.
conditional on all the covariates used in the matching process, the probability of exposure
for any unit in the set is the same. When dealing with matched pairs, that probability is ½.
The signed-rank test then assesses whether the difference in outcomes between the
exposed and control units could plausibly have resulted from random sampling error,
given that each unit in the pair had a probability of exposure of ½. The sensitivity
analysis addresses how inferences would be altered if unmeasured confounders, which
have arbitrarily strong associations with the outcome, increased the probability of
exposure for one unit in each pair (Gastwirth, Krieger, & Rosenbaum 1998; Rosenbaum
1987; Silber et al. 2009). The procedure estimates the magnitude of bias needed to
explain the study’s observed findings by simulating Wilcoxon signed-rank tests for
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within-pair probabilities of exposure other than ½. The procedure was designed for use in
studies based on propensity-score matching and detailed by Rosenbaum (2002).

Results
Table A.3.4 a shows the results of a simulation of different magnitudes of hidden
bias, that is, unmeasured variables that are arbitrarily highly associated with mobility
limitation and raise the probability of developing diabetes for one unit in each matched
pair. A research finding unlikely to have resulted from unmeasured confounding is one in
which the maximum p-value remains below a specified threshold (conventionally 0.05)
even when the magnitude of hidden bias, represented by Gamma (Γ), is fairly large. This
table shows that if some unmeasured confounder that was highly positively associated
with mobility limitations increased the probability of developing diabetes by 15%, the
significant Hodges-Lehman result shown in Table 3-3 could be completely explained by
this unmeasured confounder.
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Table A.3.4 a: Sensitivity of signed-rank test results to unmeasured confounding
Gamma (Γ)
1
1.1
1.15
1.2

Minimum p-value
0.000074
0.000000034
0.00000000040
0.0000000000033

Maximum p-value
0.000074
0.014
0.072
0.23

Gamma (Γ) is a measure of the magnitude of unmeasured confounding (hidden bias),
where Γ=1 means no unmeasured confounding. For all values of Γ, the association
between the unmeasured confounder and the outcome is arbitrarily strong and positive.
Minimum and maximum p-values are for Wilcoxon signed-rank test of the null
hypothesis of no difference in change in mobility limitations between exposed and
matched control units. A range of p-values is produced because the results are based on
simulating alternative probabilities of exposure, based on the magnitude of the hidden
bias.
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A.3.5. Results when considering only pairs in which both units were obese at
baseline
Table A.3.5 a: Signed-rank test results, pairs in which both units were obese at
baseline
(Number of pairs = 466)
p-value for H0: No difference 0.02983
between exposed and
matched-controls
Hodges-Lehman estimate:
0.25
median of pairwise Walsh
averages (approximately, the
median within-pair
difference)
95% CI for H-L estimate
[0.00003196, 0.49996307]
Source: Author’s calculations from Health and Retirement Study (United States, 19922010).
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Table A.3.5 b: Sensitivity of results to hidden bias, pairs in which both units were
obese at baseline
Gamma (Γ)
Minimum p-value
Maximum p-value
1
0.01577
0.01577
1.05
0.004686
0.04425
1.06
0.003623
0.05298
1.1
0.001236
0.1006
Source: Author’s calculations from Health and Retirement Study (United States, 19922010).
Gamma is a measure of the magnitude of hidden bias, where Γ=1 means no hidden bias.
Minimum and maximum p-values are for Wilcoxon signed-rank test of the null
hypothesis of no difference in disability change between exposed and matched control
units. A range of p-values is produced because the results are based on simulating
alternative probabilities of exposure, based on the magnitude of the hidden bias.
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Table A.3.5 c: Differences in average number of mobility limitations, both units in
pair obese at baseline
(Number of pairs = 466)
Exposed
Exposed
Control
Control
Time
mean
SD
mean
SD
Baseline
1.562 (1.531529)
1.519 (1.49862)
Last observation
pre-diagnosis
1.479 (1.542436)
1.386 (1.438691)
Censoring time
2.152 (1.722827)
1.880 (1.667701)
Average change
0.632
0.427
Average change = (# mobility limitations at censoring time) – [(# at baseline)+(# at time
t)]/2. See Equation 3 in text.
Time t = last observation before diabetes onset in exposed individual
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A.3.6. Association between duration of diabetes exposure and mobility limitations
To assess the association between duration of time since initial exposure and
mobility limitations at censoring time, against the alternative of not being exposed at the
initial exposure time (but possibly being exposed at subsequent times), I include length of
follow-up as a covariate in my Poisson model along with an interaction between exposed
status (exposed or control) and length of follow-up. The rate ratio for the interaction term
represents how many more mobility limitations are expected for the exposed person for
an additional unit of follow-up. Median length of follow-up following diabetes diagnosis
was three waves (six years), with a maximum of nine waves (18 years). Results are
shown with and without fixed effects for the total number of mobility limitations in each
matched pair; the fixed effects model is the preferred model (Lachin 2011).
The results provide no evidence for the importance of duration. The rate ratio for
the interaction term was approximately 1 and not statistically significant in either model.
The predominance of individuals with short follow-up periods (i.e. few years after
diabetes diagnosis) and the exclusion of individuals who had diabetes at study entry are
likely explanations for this null finding.
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Table A.3.6 a: Poisson regression when incorporating length of follow-up
Dependent variable = Number of mobility limitations at censoring time
Independent
(1) No fixed effects
(2) Fixed effects for total #
variable
mobility limitations at
censoring time in matched pair
exposed

1.238***
[1.109,1.381]

1.238***
[1.109,1.380]

follow-up
length

1.023*

1.003

[1.004,1.042]

[0.985,1.022]

interaction

0.994
[0.969,1.019]

0.994
[0.969,1.019]

N

3172

2534

Notes: Author’s calculations from Health and Retirement Study (United States, 19922010).
*
p < 0.05, ** p < 0.01, *** p < 0.001.
Model (2) dropped observations in matched pairs with a total number of mobility
limitations of zero.
Point estimate is the incidence rate ratio, which is the exponentiated coefficient. 95%
Confidence Intervals shown.
Each unit of follow-up length is one wave of data collection, corresponding to two years.
Interaction is the product of exposed and follow-up length.
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